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Ever since the beginning of modern medicine, the relationship between psychology 
and immune function has received considerable interest. In 1865, Claude Bernard, 
a French physiologist coined the concept milieu interieur,  describing the 
relationship between the internal physiological state and functioning in life
1
.  
“The constancy of the internal environment is the condition for a free and 
independent life"  
Over a century later, in 1981, Robert Ader founded the term 
Psychoneuroimmunology (PNI), describing the field that investigates the 
interaction between psychological factors and immune, and neuroendocrine 
systems and their influence on health and diseases, incorporating a broad range of 
disciplines such as psychology, medicine, immunology, biology, and neuroscience
2
. 
PNI still is a widely studied field covering a broad range of psychiatric disorders and 
physiological functioning in humans
2
. One of the major topics within PNI research is 
the association between depression and inflammation.  
In the 1980’s Dantzer and colleagues provided evidence for what is called cytokine 
induced sickness behavior, by injecting pro-inflammatory cytokines in healthy 
persons
3
. Sickness behavior is thought to be characterized by engaging in less 
physical activity, fatigue, and anorexia and can be viewed as a motivational state 
that is necessary to face the infection that causes the inflammation
3, 4
. In the years 
that followed up until now, the idea that there are similarities between this 
motivational behavior and (somatic symptoms of) depression, gained considerable 
interest
5
 and research provided evidence for an association between depression 
and inflammation [for an overview
6
]. It has even been proposed that this 
association could serve as a possible physiological link between highly comorbid 
somatic diseases and psychiatric complaints such as coronary heart disease (CHD) 
and depression
7
. However, it is still unknown (1) how depression and inflammation 
are associated (uni-directional or bi-directional) and (2) what the specific 
characteristics of this relationship are (e.g. persistent depressive symptoms versus 
single episodes of depression and somatic versus cognitive symptoms of 
depression). The aim of this thesis is to provide a better understanding of this 
relationship.    
 




Depression is characterized by feelings of depression or low mood and/or loss of 
interest or pleasure in normal activities
8
. In addition, these feelings of depressed 
mood are often accompanied by insomnia or hypersomnia, psychomotor 
retardation or hyperactivity, eating problems, major weight change, feelings of 
worthlessness, feelings of guilt, loss of energy, or suicidal ideation.  When at least 
five of these symptoms are present during at least two weeks, the majority of the 
day, and they interfere with everyday life functioning, a major depressive episode 
(MDD) can be diagnosed
8
.  According to the World Health Organization, MDD 
affects over 121 million people worldwide and will be the number one leading 
cause of disability in Western countries in 2020
9
. Nemesis-2, A large population 
based study conducted in the Netherlands showed that in 2009 642.800 people 
suffered from depression, which is reflected in a  one year prevalence rate of about 
6%
10
. Lifetime prevalence rates suggest that almost 19% of Dutch society will suffer 
from depression at one time point in their life.  Moreover, depression is often a 
recurrent disorder; approximately 30% of depressed patients experiences a new 





Depression and cardiovascular health 
In initially healthy people, depression has been associated with subsequent 
cardiovascular risk factors and even cardiovascular diseases
12, 13
. Also patients with 
already established CHD, and especially patients with myocardial infarction (MI), 
often experience depressive symptoms or a depression. Around 20% of all patients 
with CHD suffer from depression during the months following MI
14-16
. Another 20% 
report depressive symptoms that do not fulfil diagnostic criteria
17
. These rates are 
around three times higher than those in the general population
18
. Furthermore, 
suffering from MDD after a MI is associated with poor cardiac prognosis. Van Melle 
and colleagues
19
 and Meijer and colleagues
20
 have described the prognostic 
association between depression and coronary heart disease (CHD) in two meta-
analyses, reporting that depressed patients with CHD were at higher risk of all-
cause and cardiac mortality (OR: 1.6-2.7).  Many explanations have been proposed 
to explain this adverse association between depression and CHD, among which the 
hypothalamic-pituitary-adrenal (HPA) axis, autonomic nervous system functioning, 
adverse health behaviors (smoking, physical inactivity, alcohol consumption, and 
body mass index (BMI)), and inflammation
7
. In this thesis the focus will be on the 
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One of the physiological links that have been proposed to explain the adverse 
effects of depression on cardiovascular health is inflammation. Inflammation is a 
collective term describing the body’s response to infection or injury (also see Box 
1). It destroys or inactivates invaders and initializes tissue repair in the affected 
area. Inflammation plays an important role in the development and progression of 
atherosclerosis, a risk factor for coronary heart disease, by being involved in the 
development of plaques and destabilizing the plaque
21
.  If inflammation and 
depression are associated, it could be hypothesized that through inflammation 
people can become depressed and that this depression is a reflection of a 
subclinical cardiovascular risk factors which could eventually lead to CHD. This 
might explain why patients with CHD are at greater risk for new cardiac events or 
mortality. However, it could also be that depression causes inflammation and that 
through this mechanism depression affects the development and progression of 
atherosclerosis. This could explain why initially CHD free people and patients with 
CHD suffering from depression have an increased risk for (new) cardiovascular 
events. 
 
Depression and inflammation 
Various hypotheses have been proposed to give an explanation for the association 
between depression and inflammation, i.e. the macrophage theory
22,23
, the 
cytokine hypothesis of depression
24, 25
, the immune response system (IRS) model of 
depression
5
, and cytokine-induced sickness behaviour
26
. All these hypotheses share 
one common idea: pro-inflammatory cytokines are able to induce depression or 
depressive symptoms. In support of this hypothesis, research has shown that 
medical illnesses which are characterized by chronic inflammation are often 
accompanied by depression
24
. In addition, administration of pro-inflammatory 
cytokines in relation to cancer or multiple sclerosis treatment can cause depressive 
symptoms
27
. It also seems that inflammation is associated with neurotransmitter 
changes in several ways, e.g. a decrease in availability of tryptophan to the 
brain
27,28
, which can result in serotonin shortage and thus in depression. Finally, 
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there is evidence suggesting that inflammation can cause HPA-axis 
hyperactivity
27,28
, which is known to be associated with depression, and causes 
hypotrophy in the hypothalamus, hippocampus and pre-frontal cortex
29
. 
Epidemiological research has shown inconclusive results regarding the depression-
inflammation relationship, with results ranging from a negative association
30
 to 
positive associations. A meta-analysis conducted by Howren and colleagues 
however, showed that depression and inflammation were cross-sectionally 

















In contrast to the previous findings, there is some evidence suggesting that it is not 
inflammation that precedes depression but vice versa: depression precedes 
inflammation. Research in patients with CHD
31





 has shown that depression is associated with higher subsequent 
levels of inflammation, and not vice versa. Interestingly, recent studies have shown 
that especially recurrent episodes of depression are associated with subsequent 
inflammation
34,35
, suggesting that not those who suffer from a single episode of 
Box 1. White blood cells, Cytokines, Acute Phase Reactants, and Viruses 
White blood cells (also known as leukocytes) are cells of the immune system, involved in 
defending the body against pathogens and injury. White blood cells consist of different cell 
types: neutrophils, basophils, eosinophils, monocytes, and lymphocytes. The individual cells 
all have different functions in the immune system and are involved in the formation and 
progression of atherosclerosis.  
Cytokines are released by activated immune cells and are often referred to as messenger 
molecules that arrange cross-talk between different immune cells in order to precisely time 
the functions of the immune system. Cytokines that are determined and used in this thesis 
are interleukin 6 (IL-6) and tumor necrosis factor-α (TNF-α). IL-6 and TNF-α stimulate a 
systemic response to injury and infection and are both involved in the production of C-
reactive protein (CRP).  
Fibrinogen and C-reactive protein (CRP) are acute phase reactants, both produced in the 
liver under the influence of IL-6 and TNF-α. Fibrinogen and CRP levels are found to be higher 
in patients with CHD, with CRP levels being upregulated in the presence and progression of 
atherosclerosis and damage to the myocardium. Fibrinogen is involved in vessel damage 
repair. 
In this thesis data on presence of antibodies to herpes simplex virus 1 (HSV-1), epstein barr 
virus (EBV), and cytomegalovirus (CMV) were used. These viruses have been found in brain 
areas involved in depression and emotion processing, such as the hippocampus, the 
amygdala, and the orbitofrontal cortex. Furthermore, in response to a viral infection 
monocytes and macrophages secrete TNF-α and IL-6.  
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depression, but people who frequently experience depressive feelings are at risk 
for the adverse effects of depression on cardiac health.  
Finally, some research revealed an association between the presence of viruses and 
depression
36-38
 and this could be another possible way to look at depression and 
inflammation (also see Box 1). Presence of viruses are found in the limbic system, 
such as the hippocampus, amygdala, and orbitofrontal cortex
39,40
, areas which are 
involved in depression and emotion processing
41
.  Moreover, it has been shown 
that people with herpes simplex virus encephalitis present with volume reduction 
in the amygdala and hippocampus, as well as hypoperfusion in the pre-frontal 
cortex
42
. Furthermore, viral infections are also associated with an upregulation of 
systemic inflammation and endothelial adhesion molecules
38
. It could thus be 
argued that viruses promote depression by affecting important brain regions, with 
inflammation as a possible mediator or outcome of this depression.  
 
Somatic and cognitive symptoms of depression and inflammation 
As was explained in a previous paragraph, depression consists of a range of 
symptoms. These symptoms can be divided into two dimensions: somatic 
symptoms (sleeping problems, eating problems, weight change, and psychomotor 
problems) and cognitive symptoms (difficulty concentrating, loss of interest, 
depressed mood, suicidal thoughts, and feelings of guilt and worthlessness). Based 
on theories such as the sickness-behavior theory
26,43
, it could be hypothesized that 
these symptom dimensions are differentially associated with inflammation, with 
mainly somatic symptoms of depression being associated with inflammation and 
not cognitive symptoms of depression. The sickness-behavior theory states that in 
the presence of upregulated levels of inflammation, feelings of fatigue, reduced 
appetite, malaise, and decreased motor activity are often experienced
26,43
. These 
symptoms show similarities with somatic symptoms of depression
43
. More 
evidence for this theory comes from a study on the treatment with immunotherapy 
in patients with cancer. They found that patients who underwent IFN-α therapy 
developed neurovegetative symptoms of depression i.e. fatigue, abnormal sleep, 
abnormal appetite and psychomotor retardation (somatic symptoms). In a 
subgroup of patients, immunotherapy induced emotional/affective symptoms or 
cognitive symptoms of depression
44,45
.  Interestingly, when these patients were 
treated with an anti-depressant (Paroxetine) they were relieved from the cognitive 
symptoms, pain and disturbed mood, while the somatic symptoms were not 
effectively treated
44
. There is some epidemiological research underlining these 





. Elovainio and colleagues found in a large representative cohort that 
somatic and affective symptoms of the BDI were both associated with CRP in men 
and women. In men, the association between somatic symptoms of depression and 
CRP was robust for adjustment for demographics, health behaviors and cardiac risk 
factors but, in women the association diminished. This is further supported by 
Stewart and colleagues who reported that somatic symptoms were predictive of IL-
6, whereas cognitive symptoms were not
32
.  In contrast, there is also evidence that 
cognitive symptoms of depression are associated with inflammation
31,47,48
. Kupper 
and colleagues found in a sample of patients with heart failure that next to somatic 
symptoms of depression, cognitive symptoms were also associated with 
inflammation, both cross-sectionally and prospective
47
. Furthermore, Gimeno and 
colleagues reported that inflammation was associated with subsequent reports of 
cognitive symptoms of depression in healthy participants
48
. Thus far, results are 
conflicting which could be the result of the sample characteristics, such as age and 
disease status. However, examining the possible differential associations of somatic 
and cognitive symptoms of depression with inflammation may provide new insights 
in the depression-inflammation mechanism, possibly resulting in new treatment 
strategies. 
 
Health behaviors as an explanation for the association between depression and 
inflammation 
When the association between depression and inflammation is studied, the effects 
of (adverse) health behaviors on both depression and inflammation are 
complicating the interpretation of the result
49







, and body mass index (BMI)
56
 are found to 
be associated with both depression and inflammation.  Relationships between 
depression and health behaviors are often found to be bi-directional. For instance, 
a meta-analysis on the prospective association between obesity and depression 
revealed that obesity served as a risk factor depression, but also that depression 
predicted obesity
56
. Similar findings have been reported for physical activity and 
depression
50,51
, with physical activity being inversely associated with depressive 
symptoms, but also vice versa. Furthermore, health behaviors are found to be 
related to higher levels of inflammation. For instance, in overweight persons levels 
of CRP, IL-6, and TNF-α were higher than in normal weight controls, probably 
through the inflammatory properties of adipocytes [for an overview:
49
]. To further 
support this, research showed that by intervening in dietary intake and promoting 
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moderate physical exercise in somatic healthy people, levels of inflammation 
lowered
57
.  It could therefore be expected that health behaviors explain (a 
substantial part of) the depression-inflammation link and should be considered as a 
possible mediator of this relationship. This is supported by findings from various 
studies on the depression-inflammation relationship in healthy participants
32,35,58
. 
For instance, Hamer and colleagues found that physical inactivity, weight gain, 
alcohol consumption, and smoking were important mediators in the association 
between depressive symptoms and subsequent inflammation, with physical 
inactivity explaining the largest proportion
35
. Furthermore, Miller and colleagues
58
 
and Stewart and colleagues
32
 reported important effects of BMI on the depression-
inflammation link. Taken together, there is sufficient evidence that suggests a 
mediating role of health behaviors and when these variables are not properly 
assessed in depression-inflammation research, results might not represent true 
effects. Furthermore, if these (adverse) health behaviors indeed have a mediating 
role in the depression-inflammation relationship, targeting on promoting healthy 
behavior when treating people with depression or depressive symptoms, could 
possibly lead to more favorable health outcomes.  
 
General aim of this thesis 
The general aim of this thesis is to thoroughly investigate the association of 
depressive symptoms and depression with inflammation across the lifespan, 
especially focusing on the nature of the depression (clinical vs. subclinical, type of 
symptoms, and recurrence) and the directionality of the relation between 
depression and inflammation. Furthermore, in this thesis the influence of adverse 
health behaviors on the depression-inflammation relationship will be examined. 
Finally, the association between viral infections and depression will be evaluated. 
 
Studies used in this thesis 
For this thesis data from the following three prospective cohort studies were used: 
The Heart and Soul study 
Data from patients with stable CHD come from the Heart and Soul study. The Heart 
and Soul study is a study that started in 2000 and enrolled 1024 patients with 
stable coronary heart disease in the San Francisco Bay area. The main goal was to 
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determine why depression is associated with an increased risk of cardiovascular 
events in stable CHD outpatients. Administrative databases were used to identify 
potential participants with documented coronary artery disease at the Department 
of Veteran Affairs Medical Centers in San Francisco and Palo Alto (N = 438), the 
university medical center (university of California, San Francisco) (N = 346), and 9 
public health clinics in the Community Health Network of San Francisco (N = 240). 
Patients were eligible to participate if they had at least one of the following: history 
of myocardial infarction, angiographic evidence of at least 50% stenosis in one or 
more coronary vessels, prior evidence of exercise-induced ischemia by treadmill or 
nuclear testing, a history of coronary revascularization, or a diagnosis of coronary 
artery disease. 
 
The Netherlands Study of Depression and Anxiety (NESDA) 
The NESDA study is a prospective ongoing cohort study which investigates 1) the 
long-term course of depression and anxiety, 2) the clinical, psychosocial, biological 
and genetic  determinants of depression and anxiety on the long-term course, and 
3)  the expectations, evaluation, and provision of (mental) health care by patients 
and their association with the long-term course and consequences of depressive 
and anxiety disorders
59
. Participants were recruited from two population studies 
(ARIADNE N = 261; and NEMESIS N = 303), 65 general practices (N = 1610) and from 
mental health care institutes (807) in the area of Amsterdam, Leiden, and 
Groningen.  
 
Tracking Adolescents’ Individual Lives Survey (TRAILS)  
TRAILS is an ongoing cohort study from the north of the Netherlands aiming to 
contribute in a better understanding of the determinants of adolescents mental 
health and social development and the mechanisms underlying the association 
between these determinants and outcomes
60
. In short, selected municipalities in 
the north of The Netherlands were asked to provide names and addresses of all 
inhabitants born between October 1, 1989 (first two) and September 30, 1990 or 
October 1, 1990 and September 30, 1991 (last three). This yielded 3483 names. In 
addition, primary schools within these municipalities were asked to participate in 
TRAILS. The participation of schools was a prerequisite for eligible children and 
their parents to be approached for participation in TRAILS. Of all children 
20 Chapter 1 
 
  
approached for inclusion in the study (N = 3145), 2230 (76.0%) were enrolled in the 
study.   
 
Outline of this thesis 
This thesis consists of three parts and will discuss the association between 
depression and inflammation in a reversed chronological order. First, because 
depression and higher levels of inflammation are most prevalent in cardiac 
patients, the depression-inflammation link will be evaluated in a sample of older 
patients with stable CHD. In part 2, a community sample consisting of middle aged 
participants will be used to investigate if depression and inflammation are 
associated in people free of cardiac disease. Finally, in part 3 depression, 
inflammation, and viral infections will be discussed in an adolescent cohort to 
evaluate if the association is already present at a young age.  
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The first part will start with a meta-analysis of the cross-sectional unadjusted 
association between depression and inflammation in patients with acute and stable 
CHD (Chapter 2). In this chapter, data from carefully selected studies on the cross-
sectional association between depression and inflammation will be used to 
calculate a combined effect size. Chapter 3 and 4 will examine the bi-directional 
relationship between depressive symptoms and cytokines (Chapter 3) and white 
blood cell count (Chapter 4) in patients with stable CHD focusing on single episode 
and recurrent depressive symptoms. 
In the second part, chapter 5 will discuss the association between major depressive 
disorder and hsCRP, IL-6 and TNF-a in the NESDA cohort, considering depression 
characteristics as depression severity and onset and antidepressant medication 
use. Chapter 6 will then, also in the NESDA cohort evaluate if depressive symptoms 
and anxiety symptoms, and more specific, somatic and cognitive symptoms of 
depression and anxiety are differentially associated with IL-6, hsCRP and TNF-α. 
Part 3 will evaluate data from the TRAILS study; chapter 7 discusses the prospective 
association between trajectories of symptoms of depression over a 5 year follow-
up period and subsequent hsCRP using a latent class approach. Furthermore, 
differences between the trajectories of somatic and cognitive symptoms of 
depression will be analyzed. Chapter 8 will examine the association between virus 
infection and depression in the TRAILS sample and the possible effects of 
inflammation on this relationship. 
Chapter 9 will summarize and discuss the results from chapter 2 through chapter 8 
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Background: Around 20% of all CHD patients are suffering from major depression, 
representing a threefold increased risk compared to the general population. 
Inflammation has been suggested as a possible physiological link between 
depression and CHD. Several studies have investigated the association between 
depression and inflammation, with conflicting results. We therefore conducted a 
meta-analysis on the association between depression and inflammation in patients 
with acute and stable coronary heart disease.  
Methods: A literature search was performed in Medline, Embase and Psycinfo for 
studies reporting on the association between depression and inflammatory 
markers in patients with stable and acute coronary heart disease.  
Results: Only with respect to CRP and IL-6, we found sufficient numbers of studies 
to perform a meta-analysis. The pooled effect size combining data from 12 articles 
showed that the association between depression and CRP was d=0.30, p<0.001. For 
IL-6 the pooled effect size was d=0.005, p=0.92, based on 9 articles.  
Conclusions: We conclude that depression in patients with stable or acute 
coronary heart disease is associated with elevated levels of CRP, but not IL-6.  For 
CRP, the effect size was small to moderate. CRP could be a more general and stable 
reflection of different pro- and anti-inflammatory processes. This possibly explains 
why depression was associated with CRP, but not with IL-6.  
  




Patients with coronary heart disease (CHD), and in particular myocardial infarction 
(MI) frequently suffer from depression. Around 20% of all patients with CHD are 
found to be clinically depressed during the months following MI
1-3
, while another 
20% present with elevated depressive symptoms that do not fulfil diagnostic 
criteria
4
. These rates are around three times higher than those in the general 
population
5
. Depression in cardiac patients seems to negatively affect cardiac 
prognosis
6
. Meijer and colleagues concluded in a meta-analysis that post-MI 
depression is associated with a 2.7 time increased risk of cardiac mortality and a 
1.6 times increased risk of new cardiac events
7
.  
Several physiological mechanisms have been proposed to explain the association 
between depression and CHD outcomes, e.g., heart rate variability
8
, hypothalamus 




. Several markers of 
inflammation, such as C-reactive protein (CRP), interleukin(IL)-6 or tumor necrosis 
factor(TNF)-α have indeed been found to be higher in depressed people compared 
to people without depression
11,12
. Various researchers have proposed hypotheses 
in which the association between depression and inflammation is explained, i.e. the 
macrophage theory
13,14
, the cytokine hypothesis of depression
15,16
, the immune 
response system (IRS) model of depression
17
, and cytokine-induced sickness 
behaviour
18
. All hypotheses have in common that pro-inflammatory cytokines are 
able to induce depression or depressive symptoms. In addition, inflammation is 
proposed as a causal mechanism in the formation of atherosclerosis
19,20
, which in 
turn plays a role in the aetiology and progression of CHD
21-24
. Pai and colleagues 
reported that in initially cardiovascular disease free participants, CRP was 




Several studies have investigated the association between depression and 
inflammation in cardiac patients. Hekler and colleagues showed a positive 
association between depression and IL-6 in MI patients, but only at seven months 
after the MI had occurred. At two weeks post-MI there was no association
26
. A 
Chinese study among MI patients reported a positive association between 
depression and CRP. However, the drawback of that study is the small sample size 
(n=35)
27
.  In the largest study to date, Whooley and colleagues found no evidence 
for an association between depression and elevated levels of CRP, fibrinogen and 
IL-6 in stable CHD patients. Instead, they reported an association between lower 
32 Chapter 2 
 
 
levels of inflammation and depression
28
. Results of other individual studies on the 
association between depression and inflammation have been conflicting. 
A large-scale meta-analysis
29
 was undertaken by Howren and colleagues in which 
the association between depression and inflammatory markers was evaluated in 
several populations, including patients with heart disease. They concluded that in 
heart disease patients, depression is associated with increased levels of CRP (d = 
.18, p = .02) and IL-6 (d = .10, p = .05). However, there were some limitations to this 
specific subgroup analysis, namely that non-English studies were not included, 
patients with congestive heart failure
30-32
 (in which arguably inflammation plays a 
different role than in ACS patients) were included, as well as a study without a 
clinically overt patient sample consisting of subjects with atherosclerosis
33
.  
We therefore set out to conduct a meta-analysis of the association between 
depression and inflammatory markers in patients with CHD, to combine and 
summarize the results of individual studies and decrease the effects of their 
limitations. We hypothesized there would be a positive association between 




An exhaustive literature search was conducted in MEDLINE, EMBASE and 
PSYCHINFO between 1987 and November 2010 using pre-specified search terms 
and inclusion criteria. In addition, a search of the reference sections of eligible 
studies was performed.  
Study selection 
Three independent raters (H.D., A.M. and J.R) identified studies that met the 
inclusion criteria. Disagreements were resolved through group discussion.  
Studies were reviewed using the following criteria: 
- Studies should be observational or intervention trials containing a control 
group.  
- Patients should have either stable or acute coronary ischemia, specified as 
myocardial infarction (MI), severe angina, atypical chest pain or stenosis in 
coronary vessels at some point in their adult lives.  
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- Animal studies were excluded.  
- Depression had to be measured with a validated self-rating instrument or 
a structured interview designed to assess depression, or a psychiatric 
diagnosis had to be made by a psychiatrist based on established diagnostic 
criteria.  
- Patients had to be rated on a continuous scale of depression severity or 
divided into groups with different levels of depression.  
- Levels of inflammation had to be measured by one of the following 
inflammatory markers: IL-1ra, TNF-α, soluble receptors 1 and 2 of TNF- α 
(sTNFR1, sTNFR2), IL-6 or CRP.  
- A statistical measure of the association between depression and 
inflammation had to  be given, including the significance of the effect or a 
95% confidence interval.  
- Inflammatory markers and depression had to be measured within two 
weeks of each other.  
- Case studies, reviews, meta-analyses, editorials and commentaries were 
excluded. 
 
The authors of six studies were contacted for additional information (mean + SD) of 
CRP and IL-6 values for depressive symptoms group and no depressive symptoms 
group, number of participants per subgroup and the amount of time between 
blood collection and depressive symptoms assessment
26,34-38
. They provided us 
kindly with sufficient information to include their studies in our meta-analyses.  For 
two studies
27, 39
, information on percentage of male patients or depressed 
participants were not reported and could not be obtained from the authors. 
 
Quantitative data synthesis 
Data from all studies concerning the association between depression and 
inflammation were first converted into Cohen’s d effect sizes, and thereafter 
pooled using MIX version 1.7
40,41
. Assuming that the included studies consisted of 
different samples, pooled effect sizes were calculated using a random effects 
model
42
. Because not all the included studies adjust for covariates or adjust for 
various different covariates we did not conduct an adjusted meta-analysis. 
 





Figure 1 shows the flow diagram from the literature search. A total of 13 studies 





 and TNF-α was reported on in only two articles
34,36,43
, the 
association between depression and these markers were not evaluated any further 
and final analyses were restricted to CRP and IL-6.  
CRP and depressive symptoms 
We included 12 articles on the association between CRP and depression in cardiac 
patients
27,28,34-39,43-46
 (Table 1). These articles together comprised a total of 2429 
patients. All participants were diagnosed with either MI, unstable angina, stenosis, 
exercise-induced ischemia, or had undergone coronary revascularization, bypass 
surgery or coronary angioplasty. Time of the measurements after the cardiac event 
differed per study, varying from 1 week up to any point in their adult lives (Table 1).   
Depressive symptoms were measured with the BDI in nine studies
27,34,36,37,39,43,45,46
, 
but were analyzed in different ways. When studies used multiple questionnaires 
including the BDI, we chose to include data using the BDI, in order to increase 
comparability across the studies. Two studies did not use a cut-off score
39,46
, three 
studies used a cut-off score of 10
35,36,43
, and two studies used a cut-off score of 
14
27,45
. Shimbo and colleagues reported on associations at two different timelines, 
at baseline and after three months follow up
35
. Because all studies were cross-
sectional, we used the baseline depression measurement for analyses. Kronish and 
colleagues applied a cut-off score of ≤4 for no depressive symptoms and ≥10 for 
depressive symptoms
37
. Miller and colleagues divided the patients into three 
evenly sized groups having either no depression, mildly severe depression or 
moderately severe depression
34
. We merged the latter two groups for our analyses.  
Whooley and colleagues evaluated depression with the CDIS-IV and PHQ-9
28
. 
Bankier and colleagues used the SCID to assess major depressive disorder
44
 (table 
1). Von Känel and colleagues assessed depressive symptoms using the validated 
German version of the depression scale from the HADS
38
. They divided participants 
into ‘no depression’ (score range 0-7), ‘mild depression’ (score range 8-10), 
‘moderate depression’ (score range 11-14), and ‘severe depression’ (score range 
15-21). 
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Data from these participants with a score of ≥8 were merged in order to obtain two 
groups consisting participants with and participants without depressive symptoms. 
Out of 12 articles, five studies
27,34,35,44,45
 reported significant associations between 
CRP and depression. Three studies
39,43,46
 did not find an association, while one 
study
28
 reported a non-significant trend towards a negative association. Three 
additional studies did not report on the association between depression and CRP, 
but provided us with the data upon request, so we were able to calculate Cohen’s d 
for these studies
36-38
. Cohen’s d for each individual study is presented in figure 2.  
Data-analyses were conducted using a random effects model and showed a pooled 
Cohen’s d of 0.30 (95%CI=0.13-0.46, p<0.001) (Figure 2). In order to evaluate 
potential publication bias, the dissemination bias was calculated. The fail safe N 
was relatively high
a
 and a trim-and-fill plot revealed a fill of 1 study
b
. The Egger 
regression test was non-significant (p=0.79). All these results suggest that there is 
no publication bias. A fixed effect model showed similar results; Cohen’s d=0.30 
(95%CI=0.13-0.46, p<0.001). Heterogeneity tests revealed no heterogeneity
c
. 
Because the depression and inflammation measurements in the studies by 
Whooley and colleagues
28
 and Janszky and colleagues
39
 were administered a 
considerable amount of time after the cardiac event took place, we performed 
sensitivity analyses without their data. 
A random effects model showed that Cohen’s d increased to 0.42 (95%CI=0.20-
0.64, p<0.001). Fixed effect model analyses showed comparable results (Cohen’s 
d=0.41;95%CI=0.19-0.64, p<0.001). 
 
IL-6 and depressive symptoms 
A total of nine articles were included for analyses on depression and IL-6
26-28, 34, 36, 
38, 39, 43, 45
. These studies described data on 2080 participants with either MI or 
stable or acute CHD. Two articles did not report on number of depressed 
participants
26,39
, and one article
27
 did not explain the characteristics of the 
participants excluded from analysis. As the authors could not provide this 
information upon request, so for those we were not able to report on total 
                                                            
a
 16 unpublished studies would be needed to lower the p-value to a non-significant level. 
This is relatively high as it equals the number of studies included in the present analyses, 
suggesting that the effect size presented in this meta-analysis is a good reflection of the true 
effect size.   
b
 This did not decrease the effect size (Cohen’s d=0.30, 95%CI=0.13-0.46).  
c
 (Q=9.54, p =0.57 and I
2
=0%) 
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numbers of depressed participants and sex. Depression and inflammation level 
measurements took place varying from 2 weeks after the cardiac event up until 
anywhere in the participants’ adult life after a cardiac event (Table 2). One study 
assessed depression at baseline and seven months post discharge of the hospital
26
. 
In order to increase comparability with the remaining studies we used baseline 
data for the analyses. 
Six studies used the BDI to evaluate depressive symptoms
27, 34, 36, 39, 44, 45
, two of 
them applying a cut-off score of 14
27, 45
, and one using a cut-off score of 10
43
. One 
study used the continuous total BDI score
39
. One study provided us with additional 
data on IL-6 and  BDI using a cut-off of 10
36
.  Another study used a combination of 
the BDI and the 17-HRSD to divide patients into three groups
34
. One study used the 
validated German version of the HADS, and divided participants into ‘no 
depression’ (score range 0-7), ‘mild depression’ (score range 8-10), ‘moderate 
depression’ (score range 11-14), and ‘severe depression’ (score range 15-21)
38
. For 
more information on how we used the data from Miller and colleagues, and Von 
Känel and colleagues for analyses, see the section on CRP. Furthermore, two 
studies used either the CES-D
26
 or the CDIS-IV
28
 to assess depression (Table 2). 
None of the studies reported a significantly positive association between 
depression and IL-6. One study reported a significantly negative association 
between IL-6 and depression
28
, and another study  found a non-significant negative 
association
26
. Five studies found no association at all




did not report on the association between depressive symptoms and IL-6, but the 
authors provided us with additional data upon request, so we were able to 
calculate Cohen’s d for these studies. Cohen’s d was calculated for each study 
separately (figure 3) and then merged into a pooled effect size. A random effects 
model revealed an overall effect size of 0.04 (95%CI=-0.11-0.18, p=0.59).  To 
analyze a potential publication bias, a trim-and-fill plot was used. This did not lead 
to a major difference in effect size, and the association remained non-significant 
(Cohen’s d=0.06, 95%CI=-0.08-0.19). The fail-safe N test was low, but the effect size 
for depressive symptoms and IL-6 already was non-significant
d
.  Similar results 
were obtained using a fixed effect model (Cohen’s d=0.04; 95%CI=-0.11-0.18, 
p=0.59). 
With respect to IL-6, we performed sensitivity analyses without the data from 
studies in which depression and inflammation status was assessed a relatively long  
                                                            
d
 The fail-safe-N test indicates how many unpublished non-significant studies are needed to 
lower the pooled effect size to non-significant (37). 
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time after a cardiac event
28, 39
. The effect size did not change and remained non-
significant (d=0.05; 95%CI=-0.14-0.24,p=0.61).  
 
Discussion 
This meta-analysis revealed that depression and CRP are significantly associated in 
patients with stable or acute CHD, with a moderate effect size of 0.30. IL-6 was not 
associated with depression. Sensitivity analyses showed that the association 
between depression and CRP was stronger when CRP and depression were 
measured more closely after the cardiac event (Cohen’s d = 0.42 vs. Cohen’s d = 
0.30).  
The finding that CRP was associated with depressive symptoms, whereas IL-6 was 
not could be explained by the differences in their physiological background. CRP is 
produced in the liver during a systemic response to infection or injury under the 
influence of IL-6, but also in the presence of other inflammatory markers such as 
TNF-α, IL-1 and activated macrophages
47
. CRP secretion is thus elicited by various 
inflammatory cytokines and it could therefore be argued that CRP is a more general 
and overall reflection of systemic low grade inflammation than IL-6. 
Our results are partly in contrast with those found in a recent meta-analysis on 
depression and inflammation conducted by Howren and colleagues
29
. In their 
meta-analysis, the association between depression and inflammation, i.e. CRP, IL-1 
and IL-6 was evaluated in different samples i.e. clinical samples (amongst others 
coronary artery disease [CAD]-related diseases) and community samples. Their 
reported overall effect sizes for the link between depression with CRP and IL-6 
among patients with CHD-related diseases were rather small but statistically 
significant, 0.18 (p = 0.02) and 0.10 (p = 0.05) respectively. We did not find a 
significant association between depression and IL-6. In concordance with our 
present findings, Howren and colleagues found stronger associations between 
depression and CRP than with IL-6
29
. Still, their results differ from our current 
results, for which multiple explanations are suitable. First, Howren and colleagues 





. We excluded these studies because heart failure is a more 
advanced stage than CHD, often a consequence of MI, with a different underlying 
pathophysiology. Similarly, adding patients with atherosclerosis makes the overall 
results for persons with clinically overt CHD debatable. Atherosclerosis is an 
inflammatory process and mainly involved in the aetiology of CHD. However, it 
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does not always lead to CHD and is less severe than CHD. We identified six 
corresponding studies for both CRP and IL-6
26,28,34,35,39,43
 and we additionally 
included five papers that were published after January 2008 (when Howren and 
colleagues finished their search)
37,38,44,46
 of which one was a duplicate
45
 of a study
50
 
included by Howren and colleagues. Finally, we included one non-English paper
27
 
and one paper of which the authors for additional information upon our request
36
. 
Both studies were not identified by Howren and colleagues
29
. By excluding papers 
on heart failure and atherosclerosis, and including six more papers concerning CHD, 
we believe that the results found in the present study are more representative of 
CHD patients specifically.  The fact that Howren and colleagues found less 
pronounced associations for hsCRP may be due to the fact that they included a 
wider range of both less severe and more severe cardiovascular pathology in which 
the role of inflammation may also be different. 
There is a variety of evidence and hypotheses explaining the association between 
pro-inflammatory markers and depression in heart disease. First, there may be a 
common genetic factor affecting both inflammation and depression, as was found 
for depressive symptoms and IL-6, suggesting that depressive symptoms and 




A second explanation could be that inflammation induces sickness behaviour, 
which is closely related to or may induce symptoms of depression. It has previously 
been found that pro-inflammatory cytokines are able to cause depressive 
disorder
18
. A possible biological explanation for this is immune-to-brain 
communication, in which pro-inflammatory cytokines affect the brain causing  
feelings of depression
18
. Other sources of evidence for this theory come from 
immunotherapy in cancer patients in whom IFN-α therapy was associated with the 
development of neurovegetative symptoms of depression such as fatigue, 
abnormal sleep, abnormal appetite and psychomotor retardation. In a subgroup of 
patients, immunotherapy induced emotional/affective symptoms or cognitive 
symptoms of depression
52, 53
.  Treating these cancer patients with an 
antidepressant (Paroxetine) relieved cognitive symptoms, pain and disturbed 
mood, while neurovegetative symptoms remained present
52
. In patients with heart 
disease, such a distinction is rarely made. Elovainio and colleagues found in a large 
representative cohort that somatic and affective symptoms of the BDI were both 
associated with CRP in men and women
54
. In men, somatic symptoms of depression 
and CRP remained associated after adjustment for demographics, health behaviors 
and cardiac risk factors but, in women, the association was not robust for full 
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adjustment. Moreover, previous studies reported that somatic symptoms were 
more predictive than cognitive symptoms of new cardiac events
55, 56
, and 
associated with disease severity and all-cause mortality
57
 in patients with cardiac 
disease.  This could first of all explain the inconclusive results found in this area of 
research, but also how somatic symptoms can contribute to worse cardiac 
prognosis. Therefore, we emphasize that in future research on the association 
between depression and inflammation a distinction should be made between the 
different types of symptoms of depression.  
In contrast to the sickness behaviour theory, there is some preliminary evidence 
suggesting that it is not inflammation causing depressive symptoms, but depressive 
symptoms causing inflammation
58,59
. Stewart and colleagues found that in an 
otherwise healthy sample, depression was prospectively associated with levels IL-6, 
but not vice versa. Another prospective cohort study found that significant 
depressive symptoms were associated with subsequent levels of CRP and IL-6 after 
5 years of follow-up, whereas again, CRP and IL-6 were not prospectively associated 
with significant depressive symptoms. In addition to this, it appeared that 
subsequent levels of inflammation were highest in the participants who reported 
depressive symptoms at two or more time points, suggesting that particularly 
recurrent chronic depressive symptoms are associated with inflammation
58
. 
Furthermore, the prospective association between depressive symptoms and 
inflammation was mainly explained by health behaviors, e.g., smoking, physical 
inactivity, and obesity. Taken together, this suggests that future research should 
not only be prospective, but should also evaluate whether a depression is chronic, 
recurrent or experienced during a single episode. Finally, it would be informative to 
adjust the association between inflammation and depression for the confounding 
or mediating effects of health behaviors. 
 
Study limitations 
In this meta-analysis we only reviewed articles using cross-sectional data. There is 
hardly any longitudinal data on the association between depression and pro-
inflammatory cytokines, though this is necessary to be able to investigate causality 
in this association. Furthermore, we were not able to adjust for potential 
confounding or mediating effect of health behaviors and demographic variables 
which could possibly influence the effect sizes.  
 




We conclude that in patients with CHD, CRP appears to be moderately associated 
with depression, whereas IL-6 does not. CRP is an end product of an inflammatory 
sequence, produced in the presence of IL-6, but also in the presence of for instance 
TNF-α. CRP could therefore be a more general and stable reflection of different 
pro- and anti-inflammatory processes. This could explain why depression was 
associated with CRP, but not with IL-6. We emphasize that in future research more 
attention needs to be given to the relation between individual symptoms of 
depression and inflammation. In addition, prospective research needs to be 
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Background: Depression has been associated with inflammation in patients with 
coronary heart disease. However, it is uncertain whether depressive symptoms 
lead to inflammation or vice versa. 
 
Methods: The authors evaluated 667 outpatients with established coronary heart 
disease from the Heart and Soul Study. Depressive symptoms were assessed 
annually with the 9-item Patient Health Questionnaire. Participants were 
categorized as having no significant depressive symptoms (score below 10 at all 
interviews), depressive symptoms (score of 10 or higher) at one interview, or 
depressive symptoms at two or more interviews. At baseline and 5-year follow-up, 
fasting blood samples were collected to measure three inflammatory biomarkers: 
fibrinogen, interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hsCRP). 
 
Results: Of the 667 participants, 443 had no depressive symptoms, 86 had 
depressive symptoms at one assessment, and 138 had depressive symptoms at two 
or more annual assessments. Across the three groups, greater depressive 
symptoms were associated with higher subsequent log-transformed levels of IL-6 
and hsCRP, and the association with higher fibrinogen levels approached 
significance. Baseline inflammation did not predict subsequent depressive 
symptoms. The association of depressive symptoms with subsequent inflammation 
levels was eliminated after adjustment for health behaviors associated with 
depression - physical inactivity, smoking, and higher body mass index. 
 
Conclusions: Depressive symptoms predicted higher IL-6 and hsCRP levels among 
outpatients with coronary heart disease, but higher inflammation levels did not 
predict subsequent depressive symptoms. The association between depressive 
symptoms and inflammation was no longer significant after adjustment for health 
behaviors, which suggests these behaviors may mediate depressive effects. 
 
  




Depression is common in patients with cardiac disease, with prevalence rates 
nearly three times as high as in the general population
1, 2
. Depression is also 
associated with worse cardiac prognosis and greater mortality
3
. However, there is 
still considerable debate regarding how 
depression might contribute to a worse cardiac prognosis or mortality
4
. 
Inflammation is associated with both cardiac disease and depression and is a 
plausible physiological link between depression and coronary heart disease. Cross-
sectional studies have demonstrated an association between depression and 
inflammation in healthy subjects
5-9
 and in cardiac patients
10, 11
, but relatively little is 
known about the directionality of the association (i.e., whether depression causes 
inflammation or vice versa). Previous studies on the direction of the association 
between depression and inflammation have yielded conflicting results. Stewart and 
colleagues
12
  examined the directionality of the relationship in otherwise healthy 
subjects. They found that depressive symptoms as measured with the Beck 
Depression Inventory-II significantly predicted interleukin-6 (IL-6) levels after 6 
years of follow-up, whereas inflammation did not predict depressive symptom 
scores at follow-up, suggesting that depression leads to an up-regulation of IL-6 
levels. However, the Whitehall study came to the opposite conclusion. In over 
3,000 British civil servants followed for almost 12 years, Gimeno and colleagues 
found that inflammation preceded depressive symptoms, whereas depressive 
symptoms did not predict inflammation
13
. To our knowledge, whether depressive 
symptoms are the cause or result of inflammation has not been evaluated in 
patients with cardiovascular disease. We therefore set out to evaluate the 
prospective association between depressive symptoms and inflammation using 
repeated measurements of depressive symptoms and inflammation in patients 
with stable coronary heart disease. We evaluated whether depressive symptoms 
(assessed annually for 6 years) were associated with higher levels of subsequent 
inflammation and vice versa. In addition, we evaluated the role of health behaviors 




Design and participants  
The Heart and Soul Study is an ongoing prospective cohort study of psychosocial 
factors and health outcomes in patients with coronary heart disease. The methods 
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have been described previously
14
. Briefly, 1,024 outpatients with stable coronary 
heart disease were recruited and completed a baseline examination between 
September 2000 and December 2002. Following the baseline examination, patients 
received annual telephone calls for assessment of depressive symptoms. Between 
September 2005 and December 2007, 667 participants (80% of the 829 survivors) 
completed a 5-year follow-up examination that included measures of 
inflammation. The study protocol was approved by the appropriate institutional 
review boards, and all participants provided written informed consent.  
 
Depressive symptoms  
Depressive symptoms were assessed annually for 6 years by using the 9-item 
Patient Health Questionnaire, a self-report instrument that measures the 
frequency of depressive symptoms corresponding to the nine DSM-IV criteria for 
depression
15
. A paper-and-pencil version of the questionnaire was administered at 
the baseline examination (year 0), telephone versions were administered after 1, 2, 
3, and 4 years of follow-up, and a paper-and-pencil version was again administered 
after 5 years of follow-up. Of the 667 participants who were examined after 5 
years, 640 completed five or more interviews, 23 (3.4%) completed four interviews, 
three (0.4%) completed three interviews, and one (0.1%) completed two 
interviews.  
At each assessment, participants were asked to indicate the frequency of 
experiencing each depressive symptom during the last two weeks. Each of the nine 
symptoms was scored as 0 (not at all), 1 (on several days), 2 (more than half the 
days), or 3 (nearly every day), with total scores ranging from 0 to 27
16
. The Patient 
Health Questionnaire has demonstrated excellent validity when compared with a 
mental health interview for depression in patients with coronary heart disease
17, 18
. 
Telephone and in-person assessments yield similar results
19
. As a summary 
measure of depressive symptoms, we calculated the mean score for each 
participant as the sum of the annual questionnaire scores divided by the number of 
interviews completed. We also created a categorical variable by defining 
“depressive symptoms” as a score of 10 or higher on the Patient Health 
Questionnaire. We used this to group the participants into three categories: 
depressive symptoms at two or more interviews, depressive symptoms at one 
interview, or no depressive symptoms. We chose these groups for analysis because 
further divisions would have yielded too few participants in each category.  
Depressive symptoms, health behaviors & inflammation 55 
 
 
Inflammatory biomarkers  
Fasting blood samples were obtained at baseline and after 5 years of follow-up. 
Levels of high-sensitivity C-reactive protein (hsCRP), IL-6, and fibrinogen were 
determined from plasma and serum samples. The laboratory technicians were 
blinded to the depression status of the participants.  
A highly sensitive CRP assay was performed with a BN II nephelometer (Dade-
Behring, Newark, Del.). Interassay coefficients of variation were 1.66%–5.32%. IL-6 
was measured by using the Millipore Milliplex Map kit (Millipore, Billerica, Mass.), 
with interassay coefficients of variation from 6.3% to 11.6%. Concentrations of 
serum fibrinogen were determined by the Clauss assay with coefficients of 
variation less than 3%. We log-transformed the hsCRP and IL-6 levels because they 
were not normally distributed, and we verified that the transformation resulted in 
normal distributions. We also created three separate dichotomous variables for IL-
6, hsCRP, and fibrinogen, defining a priori a high level as one in the highest quartile. 
For IL-6 a high level was defined as above 5.40 pg/ml, for hsCRP a high level was 
one above 3.48 mg/liter, and a high fibrinogen level was defined as above 420 
mg/dl.  
 
Other assessments  
We recorded self-reported age, gender, ethnicity, education, and medical history at 
baseline and at the 5-year examination. In addition, we assessed health behaviors 
known to be associated with inflammation, such as smoking status, physical 
activity, and body mass index (BMI)
20,21
. To assess physical activity, we asked, 
“Which of the following statements best describes how physically active you have 
been during the last month, that is, done activities such as 15–20 minutes of brisk 
walking, swimming, general conditioning, or recreational sports?” Participants 
responded by choosing one of the six following categories: not at all active, a little 
active (one or two times per month), fairly active (three or four times per month), 
quite active (one or two times per week), very active (three or four times per 
week), or extremely active (five or more times per week). Self-report of physical 
activity has been shown to be valid, accurate, and reliable
22-25
. Physical inactivity 
was defined as “not at all active” or “a little active.” Height and weight were 
measured and used to calculate BMI (weight in kilograms divided by the square of 
height in meters). Alcohol consumption was measured with the AUDIT-C self report 
questionnaire
26
. Left ventricular ejection fraction was assessed by means of two-
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dimensional echocardiography. High density lipoprotein (HDL) levels were 
measured from fasting venous blood samples, and non-HDL cholesterol was 
calculated as total cholesterol minus HDL cholesterol. Participants were asked to 
bring all of their medication bottles to the study appointment, and all current 
medications were recorded. Medications were categorized by using Epocrates Rx 
(Epocrates, San Mateo, Calif.).  
 
Statistical analyses  
The goal of this study was to determine the directionality of the depression-
inflammation relationship. We used general linear models to compare mean levels 
of each marker across three groups: participants who were not depressed at any 
interview (having a score below 10 on the Patient Health Questionnaire at all 
interviews), participants who reported depressive symptoms (a score of 10 or 
higher) at one interview, and those who reported significant depressive symptoms 
at two or more interviews. To further evaluate the association between Patient 
Health Questionnaire score and levels of inflammation, we used multivariate 
analysis of variance adjusted for other patient characteristics associated with 
depressive symptoms (age, gender, education, race, aspirin use, history of 
diabetes, myocardial infarction, and congestive heart failure) and health behaviors 
(physical activity, smoking, and BMI). In addition, we evaluated change in 
inflammation over 5 years across the three subgroups. Finally, we used multivariate 
analysis of covariance (MANCOVA) to evaluate the effect of depressive symptoms 
on all three measures of inflammation as a single dependent variable, adjusted for 
the baseline level of inflammation. We also used MANCOVA to evaluate the effect 
of inflammation on subsequent depressive symptoms (as a single dependent 
variable), adjusted for the baseline level of depressive symptoms. Analyses were 
performed by using SAS 9.2 (SAS Institute, Cary, N.C.).  
 
Results 
Characteristics of participants  
As compared with the 162 patients who were alive and did not complete the 5-year 
follow-up examination, the 667 participants who completed the exam were older 
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(mean age=66 years, SD=10, versus mean=64 years, SD=12; t=–2.09, df=827, 
p=0.04) and had fewer baseline depressive symptoms as indicated by scores on the 
Patient Health Questionnaire (mean=4.75, SD=5.26, versus mean=6.77, SD=5.84; 
t=4.29, df=827, p<0.01). Participants who completed the exam also had lower log-
transformed baseline hsCRP levels (mg/liter) than those who did not complete the 
5-year exam (mean=0.57, SD=1.29, versus mean=0.85, SD=1.32; t=2.48, df=795, 
p=0.01). Baseline levels of IL-6 and fibrinogen were similar in the patients who did 
and did not complete the 5-year examination (p>0.10 in both cases).  
Of the 667 participants who completed the 5-year examination, 138 (21%) had 
depressive symptoms (i.e., a score of 10 or higher on the Patient Health 
Questionnaire) at two or more interviews, 86 (13%) had depressive symptoms at 
one interview, and 443 (66%) had no significant depressive symptoms (a score less 
than 10 on the Patient Health Questionnaire at all interviews). As compared to 
participants without significant depressive symptoms, those with depressive 
symptoms at any interview were younger and less likely to be male, to be white, or 
to have graduated from high school (Table 1). They were more likely to have a 
history of diabetes, myocardial infarction, or congestive heart failure and had 
higher BMI values. Participants with depressive symptoms were less likely to use 
aspirin and more likely to smoke and to be physically inactive. The three groups 
had similar levels of hypertension, cardiac disease severity, cardiac risk factors, and 
use of cardioprotective medications.  
 
Presence of depressive symptoms as predictor of subsequent inflammation  
MANCOVAs evaluating the effect of depression on subsequent inflammation 
showed that depressive symptoms predicted subsequent inflammation in an 
unadjusted analysis (F=2.56, df=6, 1304, p=0.02) and after adjustment for age, 
gender, education, race, history of diabetes, myocardial infarction, congestive 
heart failure, aspirin use, and baseline levels of inflammatory markers (F=2.15, 
df=6, 1182, p<0.05). This association was no longer significant after adjustment for 
health behaviors (F=1.74, df=6, 1128, p=0.11). Across the three groups, greater 
depressive symptoms were associated with higher subsequent log-transformed 
levels of IL-6 and hsCRP, and they were nonsignificantly associated with higher 
levels of fibrinogen (Table 2). Depressive symptoms remained associated with 
subsequent levels of IL-6 and were marginally related to levels of fibrinogen but 
were not associated with hsCRP, after adjustment for age, gender, education, race,  
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history of diabetes, myocardial infarction, congestive heart failure, and aspirin use 
(Table 2). However, after further adjustment for health behaviors (physical activity, 
smoking, and BMI), depressive symptoms were no longer associated with any 
inflammation index. When we evaluated the multivariable-adjusted mean change 
in levels of inflammatory markers, depressive symptoms did not predict statistically 
significant changes in IL-6, hsCRP, or fibrinogen (Table 3). When we analyzed 
depressive symptoms as a continuous variable, the average score on the Patient 
Health Questionnaire across the annual assessments predicted subsequent log-
transformed levels of IL-6 (β=0.102, p=0.009) and hsCRP (β=0.121, p=0.002) but not 
the level of fibrinogen (β=0.058, p=0.13)Again, this association was no longer 
significant after adjustment for health behaviors (log IL-6: β=0.038, p=0.36; hsCRP: 
β=0.018, p=0.67; fibrinogen: β=0.018, p=0.68). When inflammation was evaluated 
as a dichotomous variable, the proportions of participants with levels of 
inflammatory markers in the highest quartile were 22% to 24% in those without 
depression at any interview, 23% to 28% in those with depressive symptoms at one 
interview, and 30% to 35% in patients with depressive symptoms at two or more 
interviews (Figure 1).  
 
Inflammation as predictor of subsequent depressive symptoms  
MANCOVAs revealed no effect of inflammation on subsequent depression in 
unadjusted analyses (F=1.37, df=6, 1256, p=0.22) or after adjustment for age, 
gender, education, race, history of diabetes, myocardial infarction, congestive 
heart failure, aspirin use, and baseline depressive symptoms (F=0.65, df=6, 1224, 
p=0.69). In addition, baseline levels of inflammatory markers were not associated 
with subsequent depressive symptoms (Table 4). As compared with participants 
who had significant depressive symptoms at two or more annual assessments, 
those without depressive symptoms had similar baseline levels of log IL-6, log 
hsCRP, and fibrinogen.  
 
Discussion  
The aim of this study was to examine the directionality of the depression-
inflammation relationship in a group of patients with stable coronary heart disease. 
The rate of depressive symptoms was consistent with the rate in a previous study
27
:  
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Figure 1. Proportion of patients with coronary heart disease who had high levels of 












IL6 >5.4 pg/ml* CRP >3.5 mg/L** Fibrinogen >420 mg/dL
No depressive symptoms at any interview (n=443)
Depressive symptoms at one interview (n=86)
Depressive symptoms at 2 or more interviews (n=138)
 a
Inflammatory markers were measured at baseline and at the 5-year follow-up assessment. 
Depressive symptoms were assessed with the nine-item Patient Health Questionnaire at 
baseline and annually for the next 5 years.
 
*
Significant difference among groups IL-6 (χ
2
=8.45, df=2, p=0.01). 
**
Significant difference among groups hsCRP (χ
2
=5.96, df=2, p=0.05). 
 
34% of the participants had a score of 10 or higher on the Patient Health 
Questionnaire at one or more time points. We found that depressive symptoms 
were associated with higher subsequent levels of inflammation, whereas baseline 
levels of inflammation did not predict subsequent depressive symptoms. The 
association between depressive symptoms and subsequent inflammation was 
eliminated after adjustment for health behaviors associated with inflammation—
physical inactivity, smoking, and higher BMI. 
Taken together, these findings suggest that depression may lead to inflammation 
through poor health behaviors, but inflammation does not lead to depression in 
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patients with coronary heart disease. There have been only a few studies regarding 
the directionality of the depression-inflammation relationship, and to our 
knowledge, this is the first study on this subject in a cardiac population. We also 
believe this to be the first study evaluating the association of depressive symptoms 
over time with subsequent inflammation. Our results extend the findings of 
Stewart and colleagues
12
, who found that depression predicted high levels of IL-6, 
whereas high levels of IL-6 did not predict depression. However, our results differ 
from those of Gimeno and colleagues, who reported that CRP and IL-6 levels were 
predictive of subsequent depressive symptoms, but not vice versa, in the Whitehall 
II study
13
. One possible explanation for this discrepancy is that the Whitehall II 
study used a different measure of depressive symptoms. Their assessment was 
based on four items from the General Health Questionnaire (thinking of yourself as 
a worthless person, feeling that life is entirely hopeless, feeling that life is not 
worth living, and finding times when you could not do anything because your 
nerves were too bad) and did not include measures of sleep, appetite, 
concentration, energy, suicidal thoughts, or depressed mood. In contrast, we 
administered the Patient Health Questionnaire, which was specifically designed to 
assess the nine symptoms of depression. Another possible explanation for the 
difference in findings is the difference between study populations. The association 
between depressive symptoms and inflammation in the general population may 
differ from the relationship in patients with established coronary heart disease.  
It is interesting that our results show that depressive symptoms predicted high 
levels of hsCRP and IL-6 but not fibrinogen. A possible explanation could be that 
hsCRP and IL-6 are more specific for the underlying inflammation process in stable 
patients with coronary heart disease. In contrast to hsCRP and IL-6, which are both 
markers of inflammation, fibrinogen not only reflects inflammation but also is a 
blood coagulation factor
28
, which could explain why we did not find a prospective 
association between depression and fibrinogen.  
We also found that patients with depressive symptoms at two or more interviews 
had higher levels of inflammation at follow-up than patients with depressive 
symptoms at one interview. To the extent that depressive symptoms at two or 
more interviews represented chronic or recurrent depression, our findings suggest 
that persistent depression may have greater effects on inflammation than a single 
episode of depression. Consistent with these findings are the results reported by 
Hamer and colleagues
29
, who found that in a group of 3,609 aging subjects, 
participants with depressive symptoms at two timepoints had higher levels of CRP 
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and fibrinogen than those with depressive symptoms at one timepoint. In addition, 
Kaptein and colleagues
30
 showed that patients with chronic depressive symptoms 
following myocardial infarction were at higher risk for having new cardiovascular 
events than those whose depressive symptoms resolved. Taken together, the 
findings suggest that the duration of depressive symptoms may influence cardiac 
health.  
The prospective association of depression with inflammation was no longer 
significant after adjustment for health behaviors (physical inactivity, BMI, and 
smoking). Although our results cannot determine the direction of the association 
between depression and health behaviors, this raises the possibility that helping 
depressed cardiac patients improve these behaviors could potentially reduce 
inflammation. These findings are further supported by a longitudinal community-
based study in which Matthews and colleagues
31
 investigated the directionality of 
the depression-inflammation relationship among 1,781 premenopausal and early 
perimenopausal women who were free of cardiac disease at baseline. They found 
that depression, as measured with the Center for Epidemiologic Studies Depression 
Scale, was associated with higher CRP levels at follow-up. Similar to our results, this 
association was no longer significant after adjustment for a range of covariates 
including health behaviors. In addition, Hamer and colleagues
29
 found that weight 
change, waist circumference, current smoking, alcohol use, and especially physical 
activity were significant mediators in the depression-inflammation relationship. 
Finally, Dod and colleagues
32
 showed in a group of nonsmoking patients with stable 
coronary heart disease that a combination of intensive exercise and dietary 
changes significantly lowered levels of IL-6 and CRP, suggesting that physical 
inactivity and BMI may influence inflammation levels.  
Several strengths can be attributed to this study. First, the annual assessments of 
depressive symptoms and medical health status presented us with the opportunity 
to assess the direction of this association. In addition, biological and behavioral 
mediators were carefully assessed at baseline and after 5 years of follow-up. 
However, there are also several limitations. This study focused on outpatients with 
stable coronary heart disease. Our results may therefore not apply to healthy 
participants or to patients with acute coronary syndromes. Furthermore, the study 
group mostly consisted of older men, so these results may not be generalizable to 
either women or younger men. Finally, 20% (162 of 829) of the surviving 
participants did not complete the 5-year follow-up examination. However, these 
participants were younger and had worse depression scores than those who 
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completed the examination, so including them would probably have strengthened 
the association between depression and inflammation.  
In conclusion, we found no evidence of a bidirectional relationship between 
depression and inflammation. Depression was prospectively associated with IL-6 
and hsCRP, but not vice versa. This prospective association was no longer 
significant after adjustment for physical inactivity, BMI, and smoking. These 
findings raise the possibility that helping depressed cardiac patients improve health 
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Background: Depression has been associated with elevated white blood cell (WBC) 
count –indicative of systemic inflammation- in cross-sectional studies, but no 
longitudinal study has evaluated whether depressive symptoms predict subsequent 
WBC count or vice versa. We sought to evaluate the bidirectional association 
between depressive symptoms and WBC count in patients with coronary heart 
disease (CHD).  
Methods: Depressive symptoms were assessed at baseline and annually during 5 
consecutive years of follow-up in 667 outpatients with stable CHD from the Heart 
and Soul Study. The presence of significant depressive symptoms was defined as a 
score of ≥10 on the Patient Health Questionnaire (PHQ-9) at one or more 
assessments. WBC count was measured in blood samples collected at baseline and 
after 5 years of follow-up.  
Results: Of the 667 participants, 443 (66%) had no depressive symptoms (PHQ-9 
<10), 86 (13%) had depressive symptoms (PHQ-9≥10) at 1 assessment, and 138 
(21%) had depressive symptoms at 2 or more annual assessments. Across the three 
groups, participants with recurrent depressive symptoms had higher WBC levels 
after 5 years of follow-up (p<.001). This relationship was essentially unchanged 
after adjustment for demographics, traditional cardiovascular risk factors, cardiac 
disease severity, inflammatory cytokine levels, and health behaviors (p=.009). 
Baseline WBC count was not associated with subsequent depressive symptoms (p = 
.18).  
Conclusions: Depressive symptoms independently predicted higher subsequent 
WBC count in patients with stable CHD, but baseline WBC count did not predict 
subsequent depressive symptoms. These findings support a unidirectional 
relationship in which depression is a risk-factor for inflammation. 
 




Depression is common in patients with cardiac disease, with prevalence rates 
nearly three times as high as in the general population
1-3
. Depression has been 
found to have a negative influence on cardiac prognosis
4
, but the mechanisms of 
this association remain unclear
5
. Several studies have evaluated the association 
between depression and inflammatory markers, including interleukin (IL)6, high 
sensitive C-reactive protein (hsCRP), tumor necrosis factor (TNF)-α and its soluble 
receptors
6-9
. A meta-analysis reported small to moderate cross-sectional 
associations between depression and these cytokines, both in healthy subjects and 
in cardiac patients
10
. Currently, several prospective studies have been performed
8, 
11-14
.  In a recent study in heart failure patients, depressive symptoms at baseline 
were associated with current and future inflammation after one year follow-up, 
independent of classic cardiovascular risk factors, disease severity and adverse 
health behaviors
8
. In line with this, we found in a previous study that depressive 
symptoms predicted subsequent levels of hsCRP and IL-6 over a period of five years 
in patients with coronary heart disease (CHD), but not vice versa
11
. However, the 
association of depressive symptoms with subsequent inflammation in this study 
was mainly explained by the presence of adverse health behaviors
11
.    
A relatively understudied inflammatory marker in the depression-inflammation 
relationship is white blood cell (WBC) count. Like cytokines, WBCs (or leukocytes) 
are part of the immune system, but they come from different sources. WBCs are 
formed in the bone marrow from hematopoietic stem cells, whereas cytokines are 
protein messengers produced by mature immune cells, e.g. monocytes
15
. Although 
WBCs and cytokines have different physiological roles in the immune response, 
they interact in a complex way. Thus, it is unclear whether depression increases the 
production of WBC in the bone marrow, if it increases the secretion of 
inflammatory cytokines from mature WBC in peripheral vessels, or both.  
Earlier research has shown that higher WBC count is associated with increased risk 
of atherosclerosis
16,17
 and cardiac mortality
18, 19
. Furthermore, decreased 
lymphocyte percentage is associated acute coronary syndrome and major adverse 
cardiac events in CHD patients
20
, whereas higher monocyte and neutrophil count 
are associated with a history of cardiovascular disease
21
. Moreover, several studies 
have reported a cross-sectional association between high WBC count and 
depression
22-24
 in participants free of cardiac disease. In contrast, depressive 
symptoms have also been found to be associated with lower levels of WBC count in 
elderly patients with acute hospital admission
25
. Whether depressive symptoms are 
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associated with WBCs, and if so, whether depressive symptoms predict higher WBC 
levels or vice versa, has not been evaluated in patients with cardiovascular disease. 
We therefore sought to investigate the temporal, bidirectional associations 
between depressive symptoms and WBC count, while adjusting for socio-
demographic factors, traditional risk factors, cardiac disease severity, and 
inflammatory cytokines.     
 
Methods  
Design and Participants 
The Heart and Soul study is an ongoing prospective cohort study of psychosocial 
factors and health outcomes in patients with CHD. Methods have been described 
previously
26
. Briefly, 1024 outpatients with stable CHD were recruited and 
completed a baseline examination between September 2000 and December 2002. 
Following the baseline examination, patients received annual telephone calls for 
assessment of depressive symptoms. Between September 2005 and December 
2007, 667 participants (80% of the 829 survivors) completed a 5-year follow-up 
examination that included measures of inflammation. The study protocol was 
approved by the appropriate institutional review boards, and the study was 
performed in accordance with the standards of the most recent Helsinki 
declaration (2008). All participants provided written informed consent. 
 
Depressive symptoms 
Depressive symptoms were assessed at baseline and annually during 5 consecutive  
years using the 9-item Patient Health Questionnaire (PHQ-9), a self-report 
instrument that measures the frequency of depressive symptoms corresponding to 
the 9 Diagnostic and Statistical Manual-IV criteria for depression
27
. A paper and 
pencil version of the PHQ was administered at the baseline examination (year 0), 
telephone versions were administered annually (after 1, 2, 3 and 4 years of follow-
up), and a paper and pencil version was again administered after the 5
th
 year of 
follow-up (year 5).  Of the 667 participants who completed the 5-year examination, 
640 (96%) completed 5 or more interviews, 23 (3.4%) completed 4 interviews, 3 
(0.4%) completed 3 interviews, and 1 (0.1%) completed 2 interviews.  
Depressive symptoms & white blood cell count     75 
 
 
At each assessment, participants were asked to indicate the frequency of 
experiencing each depressive symptom during the last two weeks. Every one of the 
9 symptoms was scored as not at all (0), several days (1), more than half the days 
(2), or nearly every day (3), with a total score range of 0 to 27
28
. The PHQ-9 has 
demonstrated excellent validity when compared with a mental health interview for 
depression in patients with CHD
29,30
. Telephone and in-person PHQ assessments 
yield similar results
31
. As a summary measure of mean depressive symptoms over 
time, we calculated the sum of the annual PHQ scores divided by the number of 
interviews completed. We also created a 3-category variable indicating significant 
depressive symptoms at (1) 2 or more interviews (N = 138), (2) at one interview (N 
= 86), or (3) at no interview (N = 443), where significant depressive symptoms were 
defined as PHQ ≥ 10. We chose these groups for analysis because further divisions 
would have yielded too few participants in each category. 
 
White blood cell count 
Fasting blood samples were obtained at baseline and after 5 years of follow-up to 
determine WBC count. Prior to each study appointment, participants completed an 
overnight fast except for taking their regularly prescribed medications. A 21G 
butterfly needle was inserted intravenously in the forearm, and blood samples 
were drawn into EDTA tubes. WBC was measured using a Beckman Coulter 
analyzer (Beckman Coulter, Inc., California). Laboratory technicians were blinded to 
the depression status of the participants.  
 
Cytokines 
 Cytokines, amongst others, are involved in attracting white blood cells to the 
arterial wall and thus affects levels of WBC count
32
. In order to determine if 
depressive symptoms are associated with WBC count independent of cytokines, 
analyses were adjusted for IL-6, hsCRP and fibrinogen.  High sensitivity C-reactive 
protein (hsCRP), interleukin-6 (IL-6) and fibrinogen were determined from plasma 
and serum samples at baseline and after 5 years of follow-up. Laboratory 
technicians were blinded to the depression status of the participants. 
High-sensitivity C-reactive protein (hsCRP) levels were measured using the Roche 
Integra assay or the Beckman Extended Range assay. Interassay coefficients of 
variation were 1.66-5.32%. IL-6 was determined using the Millipore Milliplex Map 
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kit, with interassay coefficients of variation from 6.3 to 11.6%. Concentrations of 
serum fibrinogen were determined by the Clauss assay with coefficients of 
variation <3%.  
The individual inflammatory markers showed small, but significant correlations 
with WBC at baseline (loghsCRP: r = .28, p <.0001; IL-6: r = .26, p <.0001; fibrinogen: 
r = .26, p <.0001) and at the year 5 assessment (loghsCRP: r = .26, p  <.0001; IL-6: r = 
.25, p <.0001; fibrinogen: r = .26, p <.0001). 
 
Cardiac disease severity 
The presence of congestive heart failure (CHF) and myocardial infarction (MI) were 
determined by self-report at baseline. Year 5 CHF and MI were determined by 
reviewing medical records. CHF was defined as hospitalization for a clinical 
syndrome involving at least 2 of the following: paroxysmal nocturnal dyspnea, 
orthopnea, elevated jugular venous pressure, pulmonary rates, third heart sound, 
and cardiomegaly or pulmonary edema on chest radiography. These signs and 
symptoms must have represented a clear change from the usual clinical status
33
. 
MI was defined using standard criteria
34
. High-density lipoprotein levels were 
measured from fasting venous blood samples, and non-HDL cholesterol was 
calculated as total minus HDL cholesterol. To assess cardiac function, left 
ventricular ejection fraction was measured using 2-dimensional echocardiography. 
To assess exercise capacity, participants underwent a symptom-limited, graded 
exercise treadmill test based on a standard Bruce protocol with continuous 12-lead 
ECG monitoring. Participants were asked to exercise until they experienced 
dyspnea, symptom-limited fatigue, chest discomfort or ECG changes suggestive of 
ischemia
34
. Exercise capacity was calculated as the total number of metabolic 
equivalents (1MET = 3.5 mL of oxygen uptake/kg/min) achieved at peak exercise.  
 
Health behaviors 
At baseline and at the 5-year examination, smoking status was determined by self-
report. Participants were asked to rate their level of physical activity by answering 
the following question: “Which of the following statements best describes how 
physically active you have been during the last month, that is, done activities such 
as 15-20 minutes of brisk walking, swimming, general conditioning, or recreational 
sports?” Self-report of physical activity has been shown to be a valid, accurate and 





. Physical inactivity was defined as not at all or a little active vs. fairly, 
quite, very or extremely active. Height and weight were measured, and used to 
calculate body mass index (BMI: weight in kilograms divided by the square of 
height in meters). Waist and hip circumference were measured to calculate waist-
hip ratio. The correlation between BMI and waist and hip circumference was low 
(baseline: r = .35, p <.0001; year 5: r = .34, p <.0001). Alcohol consumption was 




Other patient characteristics 
Age, gender, ethnicity, education, and medical history were determined by self-
report both at baseline and at the 5-year examination. Participants were asked to 
bring all of their medication bottles to the study appointment, and all current 
medications were recorded. Medications were categorized using Epocrates Rx (San 
Mateo, California) and were defined as a dichotomous variable (yes or no).  
 
Statistical analyses 
We compared characteristics of participants across the three depression subgroups 
using ANOVA for continuous variables and chi-square tests for dichotomous 
variables. General Linear Models were used to compare mean levels of WBC at 
baseline and at 5-year follow-up across the three subgroups of participants. We 
used standardized βs to determine the magnitude of the associations between 
depressive symptoms (entered as both a continuous and categorical variable) and 
WBC count. To further evaluate the association between depressive symptoms and 
WBC count, we used multivariate analysis of variance and created four models 
which additionally adjusted for (model 1) other patient characteristics associated 
with depressive symptoms i.e. age, gender, education, race, aspirin and 
corticosteroid use, history of diabetes, myocardial infarction (MI), congestive heart 
failure (CHF), and exercise capacity, (model 2) model 1 + log hsCRP, log IL-6, and 
fibrinogen, (model 3) model 2 + BMI and waist hip ratio, and (model 4) model 3 + 
physical activity and smoking. BMI and waist hip ratio were analysed in a separate 
model to investigate the effects of overweight or abdominal fat separately from 
physical activity and smoking.  For analyses of baseline WBC levels, we adjusted for 
characteristics measured at the baseline exam. For analyses of 5-year WBC levels, 
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we adjusted for characteristics measured at the 5-year exam. Analyses were 
performed using SAS 9.2. 
 
Results  
Characteristics of participants 
Of the 667 participants with stable coronary heart disease who completed both the 
baseline and 5-year examinations, 443 (66%) reported no significant depressive 
symptoms (PHQ-9 score ≥ 10) at any of the annual interviews, 86 (13%) had 
depressive symptoms at one interview only, and 138 participants (21%) had 
depressive symptoms at 2 or more annual interviews. As compared with the 162 
participants who were alive after 5-years of follow-up but did not complete the 
follow-up examination, the 667 participants who completed the exam were older 
(mean age 66 ± 10 vs. 64 ± 12; p = 0.04) and had lower baseline depressive 
symptom scores (mean PHQ-9 scores 4.75 ± 5.26 vs. 6.77 ± 5.84; p < 0.001) as well 
as lower baseline WBC count (6.36 ± 1.76 vs. 6.95 ± 2.21; p <.001).  
Baseline patient characteristics stratified by depression are presented in Table 1. As 
compared to participants without depressive symptoms, those with depressive 
symptoms were younger and less likely to be male, white, or high school educated. 
They were more likely to have a history of diabetes, MI, and CHF. They had worse 
exercise capacity and higher BMI. Greater depressive symptoms were associated 
with lower hemoglobin (Hb) levels. Participants with significant depressive 
symptoms were less likely to use aspirin and more likely to smoke and to be 
physically inactive. The 3 groups had similar levels of hypertension, left ventricular 
ejection fraction, cholesterol levels, use of cardio-protective medications, and 
waist-hip ratio. 
 
Depressive symptoms as a predictor of white blood cell count 
Patients who reported significant recurrent depressive symptoms at 2 or more 
interviews had higher WBC count levels after 5 years of follow-up (p < 0.001) than 
patients who were not depressed or reported depressive symptoms at 1 interview 
only. Recurrent depressive symptoms remained significantly associated with 5-year 
levels of WBC count after adjustment for age, gender, education, race, history of 
diabetes, MI, CHF, cardiac disease severity, aspirin use, and baseline WBC count    
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(p = .001) (Table 2). Adjustment for cytokine levels (hsCRP, IL-6 and fibrinogen) 
attenuated but did not eliminate this association (p = .002) (Table 2). Even after 
adjusting for health behaviors (BMI, waist to hip ratio, physical activity, and 
smoking), significant depressive symptoms remained associated with higher WBC 
count (p = .009) (Table 2). When we analyzed both depressive symptoms and WBC 
as continuous variables, the average of PHQ scores across the annual assessments 
predicted subsequent levels of WBC count in both unadjusted and fully adjusted 
models (Table 3).  
 
White blood cell count as a predictor of subsequent depressive symptoms  
We found no evidence that baseline WBC was associated with subsequent 
depressive symptoms. Baseline WBC count was not significantly different in 
participants who reported significant depressive symptoms at 2 or more interviews 
compared to participants without significant depressive symptoms or those who 
reported significant depressive symptoms at 1 interview only (Table 4). 
 
Discussion 
The current study showed that participants with recurrent depressive symptoms 
had higher WBC levels after 5 years of follow-up than those without or only a single 
episode of depressive symptoms. These findings persisted after adjustment for 
demographic characteristics, baseline WBC count, cardiac disease severity, 
medication use, and health behaviors. In contrast, baseline WBC levels were not 
predictive of subsequent depressive symptoms. These findings suggest that 
depressive symptoms are predictive of inflammation, but inflammation does 
predict depressive symptoms in patients with coronary heart disease. 
The potential mechanisms by which depressive symptoms lead to elevations in 
WBC are unclear. In our previous study, we found that poor health behaviors 
explained the major part of the prospective relation between depressive symptoms 
and subsequent elevated levels of inflammatory cytokines
11
. In contrast, the 
present study demonstrated that depressive symptoms remained strongly 
predictive of WBC even after adjustment for hsCRP, IL-6, fibrinogen, BMI, waist hip 
ratio, physical activity and smoking. One possible explanation could be that our 
findings are a reflection of chronic stress or stress-related physiological 
dysfunction. The results showed that mainly the recurrent depressive symptoms  















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
   

















































































   
   
   
   
   
   





























































   
   
   
   
  
   
   
   
   
   
























































   
   
   
   
   
   
   























































   
   
   
   
   
   
   
   
 




  Table 3. Summary Patient Health Questionnaire 9 score (average score from 6  
annual assessments) as a predictor of white blood cell count at follow up exam. 
 Standardized β p value 
Unadjusted 0.17 <.001 
Model 1 0.11 0.002 
Model 2 0.11 0.001 
Model 3 0.10 0.003 
Model 4 0.09 0.007 
Model 1: adjusted for 5-year age, gender, education, race, history of diabetes, 
myocardial infarction, heart failure, use of aspirin, corticosteroids, exercise 
capacity, and baseline white blood cell count. 
Model 2: adjusted for model 1 variables+ year 5 log high sensitive C-reactive 
protein, log interleukin 6, and fibrinogen.  
Model 3: adjusted for model 2 variables + year 5 body mass index and waist hip 
ratio. 
Model 4:  adjusted for model 3 variables + year 5 physical activity and smoking. 
 
 
were associated with higher WBC count. It could be hypothesized that these 
recurrent symptoms of depression are a reflection of chronic stress, which may 
stimulate hematopoietic stem cells in the bone marrow to produce WBCs
15
. In this 
cascade, the role of health behaviors might be less important than in the more 
downstream depression-cytokine relationship. Another possible explanation could 
be that it in the case of chronic depression or stress, hypercortisolemia is present, 
as well as reduced vagal activity, both which may lead to higher inflammation, 
possibly manifested by more WBC
41
.  
We found that the group of participants reporting depressive symptoms at two or 
more interviews had the highest levels of WBC count. Two retrospective studies 
conducted by Liukkonen and colleagues, and by Hamer and colleagues respectively 
reported that patients with recurrent depressive symptoms had higher levels of 
inflammation
42, 43
 whereas Matthews and colleagues
44
 showed that in a group of 
middle-aged women, those who experienced recurrent depressive symptoms had 
greater progression of coronary artery calcification. Taken together, these findings 
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suggest that recurrent or chronic depressive symptoms may be more strongly 
associated with inflammation (and adverse health outcomes) than a single episode 
of depressive symptoms. 
The results of this study could be an important step in better understanding the 
underlying physiological mechanisms of the adverse cardiac effects of depression. 
Previous studies have shown that WBC is a predictor of new cardiac events or even 
cardiac death
21
. As reported in this study, WBC count is higher in patients with 
cardiac disease reporting recurrent significant depressive symptoms. It could be 
hypothesized that depression might contribute to new cardiac events through a 
higher WBC count.  However, it should be kept in mind that more factors could play 
a role in the relationship between depression and CHD. For instance, Kop and 
colleagues
24
 found in a healthy sample that autonomic nervous system (ANS) 
dysfunction and elevated levels of inflammatory cytokines explained a small 
proportion of the mortality risk associated with depression. We have also found
26
 
that inflammatory cytokines explain a small part of the association between 
depressive symptoms and adverse cardiovascular events, but most of this 
association is explained by poor health behaviors. Future research is needed to 
provide more insight on the mechanisms underlying the depression-CHD 
relationship. Repeated assessments of depression, as well as simultaneous 
assessment of multiple physiological mechanisms and health behaviors, could help 
better define the joint pathophysiology.  
The results of the current study should also be viewed in light of several limitations. 
The present study determined  the complete WBC count, even though there are 
five different white blood cell types included in the complete count, all having  
different functions
15
. For example, monocytes can activate cytokine production in 
the blood or differentiate into macrophages which on their turn activate cytokine 
production
15
. To elaborate further on this, especially monocytes are associated 
with atherogenesis
45 
and in addition to this, monocyte and neutrophil counts were 
associated with a history of cardiac disease, whereas lymphocyte, eosinophil, and 
basophil counts were not
21
. Furthermore, psychological factors, such as emotional 
support and perceived control have been found to be associated with % monocytes 
in acute coronary syndrome patients, but not total WBC count
46
. Differentiating 
between these cells could possibly provide more insight into the relationship 
between depression, inflammation and cardiac disease. In addition, WBC count 
was only determined at baseline and at the year 5 follow-up. Furthermore, this 
study focuses on outpatients with stable coronary heart disease. Our results may 
therefore not apply to healthy participants or to patients with acute coronary 
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syndromes. Also, the study population mostly consists of older men, so therefore 
might not be generalized to either women or younger men. Finally, 20% (162/829) 
of surviving participants did not complete the 5-year follow up examination. These 
participants had worse depression scores than those who completed the 
examination, so including them would probably have strengthened the association 
between depression and WBC levels. 
In conclusion, we found that recurrent depressive symptoms were prospectively 
associated with subsequent levels of WBC count, independent of inflammatory 
cytokine levels and health behaviors or baseline WBC. These findings raise the 
possibility that WBC count is a potential mediator in the relationship between 
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Background: Growing evidence suggests that immune dysregulation may be 
involved in depressive disorders, but the exact nature of this association is still 
unknown and may be restricted to specific subgroups.  
Methods: This study examines the association between depressive disorders, 
depression characteristics and antidepressant medication with inflammation in a 
large cohort of controls and depressed persons, taking possible sex differences and 
important confounding factors into account. Persons (18-65 years) with a current 
(N=1132) or remitted (N=789) depressive disorder according to DSM-IV criteria and 
healthy controls (N=494) were selected from the Netherlands Study of Depression 
and Anxiety. Assessments included clinical characteristics (severity, duration, age of 
onset), use of antidepressant medication and inflammatory markers (C-reactive 
protein [CRP], interleukin-6 [IL-6], tumor-necrosis factor-alpha [TNF-α]).  
Results: After adjustment for sociodemographics, currently depressed men, but not 
women, had higher levels of CRP (1.33 versus 0.92 mg/l, p<.001, Cohen’s d=0.32) 
and IL-6 (0.88 versus 0.72 pg/ml, p=.01, Cohen’s d=0.23) than non-depressed peers. 
Associations reduced after considering lifestyle and disease indicators - especially 
body mass index - but remained significant for CRP. After full adjustment, highest 
inflammation levels were found in depressed men with an older age of depression 
onset (CRP, TNF-α). Furthermore, inflammation was increased in men using 
serotonin-norepinephrine reuptake inhibitors (CRP, IL-6) and in men and women 
using tri- or tetracyclic antidepressants (CRP), but decreased among men using 
selective serotonin reuptake inhibitors (IL-6).  
Conclusion: In conclusion, elevated inflammation was confirmed in depressed men, 
especially those with a late-onset depression. Specific antidepressants may differ in 
their effects on inflammation. 
  




Depression is a complex heterogeneous disorder, which may need a similarly 
heterogeneous offer of treatment possibilities. Currently available antidepressant 
medications largely target monoamine pathways, but treatment of depression is 
only effective in about a third to a half of patients
1, 2
. Identification of additional 
pathophysiological pathways involved in depression (subtypes) is needed to guide 
the development of alternative treatment strategies. Increasing interest has been 
directed to immune dysregulation in depression. Recently, two meta-analyses have 
shown that inflammatory marker levels such as C-reactive protein (CRP), 
interleukin (IL)-6 and tumor-necrosis factor (TNF)-α are increased in depressed 
persons compared with non-depressed subjects
3, 4
. 
Although the results of these meta-analyses are promising, the evidence for 
immune dysregulation in depression is not conclusive. A substantial portion of 
studies included in these meta-analyses did not adequately adjust for possible 
confounding factors. The association between depression and inflammation 
appeared much smaller, although still present, in studies adjusting for body mass 
index
4
. The effect estimate after a more complete adjustment (including several 
lifestyle and disease factors) is not entirely clear. Also, most of the larger studies 
examining depression and inflammation have used depressive symptoms 
questionnaires instead of assessing psychiatric diagnoses by means of clinical 
interviews. The former is much more prone to confounding by somatic health as a 
person can score high on these questionnaires based on having many physical 
complaints. Furthermore, a large part of previous studies has been conducted 
within older populations. More studies within younger age samples are therefore 
needed. 
Next to these general limitations, meta-analyses have found very large 
heterogeneity across studies
3, 4
. It is plausible that immune dysregulation is not 
generally present in depression, but restricted to particular subgroups of depressed 
persons. Several factors that could influence the depression-inflammation 
relationship need further investigation to help delineate the depressed person with 
immune dysregulation. This is important to give direction to whom new treatment 
strategies could be targeted. 
First, sex differences might exist, but results are thus far inconsistent. Stronger, 
weaker or similar effects have been found for women compared with men for 
different inflammatory markers
4, 5
. Inflammation levels fluctuate throughout 
female life according to hormonal changes due to phase of menstrual cycle, use of 
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hormonal contraceptives, menopause and use of estrogens
6-8
, which might 
influence the relationship between depression and inflammation. 
Second, it is largely unknown whether specific depression characteristics indicate 
immune dysregulation
3
. In line with a dose-response assumption, more severe 
and/or more chronic disorders can be hypothesized to show the most 
inflammation
9, 10
. In addition, late-onset depression has been associated with 




. As immune 
dysregulation is critically involved in vascular disease
13
, it can be hypothesized that 
increased inflammation is specifically present in those with late-onset depressive 
disorders. 
Third, antidepressant medication might influence inflammation levels and this 
effect might differ across type of medication. As summarized by Miller et al.
14
, 
several studies showed that antidepressant treatment, mainly selective serotonin 
reuptake inhibitors, was associated with decreases in inflammatory markers. In 
contrast, recent results of two large studies suggest that use of antidepressants, 
mainly tricyclic antidepressants, is associated with elevated inflammation levels
15
. 
To address the issues raised above, the first aim of the present study was to 
examine the association between diagnosed depressive disorders and 
inflammatory markers (CRP, IL-6, TNF-α), using a large and relatively young cohort 
of depressed persons and controls, taking possible sex differences and important 
confounding factors into account. The second aim was to investigate whether 
specific depression characteristics (severity, duration, age of onset) could further 
delineate the depressed person with increased inflammation. Lastly, possible 
effects of (specific types of) antidepressant medication on inflammation levels 
were examined. 
 
Subjects and methods 
Sample 
The Netherlands Study of Depression and Anxiety (NESDA) is an ongoing cohort 
study designed to investigate the long-term course and consequences of 
depressive and anxiety disorders. Participants were 18 to 65 years old at baseline 
assessment in 2004-2007 and were recruited from the community (19%), general 
practice (54%) and secondary mental health care (27%). A total of 2981 persons 
were included, consisting of persons with a current or past depressive and/or 
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anxiety disorder and healthy controls. A detailed description of the NESDA study 
design and sampling procedures can be found elsewhere
16
. The research protocol 
was approved by the Ethical Committee of participating universities and after 
complete description of the study all respondents provided written informed 
consent. 
During the baseline interview, presence of depressive disorder (major depressive 
disorder, dysthymia) and anxiety disorder (social phobia, generalized anxiety 
disorder, panic disorder, agoraphobia) was established using the Composite 
Interview Diagnostic Instrument (CIDI) according to DSM-IV criteria
17
. The CIDI is a 
highly reliable and valid instrument for assessing depressive and anxiety disorders
18
 
and was administered by specially trained research staff. In addition, the severity of 
depression was measured in all participants using the 28-item self-report Inventory 
of Depressive Symptoms (IDS)
19
. For the present analyses we selected persons with 
a current (i.e. past 6 months; N=1158) or remitted (lifetime, but not current; 
N=815) depressive disorder and healthy controls without any lifetime depressive or 
anxiety disorder and an IDS score below 14 (N=506). Of these 2479 persons, 64 
were excluded due to missing information on inflammatory markers, leaving a 
sample of 2415 persons for the present study. Persons with missing data on 
inflammation did not differ from included persons in terms of sex, age, years of 
education and depressive disorder status. 
 
Inflammatory markers 
Markers of inflammation were assessed at the baseline NESDA measurement and 
included CRP, IL-6 and TNF-α. Fasting blood samples of NESDA participants were 
obtained in the morning around 8 am and kept frozen at -70°C. CRP and IL-6 were 
assayed at the Clinical Chemistry department of the VU University Medical Center. 
High-sensitivity plasma levels of CRP were measured in duplicate by an in-house 
ELISA based on purified protein and polyclonal anti-CRP antibodies (Dako, Glostrup, 
Denmark). Intra- and inter-assay coefficients of variation were 5% and 10%, 
respectively. Plasma IL-6 levels were measured in duplicate by a high sensitivity 
enzyme-linked immunosorbent assay (PeliKine Compact
TM
 ELISA, Sanquin, 
Amsterdam, The Netherlands). Intra- and inter-assay coefficients of variation were 
8% and 12%, respectively. Plasma TNF-α levels were assayed in duplicate at Good 
Biomarker Science, Leiden, The Netherlands, using a high-sensitivity solid phase 
ELISA (Quantikine® HS Human TNF-α Immunoassay, R&D systems Inc, Minneapolis, 
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Next to CIDI depressive disorder diagnosis, depression characteristics included 
depressive symptoms severity as measured by the IDS, and depressive symptoms 
duration, using the Life Chart method
20
, in which a detailed account of the 
presence of depressive symptoms during the past four years was assessed. From 
this, the percent of time patients reported depressive symptoms was computed. 
Additionally, age of depression onset was derived from the CIDI interview. 
 
Antidepressant medication 
Medication use was assessed based on drug container inspection of all drugs used 
in the past month and classified according to the World Health Organization 
Anatomical Therapeutic Chemical classification
21
. Antidepressant medication was 
only considered when taken on a regular basis (at least 50% of the time) and 
included selective serotonin reuptake inhibitors (SSRI; N06AB), serotonin-
norepinephrine reuptake inhibitors (SNRI; N06AX16, N06AX21), tricyclic 
antidepressants (TCA; N06AA) and tetracyclic antidepressants (TeCA; N06AX03, 
N06AX05, N06AX11). 
Covariates 
Sociodemographic characteristics included age, sex, and years of education. As 
lifestyle characteristics can be associated with both depression and inflammation, 
smoking status (never, former, current; assessed by self-report), alcohol intake (<1, 
1-14 [women] / 1-21 [men], >14 [women] >21 [men] drinks per week; based on 
general guidelines that are used in health organizations in the Netherlands
22
 and as 
used in other studies
23
), body mass index (BMI; weight in kilograms divided by 
height in meters squared) and physical activity (measured with the International 
Physical Activity Questionnaire
24
 in MET-minutes [ratio of energy expenditure 
during activity compared to rest times the number of minutes performing the 
activity] per week) were assessed. In addition, several disease related covariates 
were taken into account including presence of cardiovascular disease (assessed by 
self-report supported by appropriate medication use [see
25
 for detailed 
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description]), presence of diabetes (fasting plasma glucose level ≥7.0 mmol/l or use 
of anti-diabetic medication [A10]), and the number of other self-reported chronic 
diseases for which persons received treatment (including lung disease, 
osteoarthritis or rheumatic disease, cancer, ulcer, intestinal problem, liver disease, 
epilepsy and thyroid gland disease). As suggested by Howren et al.
4
, to control for 
possible medication effects, we assessed statin use (C10AA, C10B) and use of 
systemic anti-inflammatory medication (M01A, M01B, A07EB, A07EC). In women, 
we additionally assessed use of sex hormones (self-reported use of oral 
contraceptives or ATC code G03), self-reported menstrual cycle phase (menstrual 
[0-3 days since start last menstruation], follicular [4-13 days], luteal [14-32 days]), 
and self-reported postmenopausal status (yes/no). 
 
Statistical analyses 
All analyses were conducted using SPSS version 15.0 statistical software. 
Differences in baseline characteristics across sex were tested for statistical 
significance using chi-square statistics for dichotomous and categorical variables 
and independent t-tests and Mann-Whitney U tests for normally and non-normally 
distributed continuous variables. For subsequent analyses, CRP, IL-6 and TNF-α 
were ln-transformed to normalize distributions and presented back-transformed. 
Associations between baseline characteristics and inflammatory markers were 
tested using independent samples t-tests for dichotomous variables, one-way 
analyses of variance for categorical variables and Pearson’s correlations for 
continuous variables. 
Associations between depressive disorders and inflammatory markers were 
examined using analyses of (co)variance and (adjusted) means across depression 
groups (no, remitted, current) were presented. To take the effects of important 
confounding factors into account, three different models were tested: unadjusted, 
adjusted for sociodemographics (sex, age, education), and additionally adjusted for 
lifestyle and disease (smoking status, alcohol intake, BMI, physical activity, 
cardiovascular disease, diabetes, number of other chronic diseases, statins, anti-
inflammatory medication). To investigate possible sex differences, we tested for 
sex-interactions by including a sex*depressive disorder interaction term. When 
present, analyses were repeated sex-stratified. For significant associations, Cohen’s 
d was calculated in order to assess effect size. To test whether specific depression 
characteristics were related to elevated inflammation levels, we performed linear 
regression analyses for each depression characteristic within the sample of persons 
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with a current depressive disorder. Sex-interactions were again tested and if 
present, shown sex-stratified. To investigate possible effects of antidepressant 
medications, adjusted means of inflammation levels across different medication 
groups were calculated using analyses of covariance and presented sex-stratified in 
case sex-interaction was present. 
 
Results 
Baseline characteristics of the total sample and for men (N=800) and women 
(N=1615) separately are shown in Table 1. Women were younger, less often 
smokers, more often non-drinkers, had a lower BMI, less often cardiovascular 
disease or diabetes, and less often used statins than men. In addition, women had 
higher levels of CRP, but lower levels of IL-6 and TNF-α than men. In men, older 
age, less education, smoking, heavy or non-drinking, higher BMI, lower physical 
activity, cardiovascular disease, diabetes, higher number of other chronic diseases, 
statin use and use of anti-inflammatory medication were associated with higher 
levels of at least one of the inflammatory markers (data not shown). In women, 
similar associations were found, except for smoking, heavy drinking, and physical 
activity. The Pearson’s correlations between inflammatory markers were modest, 
likely reflecting only partial biological overlap, and somewhat higher in men (CRP-
IL-6: r=.40; CRP-TNF-α: r=.22; IL-6-TNF-α: r=.17) than in women (CRP-IL-6: r=.28; 
CRP-TNF-α: r=.10; IL-6-TNF-α: r=.09). 
Table 2 shows (adjusted) mean inflammation levels across depression groups 
(controls, remitted, current depressive disorder) based on analyses of (co)variance. 
In the total sample, current depressive disorders were significantly associated with 
higher levels of CRP and IL-6 in the unadjusted model. After additional adjustment 
for sociodemographics, lifestyle and disease factors, these associations 
disappeared. No associations were found for TNF-α. For current depressive 
disorders, sex-interactions were found for CRP (p-interaction<.001) and IL-6 (p-
interaction=.009), but not TNF-α (p-interaction=.99). 
In men, after adjustment for sociodemographics, a current depressive disorder was 
associated with higher CRP levels (1.33 versus 0.92 mg/l, p<.001, Cohen’s d=0.32) 
and IL-6 levels (0.88 versus 0.72 pg/ml, p=.01, Cohen’s d=0.23). Even after full 
adjustment for lifestyle and disease factors, men with a current depressive disorder 
had higher CRP levels compared with controls (1.29 versus 1.04 mg/l, p=.02, 
Cohen’s d=0.21), and marginally higher IL-6 levels (0.87 versus 0.76 pg/ml, p=.10, 
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Cohen’s d=0.15). No associations with TNF-α were found in men. Overall, BMI 
weakened the associations most, followed by number of other chronic diseases. 
Smoking status, alcohol use and physical activity weakened associations slightly 
further. Adjustment for cardiovascular disease, diabetes, statins, and anti-
inflammatory medication hardly affected associations. 
In women, depressive disorders were not associated with inflammatory markers 
before or after adjustment. Although sex hormone use, menstrual cycle phase and 
postmenopausal status were strongly associated with inflammation levels, 
additional adjustment for these factors did not change the results for women. Also, 
there were no significant postmenopausal status*depression interactions in the 
associations with inflammation levels (all p>.40) suggesting that associations 
between depression and inflammation appeared absent in both premenopausal 
(N=1076) and postmenopausal women (N=539).   
To investigate whether specific depression characteristics (severity, duration, age 
of onset) were associated with higher inflammation levels, linear regression 
analyses were performed within the subgroup of currently depressed persons 
(N=1132; Table 3). Women with more severe depressive symptoms had higher 
levels of TNF-α. No associations were found for duration of depressive symptoms. 
Men with an older age of depression onset had higher levels of CRP and TNF-α than 
those with a younger age of depression onset.  
Lastly, the association between antidepressant medication use and inflammation 
levels was examined. To incorporate possible differences in depression severity 
between persons who were or were not using antidepressants, we selected a 
control group of medication-free depressed persons with a current diagnosis and 
an IDS score>25 (N=426). In this medication-free reference group the mean IDS 
score was comparable to the other medication groups. As effects of TCA and TeCA 
users were comparable, they were grouped together to increase numbers. Sex-
interactions in the association between antidepressant medication group (no 
medication, SSRI, SNRI, TCA/TeCA) and inflammatory markers were found (CRP: p-
interaction=.06, IL-6: p-interaction=.02; TNF-α: p-interaction=.90). Therefore, 
Figure 1 shows adjusted mean inflammation levels comparing antidepressant users 
with medication-free persons, for men and women separately. Increased levels of 
CRP were found for men using SNRI (1.98 versus 1.21 mg/l, p=.02, Cohen’s d=0.44) 
or TCA/TeCA (2.05 versus 1.21 mg/l, p=.02, Cohen’s d=0.48) as compared to 
medication-free depressed men. A trend for higher CRP in TCA/TeCA users was also 
found for women (2.10 versus 1.53 mg/l, p=.08, Cohen’s d=0.28). In men only, IL-6 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 of depression characteristics with inflammatory markers in persons 








Depression characteristic   Β P   β p   Β P 
Severity (IDS score) -.020 .47  .038 .22  .040   .20 
Men     -.048   .36 
Women      .085   .02 
Duration of depressive symptoms -.005 .87 -.017 .58  .012   .70 
Age of depression onset  .064 .04 -.002 .95  .043   .22 
Men  .140 .003    .149   .004 
Women  .016 .67   -.025 .55 
CRP = C-reactive protein; IL-6 = interleukin-6; TNF-α = tumor necrosis factor-alpha; IDS = 
inventory of depressive symptoms.  
1
 Based on linear regression analyses adjusted for (sex,) age, education, smoking status, 
alcohol intake, body mass index, physical activity, cardiovascular disease, diabetes, number 
of other chronic diseases, statins, anti-inflammatory medication; sex-specific associations 
are shown in case p sex-interaction ≤.05.  
2






Figure 1. Adjusted mean inflammatory levels across medication groups and sex  
based on ANCOVA adjusted for age, education, smoking status, alcohol intake, body mass index, physical 
activity, cardiovascular disease, diabetes, number of other chronic diseases, statins and anti-
inflammatory medication; to normalize distributions CRP, IL-6 and TNF-α were ln-transformed, for 
interpretation purposes presented means were back-transformed.  
IDS = inventory of depressive symptoms score; CRP = C-reactive protein; IL-6 = Interleukin-6; TNF-α = 
Tumor necrosis factor-alpha; SSRI = selective serotonin reuptake inhibitor; SNRI = serotonin-
norepinephrine reuptake inhibitor; TCA = tricyclic antidepressant; TeCA = tetracyclic antidepressant.  
1
 Current depressive disorder and IDS ≥ 25 without medication use (= reference); only significant 
differences from reference are shown: * p < .10; ** p < .05. 
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levels were lower in SSRI users (0.70 versus 0.91 pg/ml, p=.02, in SNRI users (1.37 
versus 0.91 pg/ml, p=.01, levels were lower Cohen’s d=0.49) compared to 
medication-free depressed men. No associations were found for TNF-α. For 
comparison, inflammation levels in persons with cardiovascular disease were 1.84 
mg/l for CRP and 1.06 pg/ml for IL-6, suggesting that the putative effects of 
antidepressant medication are at least of similar magnitude as having 
cardiovascular disease. Because antidepressant medication effects were found, we 
checked whether these influenced the findings from Tables 2 & 3, but results 
remained similar after additional adjustment for antidepressant medication group.  
 
Discussion 
The present study examined the association between depressive disorders, 
depression characteristics, and antidepressant medication with inflammation in a 
large cohort of depressed persons and controls. After taking a large set of possibly 
confounding factors into account, it was found that men with current depressive 
disorders had higher levels of CRP, and marginally higher levels of IL-6, but not of 
TNF-α. No overall associations were found in women. Increased inflammation was 
in particular found in depressed men with an older age of depression onset (CRP, 
TNF-α). Users of SNRI (men only), TCA, and TeCA had increased levels of CRP and IL-
6, whereas men using SSRI had significantly lower levels of IL-6. 
Our results confirm previous findings of immune dysregulation in depressed 
persons
3,4
. In men, effect sizes for current depression were small to moderate for 
both CRP and IL-6. These effect sizes are comparable to those reported by the 
meta-analysis of Howren
4
, in which stronger effects were found for studies using 
clinical interviews compared with studies using self-report questionnaires. 
Compared with symptom questionnaires, a depressive disorder diagnosis is less 
confounded by somatic health problems. Together with the fact that our results 
were elaborately adjusted for possibly confounding factors, our findings suggest a 
true relationship between depression and inflammation in men. 
No clear associations between depression and inflammation were found in women. 
This is in line with results from another large and relatively young cohort study in 
which history of depression was associated with CRP levels in men, but not 
women
5
. Hormonal changes throughout female life due to phase of menstrual 
cycle, use of hormonal contraceptives, menopause and use of estrogens greatly 
impact on inflammation levels
6-8
, which could confound a clear association 
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between depression and inflammation. However, in our study, associations 
between depression and inflammation appeared absent in both pre- and 
postmenopausal women and adjusting for several hormonal factors did not change 
our findings. Another explanation might be that in women, psychosocial factors 
play a larger role in depression and therefore override the effects of biological 
factors. For instance, insufficient social support and stressful life events have been 
found to pose a greater risk for depression among women compared to men
26, 27
. 
Results of increased inflammation were particularly present in men with late-onset 
depression. In contrast, characteristics that are more often associated with an early 
age of onset such as higher severity and longer duration were not consistently 
associated with increased inflammation. Interesting to note is that women in our 
study also had an earlier age of depression onset compared to men. A distinct 
etiology in late-onset versus early-onset depression was also found by Kendler et 
al.
28
. This study showed that depression with an early age of onset was associated 
with a family history of depression, while late-onset depression was associated 
with a family history of vascular disease. Also, subclinical vascular dysregulations, 
such as atherosclerosis, have been found to relate to late-onset depression
11,12
. 
These findings are in line with the vascular depression hypothesis which suggests 
that vascular damage in the brain predisposes to late-onset depression
29
. As 
immune dysregulation is critically involved in vascular disease
13
, this vascular 
damage could be the result of increased inflammation. 
Instead of inflammatory or vascular, the true etiology of depression in this 
subgroup of men with late-onset depression might have a metabolic nature. 
Several studies have confirmed an association between CRP, IL-6 and TNF-α with 
the metabolic syndrome and visceral fat depots release cytokines
30
. The metabolic 
syndrome and in particular visceral fat have been bidirectionally associated with 
depression in late life
31, 32
, specifically in men. Men possess higher amounts of 
visceral fat compared to women and are therefore more likely to experience 
related inflammation and depression. Involvement of metabolic processes is 
further supported by our finding that the association between depression and 
inflammation in particular decreased after adjustment for BMI. 
Several biological mechanisms could further explain the relationship between 
depression and inflammation. Depression has been associated with dysregulation 
of important stress systems of the human body, i.e. the hypothalamus-pituitary-
adrenal (HPA)-axis
33
 and the autonomic nervous system
34
. Although the HPA-axis in 
normal situations should temper inflammatory reactions, prolonged hyperactivity 
of the HPA-axis could result in blunted anti-inflammatory responses to 
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glucocorticoids resulting in increased inflammation
35, 36
. In addition, both decreased 
parasympathetic
37
 as well as increased sympathetic nervous system activity
38
 have 
been associated with increased inflammation. Furthermore, pro-inflammatory 
cytokines might inhibit hippocampal neurogenesis
39
 which could lead to a reduced 
hippocampal volume
40
 which is also seen in depression
41
. Also, several 
inflammatory markers have been shown to promote indoleamine-2,3-dioxygenase 
activation
42
, which catalyzes tryptophan, the precursor of serotonin, to kynurenine, 
thereby indirectly reducing the availability of serotonin
43
. Lastly, specific genes 
might underlie both increased inflammation and depression, as several 




Our study also shows that inflammation levels differ across persons using different 
types of antidepressant medication. Highest inflammation levels were found in 
men using SNRI, TCA or TeCA, while IL-6 levels in men using SSRI were lower 
compared to medication-free depressed men. Interesting to note is that the first 
three classes of medication have a combined serotonergic/noradrenergic effect, 
while SSRI act purely serotonergic. Earlier studies found decreases in inflammatory 
marker levels after antidepressant treatment, mainly SSRI (see
14
 for an overview), 
while two recent large studies found that use of antidepressants, mainly TCA, was 
associated with elevated inflammation levels
15
. Possibly, noradrenergic effects are 
driving increased inflammation mechanisms. Noradrenaline is part of the human 
stress response and has been suggested to potentiate cytokine production
45
. Use of 





 and the metabolic syndrome
48
. Although it is 
possible that persons using SNRI, TCA or TeCA are in other ways different from SSRI 
users and medication-free depressed persons, we constructed our groups in such a 
way that depression severity levels were very comparable. In addition, we adjusted 
our analyses for a large set of covariates and have therefore taken possible 
differences in lifestyle or disease factors into account. On the other hand, evidence 
suggests that increased inflammatory activity prior to treatment predicts non-
response
49, 50
. Possibly, persons with elevated inflammation did not respond to SSRI 
and were therefore prescribed SNRI, TCA or TeCA. 
Associations found in this study were not always consistent across all inflammatory 
markers. Correlations between inflammatory markers were only modest and were 
highest between CRP and IL-6. Regulation of the immune system is rather complex 
and involves many different inflammatory mechanisms. Most consistent findings 
were found for CRP, which is a very general marker of inflammation. IL-6 and TNF-
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α, on the other hand, only tap part of the immune system. This seems to suggest 
that inflammation is indeed involved in depression, but it is still unclear which part 
of the immune system is most critically involved. Nonetheless, expected 
associations with covariates (e.g. age, smoking, alcohol use, BMI, physical activity, 
somatic disease [medication]) were found for all inflammatory markers. 
What do the findings of our study implicate with regard to treatment of 
depression? Considering the heterogeneity of depression and the fact that current 
treatment of depression is only effective in about a third to a half of patients
1, 2
, 
this indicates that new treatments are needed for specific subgroups. Our finding 
of increased inflammation in men with late-onset depression, together with 
previous findings of high inflammation indicating non-response to 
antidepressants
49,50
, might suggest that this specific subgroup could benefit from 
alternative treatments, with anti-inflammatory medication being a likely candidate. 
Preliminary evidence from studies among patients treated with anti-inflammatory 
agents for other indications suggests that these agents may have beneficial effects 
on mood
51
. One study found positive effects on mood in medically healthy, major 
depressed patients
52
. On the other hand we found, like others
14
, that SSRI might 
have a beneficial effect on inflammation, suggesting that SSRI could be effective in 
depressed patients with immune dysregulation through this anti-inflammatory 
effect. Furthermore, behavioral interventions, such as exercise, have been shown 
to normalize immune and metabolic dysregulation
53
, as well as to improve 
depressive symptoms to some degree
54
, and might therefore be an indicated 
treatment for a immune/metabolic depression subgroup. At this moment, these 
considerations for treatment implications are still very speculative. Follow-up 
(longitudinal) research should confirm and further delineate an inflammatory (or 
metabolic) depression subtype, taking into account age, sex, depression 
characteristics and course. Experimental studies are needed to examine and 
compare the effects of different types of currently available antidepressants, anti-
inflammatory medication and behavioral (exercise) interventions on both 
immune/metabolic parameters and depression. 
Our study has some important strengths such as a large sample size, assessment of 
multiple inflammatory markers, clinical diagnoses of depression, adequate 
adjustment for potential confounders, and the ability to examine the role of 
depression characteristics and antidepressant medication. However, some 
limitations need to be acknowledged. As our data are cross-sectional, we cannot 
make any inferences about the direction of the association. Longitudinal studies 
are needed to investigate whether immune dysregulation is a precursor or the 
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result of depression (treatment), or whether this relationship is bidirectional. The 
few available prospective studies have shown contradicting results
9,55,56
. Further, 
like most other studies, we assessed circulating levels of inflammatory markers, 
which show a high degree of intra-individual variation which could explain the 
rather modest overall associations between depression and inflammation in our 
study. 
In conclusion, our study suggests that immune dysregulation plays a role in a 
subgroup of depressed persons, in particular in men with a late onset depression. 
Treatment trials should further examine the differential effects of different types of 
antidepressants on inflammation. Whether a specific treatment strategy (SSRI, anti-
inflammatory drugs, exercise) is indicated for a subgroup of late-onset depressed 
patients with immune dysregulation needs to be further investigated using 
longitudinal and experimental study designs. 
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Background: Depression and anxiety have been suggested to be associated with a 
systemic inflammation upregulation. However, results are not always consistent, 
which may be due to symptom heterogeneity of depression and anxiety disorders 
as some indications have been found that associations with inflammation are 
mainly driven by somatic symptoms of depression and anxiety. We therefore set 
out to evaluate the differential association of somatic and cognitive symptoms of 
depression and anxiety with inflammation. 
Methods: We evaluated baseline data from 2799 participants from the 
Netherlands Study on Depression and Anxiety (NESDA), an ongoing prospective 
cohort study. We used the Inventory of Depressive Symptomatology and the Beck 
Anxiety Inventory to assess depressive symptoms and anxiety symptoms. For both 
scales somatic and cognitive symptoms scales were calculated. Blood samples were 
collected to determine high sensitive C-Reactive Protein (hsCRP), interleukin 6 (IL-6) 
and Tumor Necrosis Factor-α (TNF-α). We used linear regression to analyze the 
association between depressive and anxiety symptoms and inflammation. 
Results: After adjustment for sociodemographic and health indicators, depressive 
symptoms were associated with higher levels of hsCRP, IL-6 and TNF-α. This 
association was mainly driven by somatic symptoms and not cognitive symptoms. 
For anxiety, somatic symptoms were associated with higher levels of CRP, IL-6 and 
TNF- α, whereas cognitive symptoms were only associated with hsCRP as well (in 
men only). Lifestyle factors explained most of all significant associations.  
Conclusions: Especially through their somatic symptoms, depression and anxiety 
are associated with inflammation. However, this association was mostly mediated 











Depression and anxiety have been found to be prognostically associated with 







Low grade inflammation has been proposed as one of the physiological links 
between both depression and anxiety and adverse somatic outcomes
3, 5
. In the last 
decade a substantial amount of research has been published on the depression-
inflammation relationship, in healthy
6
 and cardiac populations
5
. Most of these 




 Despite the substantial amount of research published on the depression-
inflammation link , results are still conflicting
5
, with some studies reporting positive 
associations
11, 12
 and others reporting negative findings
13, 14
.  Stewart and 
colleagues
8
 found that depressive symptoms predicted an upregulation of 
interleukin (IL) 6 after a 6-year follow-up in an otherwise healthy sample, but 
inflammation did not predict depressive symptoms after 6 years. Another study 
reported that recurrent depressive symptoms were associated with subsequent 
inflammation, although this association was largely explained by health behaviors
9
. 
In contrast, Gimeno and colleagues
10
 found that after 11 years of follow-up, C-
reactive Protein (CRP) and IL-6 were predictive of cognitive symptoms of 
depression, but not vice versa. It is obvious from the preceding that there is still 
considerable debate on whether or not depression and inflammation are 
associated and which factors contribute to this relationship.  
A possible explanation for inconsistencies in the depression and inflammation link  
could be that most studies report only on depression as a whole, whereas it might 
be more suitable to pay attention to individual depressive symptoms or dimension 
scores in relation to inflammation
15
. Based on the sickness behavior theory
16
, which 
argues that depressive-like symptoms such as fatigue, sleeping problems, anorexia 
and motor slowing tend to be more present in the case of upregulated 
inflammation levels, one could expect that possible associations between 
depression and inflammation are being missed when taking depression as a whole 
into account. It could thus be hypothesized that somatic symptoms show a 
stronger association with inflammation than cognitive symptoms, and this should 
to be taken into account when investigating the depression-inflammation 
relationship. 
In the case of anxiety, less research is conducted on the associations with 
inflammation. However, there is some evidence suggesting that anxiety is 





. As with depression, anxiety also consists of 
somatic and cognitive symptoms. One study found that in women somatic 
symptoms of anxiety were associated with an increased CHD risk, whereas more 
psychological symptoms of anxiety were not
20
. 
 An additional possible explanation for prior conflicting results of studies examining 
the link between anxiety/depression and inflammation could be that possible 
mediating effects of for instance health behaviors such as smoking, physical 
activity, alcohol consumption and overweight. These factors are not always 
included in multivariate analyses, even though there is considerable evidence that 
lifestyle factors are associated with both depressive
4, 21, 22
 and anxiety symptoms
23, 
24
 as well as inflammation
25-27
. Finally, as the majority of studies has a rather small 
sample size (N< 100), reported effect sizes can be masked. In order to detect true 
significant associations and to be able to adjust for important confounders or 
mediators, one needs a sufficient number of participants.   
We previously found in a large sample of participants that depression diagnosis was 
associated with immune dysregulation in men with a late onset depression
28
, but 
we did not distinguish in symptom dimensions of depression. We therefore set out 
to conduct a study in this same sample in which we will thoroughly investigate the 
relationship between symptoms profiles of depression and anxiety with 
inflammation. We hypothesize that 1) mainly the somatic symptoms of depression 
and anxiety  are associated with inflammation, and 2) that the association between 
(somatic) depressive and anxiety symptoms and inflammation will be partly 




Design and participants 
NESDA is an ongoing multi-center cohort study on the course of depressive and 
anxiety disorders in the adult (18-65 years) population. A total of 2981 participants 
were recruited from the community (n=564:19%), primary care (n=1610: 54%) and 
specialized mental health care (n=807: 27%) including controls and persons with a 
current or past depressive and/or anxiety disorder for the baseline assessment 
from 2004-2007. Exclusion criteria were a primary clinical diagnosis of a psychiatric 
disorder like psychotic disorder, obsessive compulsive disorder, bipolar disorder or 
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severe addiction disorder and not being fluent in Dutch. A detailed description of 
the NESDA study design and sampling procedures can be found elsewhere
29
. 
Participants who had missing data on either CRP, IL-6, or TNF-α were excluded from 
the analyses (n = 63). Additionally, participants who had not returned the 
questionnaire or had too many missing values on the Inventory of Depressive 
Symptomatology (IDS) or Beck Anxiety Inventory (BAI) (n = 39) were also excluded. 
This resulted in a total sample of 2861 participants. Excluded participants were on 
average more often male (43%), current smokers (50%) and more often used 1-14 
glasses of alcohol a week (64%). Their scores on the IDS and Beck Anxiety Inventory 
BAI were on average slightly higher. Inflammation levels were on average not 
different. 
 
Depressive and anxiety symptoms 
Depressive symptoms - The 30-item IDS self-report version was administered
30
. The 
IDS assesses the DSM-IV criterion symptom domains for major depressive disorder, 
and in addition commonly associated symptoms (e.g. anxiety, irritability) and 
symptoms relevant to melancholic and atypical features. The questionnaire 
consists of 30 items, each with four answer options (coded 0 through 3). The 
questionnaire uses a 7-day timeframe for assessing symptom severity. The 
psychometric properties of the IDS have shown to be acceptable; high correlations 
were found between the IDS scores on the Hamilton Depression Rating Scale and 
the Beck Depression Inventory
31
.  
Principal Component Analysis performed by Wardenaar and colleagues
32
 on the IDS 
revealed three dimensions, a mood cognition dimension, an anxiety arousal 
dimension and a sleep dimension. However, none of these subscales represent a 
pure somatic or cognitive symptoms scale as based on the symptoms from the 
DSM-IV. (somatic: weight loss or gain, insomnia or hypersomnia, psychomotor 
agitation or retardation, and loss of energy of feeling tired; cognitive: anhedonia, 
feeling depressed, feelings of worthlessness, concentration problems, and 
recurrent thoughts of death). The anxiety arousal dimension encompasses somatic 
symptoms such as psychomotor agitation and psychomotor slowing. However, it 
also contains somatic complaints, gastrointestinal complaints and panic/phobic 
symptoms
32
, which are not a part of sickness behavior. We therefore created a 
pure somatic and a pure cognitive symptom scale based on DSM-IV criteria and 
previous research on somatic and cognitive depression symptoms
33, 34
 (Table 1). 
Both the somatic and the cognitive subscale consisted of 10 items derived from the  
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Table 1. Overview of the somatic and cognitive symptoms of depression (IDS) and anxiety 
(BAI) as measured with the items of the Inventory of Depressive Symptoms 
Depressive symptoms (IDS) 
Somatic symptoms  Cognitive symptoms 
Falling asleep Merged 
to sleep 
variable 
 Feeling sad 
Sleep during the night  Feeling irritable 
Waking up to early  The quality of your mood 
Sleeping too much  Concentration / decision making 
Decreased or increased appetite   View of myself 
Decreased or increased weight   Thoughts of death or suicide 
Energy level   General interest 
Feeling slowed down   Capacity for pleasure or enjoyment (excluding sex) 
Feeling restless   Interest in sex 
Leaden paralysis / physical 
energy 
  Interpersonal sensitivity 
 
Anxiety symptoms (BAI) 
Somatic symptoms   Cognitive symptoms 
Numbness or tingling   Unable to relax 
Feeling hot   Fear of worst happening 
Wobbliness in legs   Terrified or afraid 
Dizzy or light-headed   Nervous 
Heart pounding/racing   Fear of losing control 
Unsteady   Fear of dying 
Feeling of choking   Scared 
Hands trembling    
Shaky/unsteady    
Difficulty in breathing    
Indigestion    
Faint/light-headed    
Face flushed    
Hot/cold sweats    
IDS = Inventory of Depressive Symptomatology, BAI = Beck Anxiety Inventory 
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IDS (Table 1). Because the sleep symptoms were over represented (4 items), we 
created a variable combining the four sleep items by taking the mean score of all 
four items. This resulted in Cronbach’s α = 0.69 for the somatic symptom 
dimension and Cronbach’s α = 0.89 for the cognitive symptom dimension. 
Anxiety symptoms –  We used the 21-item BAI
35
 to measure symptoms of 
generalized anxiety and panic symptoms. Respondents are asked to rate how much 
they have been bothered by each symptom over the past week on a 4-point scale, 
ranging from 0 (not at all) to 3 (severely, I could barely stand it). The BAI is scored 
by summing the ratings for all of the 21 symptoms to obtain a total score that can 




In order to differentiate between somatic and cognitive symptoms of anxiety, 
previous research has shown that factorial validity analysis revealed that the BAI 
consists of two subscales accounting for 84% of the variance i.e. a somatic subscale 
and a subjective – or cognitive - subscale
38
. Factor one consists of 14 items and 
forms a somatic scale (Cronbach’s alpha = .90) (Table 1). Factor two consists of 7 
items and forms a cognitive scale (Cronbach’s alpha = .88) (Table 1). These two 








 markers of inflammation were assessed at the baseline 
NESDA measurement and include interleukin-6 (IL-6), high sensitive C-Reactive 
Protein (CRP) and Tumor Necrosis Factor (TNF)-α. IL-6 is a pro-inflammatory 
cytokine secreted by activated macrophages and CRP is a non-specific acute phase 
protein synthesized in the liver in response to amongst others stimulation from IL-
6. TNF-α is the prototypic ligand of the TNF superfamily and plays a central role in 
inflammation. After an overnight fast, 50 ml blood was drawn which was 
immediately transferred to a local laboratory and kept frozen at -80°C. Plasma IL-6 
levels were measured in duplicate by a high sensitivity enzyme-linked 
immunosorbent assay (PeliKine Compact
TM
 ELISA, Sanquin, Amsterdam). The IL-6 
assay was standardized against a recombinant human IL-6 standard. The lower 
detection limit of IL-6 is 0.35 pg/ml and the sensitivity 0.10 pg/ml. Intra- and inter-
assay coefficients of variation were 8% and 12%, respectively. High-sensitivity 
plasma levels of CRP were measured in duplicate by an in-house ELISA based on 
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purified protein and polyclonal anti-CRP antibodies (Dako, Glostrup, Denmark). The 
CRP assay was standardized against the CRM 470 reference agent. The lower 
detection limit of CRP is 0.1 mg/l and the sensitivity is 0.05 mg/l. Intra- and inter-
assay coefficients of variation were 5% and 10%, respectively. Plasma TNF-α levels 
were assayed in duplicate at Good Biomarker Science, Leiden, The Netherlands, 
using a high-sensitivity solid phase ELISA (Quantikine® HS Human TNF- α 
Immunoassay, R&D systems Inc, Minneapolis, MN, United States). The TNF-α assay 
was calibrated against a highly purified E. coli-expressed recombinant human TNF-
α. The lower detection limit of TNF-α is 0.10 pg/ml and the sensitivity 0.11 pg/ml. 
Intra- and inter-assay coefficients of variation were 10% and 15%, respectively. We 
log transformed IL-6, hsCRP, and TNF-α, because of non-normality which resulted 
in normal distributed variables. 
 
Covariates 
Sociodemographic factors included age, sex, and years of education. In order to 
ascertain the presence of cardiovascular disease (CVD), self-reports and medication 
use were used (based on drug container inspection and World Health Organization 
Anatomic Therapeutic Chemical (ATC) coding; see Vogelzangs and colleagues for a 
detailed description
39
). Presence of diabetes was based on fasting plasma glucose 
level≥7.0 mmol/l or use of anti-diabetic medication (ATC code A10).  
Participants were asked to bring the containers of the medication used during the 
month prior to the interview, so the research assistant could copy medicine names. 
We used the ATC classification
40
 to classify frequently used (>50% of all days in past 
month) medication (Table 2).  For antidepressant medication selective serotonin 
reuptake inhibitors (SSRI; N06AB), serotonin–norepinephrine reuptake inhibitors 
(SNRI; SNRI; N06AX16 and N06AX21), tricyclic antidepressants (TCA; N06AA), and 
tetracyclic antidepressants (TeCA; N06AX03, N06AX05 and N06AX11) were 
classified. Furthermore, we included use of systemic anti-inflammatory medication 
(M01A, M01B, A07EB, and A07EC) and statin (C10AA, C10B). 
Health behaviors were considered as covariates, because they have been linked to 
both psychopathology and inflammation. Body Mass Index (BMI) was determined 
as measured weight in kilograms divided by the square of the measured height in 
meters. Alcohol use was measured with the Alcohol Use Disorders Identification 
Test
41, 42
 and defined as < 1 glass per week, 1-14 glasses per week and > 14 glasses 
per week, and smoking status was categorized as nonsmoker, former, and current 
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smoker. Physical activity was assessed using the International Physical Activity 
Questionnaire
43
 and defined as total MET-minutes per week (ratio of energy 
expenditure during activity compared to rest times the number of minutes 
performing the activity).   
 
Statistical analyses 
Characteristics of the participants compared across men and women using 
independent t-tests for continuous variables, chi-square statistics and ANOVA’s for 
dichotomous and categorical variables, and Mann-Whitney U for the inflammatory 
markers. 
Linear regression analyses were used to assess the association of depressive and 
anxiety symptom scores, as well as the association of somatic and cognitive 
symptoms scores separately with IL-6, CRP and TNF-α. Depressive and anxiety 
symptoms were considered as predictors and levels of IL-6, CRP, and TNF-α as 
outcome variables. First a demographics and health model was evaluated, 
adjusting for age, sex, education level, anti-inflammatory medication and statin 
use, and presence of CVD and diabetes were taken into account as covariates. 
Secondly, when significant correlations between inflammatory markers and specific 
antidepressant medication were present, analyses were further adjusted for those 
antidepressant medications. We chose to restrict analyses to these medications, 
because adjusting for all antidepressant medication possibly leads to overadjusting 
by adjusting for those participants with the most severe depressive and anxiety 
symptoms. CRP was significantly negatively correlated with SSRI, and positively 
correlated with TCA, and TeCA use (p<.05). TNF-α was positively correlated with 
TCA (P<.01). There were no significant correlations between IL-6 and 
antidepressant medication use.  Because of possible mediating effects of lifestyle 
factors
44
 smoking, alcohol consumption, BMI, and physical activity were added in a 
final to the previous models.  
Since Vogelzangs and colleagues found sex differences in the association between 
depression and inflammation
28
 we tested for the presence of interaction effects for 
sex and included the following interaction terms for sex (sex*ids, sex*ids somatic, 
sex*ids cognitive, sex*bai, sex*bai somatic, sex*bai cognitive). When the 
interaction effect was found significant, regression analyses were repeated 
stratified for gender. 





Table 2 shows the descriptive characteristics of the total study sample (N = 2861) of 
which 950 were male (33.2%). Men were significantly older than women (p <.01), 
were less often nonsmoker (p <.01), less often used < 1 glass per week (p < .01), 
and had higher levels of BMI (p <.01). Furthermore, cardiovascular disease (p <.01) 
and diabetes (p <.01) were more present in men and men used statins (p <.01) 
more often than women. Women had higher total BAI scores (p <.01). Men had 
higher IDS somatic symptoms scores than women (p <.01), whereas women had 
higher total BAI (p <.01), BAI somatic (p <.01), and BAI cognitive scores (p <.01). 
Finally, women had higher median levels of hsCRP (p < .01), IL-6 (p <.01) and TNF-α 
(p <.01) (Table 2).   
Symptoms of depression and inflammation 
Significant sex interactions were found with IDS total depressive symptoms in 
predicting CRP (p = .02), which lead us to stratify the concerning analyses for sex. 
Considering somatic symptoms and cognitive symptoms of depression there were 
no significant interactions with sex for any of the markers (all p values for sex 
interactions>.06).  
In line with our previous findings
28
, demographic and health adjusted regression 
analyses revealed a positive significant association between total IDS score and CRP 
(men only: β = .104, p <.01), IL-6 (β = .046, p = .02) and TNF-α (β = .039, p = .04). 
Somatic symptoms, but not cognitive symptoms, of depression were significantly 
associated with CRP (β = .078, p <.01), IL-6 (β=.054, p = <.01), and TNF-α (β= .045, p 
= .02) in the demographics and health model. Additional adjustment for those 
specific antidepressant use that showed associations with inflammatory markers, 
only had an effect on the association between total IDS score and TNF-α (adjusted 
for TCA)(p>.07). Final additional adjustment for lifestyle factors made the 
remaining associations non-significant for all three markers (p>.12) (Table 3). In the 
lifestyle adjusted analyses, BMI had the largest reducing effect on the depressive 
symptoms and inflammation association, followed by an inverse effect of moderate 
alcohol consumption, and former smoking (CRP) or current smoking (TNF-α). 
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Symptoms of anxiety and inflammation 
Significant interactions were found for sex and total symptoms of anxiety, somatic 
symptoms of anxiety and cognitive symptoms of anxiety when CRP was analyzed 
(p<.05), therefore these results are presented stratified for sex.  
In men, but not in women, total BAI score was significantly associated with higher 
levels of CRP in the demographics and health model (β = .106, p =. <01). Overall 
symptoms of anxiety were not associated with IL-6 (β = .034, p = .07), and TNF-α (β 
= .035, p = .07). However, in a similar model, somatic symptoms of anxiety were 
significantly associated with CRP (men only: β = .116, p <.01), IL-6 (β = .050, p = 
<.01), and TNF-α (β = .038, p = .05)  (Table 4). Cognitive symptoms of anxiety and 
CRP were associated in men only (β = .073, p = .02). Additional adjustments for 
antidepressant use diminished the association between somatic symptoms and 
followed by an inverse effect of moderate alcohol intake and former smoking.         
TNF-α (adjusted for TCA), and cognitive symptoms and CRP (adjusted for SSRI, TCA, 
and TeCA). Finally, adjusting for lifestyle factors resulted in diminished, non-
significant associations for CRP and somatic and total symptoms of anxiety (p>14). 
From the lifestyle factors, BMI had the largest diminishing effect on all associations, 
 
Discussion 
This study shows that higher depressive symptoms were associated with increased 
inflammatory levels of CRP, IL-6, and TNF-α, but this was mainly driven by the 
somatic – and not the cognitive – symptoms of depression. This supports the 
hypothesis that somatic symptoms and cognitive symptoms of depression are 
differently associated with inflammation. Regarding symptoms of anxiety, total, 
somatic and cognitive symptoms were all similarly associated with higher CRP (men 
only). IL-6 and TNF-α levels were only associated with somatic symptoms of 
anxiety. For all significant associations, health behaviors played an important role, 
with BMI explaining most of the relationship. 
The results from this study support the hypothesis that somatic and cognitive 
symptoms are differently associated with inflammation suggesting that the 
association between depression and inflammation is mainly driven by somatic 
symptoms. This is in concordance with some previous findings. Elovainio and 
colleagues  found that somatic symptoms were more strongly associated with CRP 
in men than in women, even after full adjustment for covariates
15
. In contrast to  




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































our findings, Elovainio and colleagues found significant associations between 
cognitive symptoms and CRP. However, these were unadjusted or for every 
covariate separately adjusted analyses. We did not present unadjusted or 
separately adjusted analyses, because of the already known age effects on 
inflammation
46, 47
. However, contradictory findings have also been reported. 
Kupper and colleagues found that both somatic and cognitive symptoms were 
cross-sectionally associated with inflammation in a sample of heart failure 
patients
48
. Furthermore, cognitive symptoms of depression were associated with 
subsequent inflammation, whereas change in somatic symptoms over a 12 month 
period were associated with inflammation
48
. One possible explanation for the 
differences in the cross-sectional results between these studies could be that our 
study and Elovainio and colleagues’ study consisted of somatic healthy participants, 
whereas Kupper and colleagues used a sample of heart failure patients, whom 
probably have higher levels of inflammation to begin with due to their disease 
status. Furthermore, the heart failure sample is on average older, which possibly 
affects cognitive functions comparable to cognitive symptoms of depression (i.e. 
concentration).  
As was found in previous research
8, 9, 48
, this study shows that lifestyle factors, and 
mainly BMI, explained a significant part of the association between depressive 
symptoms and inflammation. Obesity has been found to be associated with 
depression
4, 49
. A meta-analysis on the prospective association between overweight 
and depression showed that the relationship is bi-directional: depression predicts 
obesity and obesity is a risk factor for depression
4
. Obesity has also been found to  
Table 3. Demographics + health: age, sex, years of education, anti-inflammatory medication use, 
statin use, presence of cardiovascular disease and diabetes 
Lifestyle: Demographics + health + smoking, alcohol consumption, BMI, and physical activity 
IDS = Inventory of Depressive Symptomatology, CRP = high sensitive C-reactive protein, IL-6 = 
Interleukin 6, TNF-α = Tumor Necrosis factor- alpha 
Bold faced: p<.05 
*Only adjusted for antidepressant medication use when significant correlation was present with 
inflammatory marker. CRP analyses were adjusted for selective serotonin reuptake inhibitor (p=.04), 
tricyclic antidepressants (p<.01), and tetracyclic antidepressants (p<.01). TNF-α analyses were 
adjusted for tricyclic antidepressants (p<.01). There were no significant correlations between IL-6 and 
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be associated with higher levels of inflammation
44, 50
. Research suggests that 
adipose tissue produces IL-6 and TNF-α
44, 50
 and this is therefore a plausible link 
between depressive symptoms and inflammation
50
. Furthermore, Dod and 
colleagues found that intervening in lifestyle, by changing food intake and 
enhancing moderate exercise, had significant effects on lowering inflammation 
levels after 12 weeks
25
. As higher levels of inflammation are found to be associated 





promoting weight loss in people with depressive symptoms could have beneficial 
effects on levels of inflammation and possibly future health status.    
Regarding anxiety and inflammation, we found a significant association between 
total anxiety symptoms and IL-6 and CRP (men only) whereas somatic symptoms 
were associated with CRP (men only), IL-6, and TNF-α. These associations also 
diminished after lifestyle factors were considered. In line with our findings on total 
symptoms of anxiety, previous studies also reported on a positive association 
between anxiety and inflammation
52,53
. Liukkonen and colleagues found that men 
reporting anxiety symptoms had elevated levels of CRP levels compared to those 
who did not report symptoms of anxiety. However, their findings were not affected 
by adjustment for a range of covariates including BMI
52
 , whereas our results 
became non-significant after adjusting for health behaviors (smoking, BMI, physical 
inactivity, and alcohol use), with BMI having the strongest effect on the association. 
Furthermore, similar to our findings, they did not find support for this association 
in women. In contrast, Pitsavos and colleagues did find significant associations for 
anxiety and inflammation in women
53
. Interestingly, the results published by 
Liukkonen and colleagues and Pitsavos and colleagues did not diminish after 
adjustment for health behaviors as our results did. Previous research has shown a 
positive relationship between BMI and inflammation on one hand
54, 55
 and BMI and 
anxiety on the other hand
56
. One possible explanation could be that our sample 
partly consists of psychiatric patients, in contrast to the healthy samples used by 
Pitsavos and colleagues and Liukkonen and colleagues.  Around 27% of the 
participants are recruited in specialized mental health care. It could be that this 
group of participants has more adverse health behaviors contributing to 
inflammation and/or anxiety compared to healthy participants.  Furthermore, our 
results suggest that the anxiety-inflammation relationship is mainly driven by 
somatic symptoms. Somatic symptoms of anxiety consist of hot flushes, 
respiration, heart pounding, shaking hands and difficulty breathing. This sheds a 
new light on anxiety and inflammation. In contrast to somatic symptoms of 
depression, somatic symptoms of anxiety are not similar to symptoms of sickness 
behavior, but may be seen as a reflection of autonomic control, suggesting a role 
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for the autonomic nervous system (ANS). The ANS is also associated with higher 
levels of inflammation
57-59
 and could possibly be involved in the anxiety-
inflammation link. However, studies examining anxiety and the ANS show 
conflicting results
60-62
 as to whether the ANS and anxiety are associated. Possibly, 
the ANS is only involved in the somatic symptoms of anxiety and affects immune 
function simultaneously.  
This study is conducted on cross-sectional data, implying that no inferences can be 
made on the direction of the relationship of depression and anxiety with 
inflammation. There is some evidence that suggests that depressive symptoms are 
associated with subsequent inflammation
8, 9, 48, 63
, but the opposite has been 
reported as well
10
. Regarding anxiety there is little evidence up to date on the 
direction of association, though it has been suggested that pro-inflammatory 
cytokines rise in the presence of anxiety, due to chronic stress
65
. Up to date there is 
no longitudinal research conducted which could provide insight into the direction 
of the anxiety-inflammation relationship and a more thorough understanding of 
mechanism involved in this relationship.   
Some strengths can be attributed to our study, such as a large sample size with a 
wide range on psychopathology thereby increasing the power of our analyses, 
which made it possible to adequately adjust for potential confounders. In addition, 
multiple inflammatory markers were assessed. However, some limitations need to 
be acknowledged. Our data is cross-sectional, which makes it impossible to draw 
any conclusions on the direction of the relationship between symptoms of 
depression or anxiety and inflammation. Association of depression and anxiety 
inflammation with inflammation may be different in prospective research. 
Furthermore, we assessed circulating levels of inflammatory markers, which show a 
high degree of intra-individual variation. This could explain why we found the 
rather modest associations between symptoms of depression and anxiety with 
inflammatory marker levels in our study.  
In conclusion, our results suggest an association between depressive and anxiety 
with inflammation, in which associations were mainly driven by the somatic 
symptom components.  Nevertheless, adjustment for lifestyle factors diminished all 
associations to non-significance indicating that it is the poorer lifestyle of 
depressed and anxious patients that puts them at risk for inflammation.  
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Background: Depression and inflammation have been found to be related both in 
healthy and diseased adults. As depression and inflammation are also known 
metabolic and cardiac risk factors, we set out to evaluate the trajectories of 
depressive symptoms, somatic symptoms of depression, and cognitive symptoms 
of depression in adolescence over the course of 5 years and their relationship to 
subsequent levels of inflammation.  
 
Methods: 1166 Dutch adolescents were followed for TRacking Adolescents’ 
Individual Lives Survey (TRAILS) from 2001 until 2008. Three assessments over a 
period of 5 years took place in which the Youth Self Report (YSR) was administered, 
and information on demographics and health behaviors was collected. The YSR 
provided the overall depressive symptoms score, as well as a somatic and a 
cognitive subscale score. At the third assessment, blood was collected to determine 
hsCRP. Cluster analysis was used to determine 5-year trajectories of depression. 
GLM was used to determine the association between the clusters and hsCRP.  
 
Results: Adolescents with steady mild depressive symptoms had higher levels of 
subsequent hsCRP than those reporting decreasing depressive symptoms after 
adjustment for demographics. Additional adjustment for health behaviors 
diminished this relation to non-significance. Consistently high scores on somatic 
symptoms and cognitive symptoms were associated with higher levels of hsCRP 
compared to consistently low scores on these dimensions, but this difference 
became non-significant after adjustment for demographics.   
 
Conclusion: Persistent depressive symptoms were associated with subsequent high 
levels of hsCRP. Smoking, BMI, and physical activity play an important role in this 
association, suggesting a mediating role of health behaviors in the depression-










In the past decades a substantial amount of research has evaluated the relation 
between depression and inflammation both in healthy and diseased adults
1, 2
. 
Within this body of research, inflammation has been suggested as one of the 
physiological mechanisms explaining the adverse association between depression 
and progression of heart disease
3
, and to a lesser extent the development of heart 
disease
4
. Most of the studies to date have been conducted in adult healthy 
populations [e.g.
5
] and psychiatric [e.g.
6
] or somatic patient populations [e.g.
7, 8
] 
while only a very limited number of studies considered adolescents.  
 
Still, especially adolescence may be an important period in which this association 
should be evaluated. Adolescence is a period in life where many of the first onsets 
of depression or depressive symptoms start to develop
9
. Prevalence estimates of 
depression range from approximately 0.3% in early adolescence up to 23.2% in late 
adolescence
9
. It is therefore of interest to evaluate whether the association 
between depression and inflammation is already present in adolescents. The few 
studies to date that have investigated the relationship between depression and 
inflammation in adolescents report inconsistent results
10-12
. Chaiton and colleagues 
examined the cross-sectional depression-inflammation relationship in adolescents, 
but failed to find an association
10
, while a recent prospective study reported that 
adolescents who had repeatedly experienced depressive symptoms had higher 
levels of subsequent C-reactive protein (CRP) than those who did not
11
. This finding 
suggests that mainly recurrent depressive symptoms are associated with CRP, a 
finding that is in line with previous reports on depression and inflammation in 
coronary heart disease patients
7
. Finally, Elovainio and colleagues reported that 
depression in young Finns was associated with subsequent hsCRP, with an 
important role for BMI and triglycerides
12
, suggesting a mediating effect of 
overweight which has also been suggested in previous research
13
. An important 
shortcoming of the prospective studies conducted thus far
11, 12
 is that these authors 
did not look into the trajectories of depressive symptoms over time. Looking into 
trajectories over time may provide insight in the chronicity of the symptoms and its 
temporal association with inflammation. 
 
Another important distinction in the association between depression and 
inflammation may be the differential association of inflammation with cognitive 
and somatic symptoms of depression, with studies demonstrating the somatic 
symptoms of depression (e.g., sleeping problems, lack of sleep, eating problems, 
and psychomotor retardation) to be associated with inflammation and not the 
146 Chapter 7 
 
 
cognitive symptoms in healthy adults
5
 and cancer patients
14
. In contrast, a 
prospective study in patients with heart failure by Kupper and colleagues reported 
that markers of inflammation were associated with both somatic and cognitive 
symptom dimensions of depression
8
.  
To assess whether the course of depressive symptoms in a population based 
sample of adolescents is associated with subsequent inflammation, we set out to 
evaluate the trajectories of depressive symptoms, somatic symptoms of 
depression, and cognitive symptoms of depression in adolescence over the course 
of 5 years and their relationship to subsequent levels of inflammation. Our first aim 
was to identify longitudinal development classes for depressive symptoms, somatic 
symptoms of depression, and cognitive symptoms of depression separately. 
Secondly, we aimed to investigate whether these classes were differentially 





We used data from the Tracking Adolescents’ Individual Lives Survey (TRAILS), a 
large ongoing prospective cohort study of Dutch adolescents. In this study, data 
from wave 1 (March 2001 to July 2002), wave 2 (September 2003 to December 
2004), and wave 3 (September 2005 to August 2008) were used. Sample selection 
is described in more detail elsewhere
15
. In short, selected municipalities in the 
north of The Netherlands were asked to provide names and addresses of all 
inhabitants born between October 1, 1989 and September 30, 1990 or October 1, 
1990 and September 30, 1991. This yielded 3483 names. In addition, primary 
schools within these municipalities were asked to participate in TRAILS. The 
participation of schools was a prerequisite for eligible children and their parents to 
be approached for participation in TRAILS. Of all children approached for inclusion 
in the study (N = 3145), 2230 (76.0%) were enrolled in the study. Parents had to 
provide a written informed consent. At waves 2 and 3 the adolescents gave 
additional written informed consent. Of the total baseline sample (N = 2230, mean 
age = 11.1, SD = .06) 2149 adolescents (96.4 %, mean age = 13.65, SD = .53) took 
part in wave 2, two to three years after the baseline assessment. At wave 3, 1816 
adolescents (81.4%, mean age = 16.27, SD = .73) participated in the study.  
For the sample used in this study, adolescents who had too many missings on the 
Youth Self-Report (YSR) (wave 1 N = 28, wave 2 N = 137, and wave 3 N = 570) and 
for whom hsCRP values were not available (N = 1017) were excluded from the 
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analyses. This resulted in a final N of 1166. TRAILS was approved by the Central 





Depressive symptoms were measured by the Affective Problems scale of the Youth 
Self-Report (YSR), a self-report questionnaire assessing emotional and behavioral 
problems during the past 6 months. The Affective Problems scale contains 13 
items, which were scored on a 3-point Likert scale (0 = not true; 1 = somewhat or 
sometimes true; or 2 = very true). The scale reflects the symptoms of a Major 





. Bosch and colleagues earlier showed in this 
sample that omission of one sleep item (‘I sleep more than most kids’) increased 
the internal consistency of the scale, so we followed this suggestion
17
. The 
remaining 12 items covered depressed mood, anhedonia, loss of energy, feelings of 
worthlessness and guilt, suicidal ideation, sleep problems, and eating problems, 
and had an internal consistency (Cronbach’s α) of .73 at wave 1, of .78 at wave 2 
and .79 at wave 3.  
 
In order to evaluate the effects somatic and cognitive symptoms of depression, the 
items were divided into two subscales; a somatic symptoms subscale and a 
cognitive symptoms subscale (described earlier by Bosch and colleagues
17
 and 
presented in table 1). The internal consistency of the cognitive symptoms scale was 
.67-.74 for the 3 data waves, while the consistency of the somatic symptoms scale 
was .58-.67.  Total depressive symptoms could be determined for 2202 (wave 1), 
2093 (wave 2), and 1660 (wave 3) adolescents respectively. We used corrected-
item-mean (CIM) imputation to handle missing data if less than 30% of the items 
were not answered
18
. From the total sample, 1627 adolescents  
completed all 3 YSRs, 478 completed 2, and 118  completed 1 YSR. Missing values 
are replaced by the item mean, corrected for participants’ score on the items 
compared with the mean score on these items in the total sample
18
. When more 
items were unanswered, the YSR Affective Problems Scale was considered 
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Table 1. Depressive Symptoms used in this study.  
Somatic symptoms Cognitive symptoms 
Lack of appetite Loss of pleasure 
Overtired Crying 
Reduced sleep Self-harm 
Trouble sleeping Suicidal Ideation 
Lack of energy Feelings of worthlessness 






At wave 3, 39.5 ml fasting blood was drawn, which was transported to the 
laboratory within four hours. High sensitive-C reactive Protein (hsCRP) was 
determined using a immunonephelometric method, BN2, CardioPhase® hsCRP, 
Siemens with a lower detection limit of 0.175 mg/L. Intra-assay coefficients of 
variance ranged from 2.1 to 4.4, and inter-assay coefficients of variation 
coefficients of variance ranged from 1.1 to 4.0. HsCRP was not normally 
distributed, so we applied a log transformation to achieve normality. In the tables 





We included sex, age, socio-economic status, body mass index (BMI), physical 






Socio-economic status was based on baseline data (wave 1) on parental education, 
income, and occupation according to  the International Standard Classification
22
. 
The lowest 25%, intermediate 50% and highest 25% of the scores were defined as 
low, middle, or high. 
Finally, health behaviors might serve as mediators in the depression-inflammation 
relationship
7, 11, 19
. Individual indicators of health behavior (i.e. physical activity, 
BMI and current smoking) were therefore added to the analyses in a second step. 
Physical activity at wave 3 was calculated by means of metabolic equivalent scores 
(METs). METs are the ratio of the work metabolic rate to the resting metabolic rate. 
One MET is defined as 1 kcal/kg/hour and is roughly equivalent to the energy cost 
of sitting quietly
23
. Smoking was determined at wave 3 by self-report and defined 
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as no, former, or current smoker. BMI was measured by a research assistant at 







Cross-sectional analyses – Linear regression analyses were conducted to examine 
the cross-sectional association between wave 3 depressive symptoms, somatic 
symptoms of depression, and cognitive symptoms of depression with hsCRP.  After 
exploring the unadjusted association, the “Demographics” model added the 
variables age, sex, and socio-economic status. The final model, named “Health 
behaviors” additionally included the health behaviors (smoking, BMI and physical 
activity) .   
 
Course of depression - Latent class ordinal regression modeling in Latent Gold 4.0
24
 
was used to determine the number of latent classes in the course of depressive 
symptoms over 5 years (3 data waves) in the TRAILS sample, and to evaluate the 
course of depressive symptoms, somatic symptoms and cognitive symptoms within 
these latent classes. Because depressive symptoms, somatic symptoms, and 
cognitive symptoms were discrete variables, they were handled as ordinal 
dependent variables. Time was used as a predictor. Eight models were compared 
with an increasing number of classes (1-8). The Bayesian Information Criterion (BIC) 
was used to compare the fit of the subsequent models
25
. BIC provides a 
quantitative index of the extent to which a model maximizes the correspondence 
between the observed and model predicted responses while minimizing the 
number of parameters. A BIC difference of > 10 is strong evidence that the models 




Association with hsCRP - Trajectory membership was exported to PASW statistics 
17.  Trajectories were reorganized for all depression scales in such a way that the 
trajectory with the lowest scores on the depression scales represented the lowest 
number and the highest score on the scales represented the highest number.  
Finally, the General Linear Models procedure in PASW was used to examine 
whether class membership was differentially associated with hsCRP, in unadjusted 
and adjusted analyses. In the first model unadjusted associations were tested. The 
second model evaluates the association adjusted for demographic variables; age, 
sex, and socio-economic status. In the final model health behaviors were 
additionally included. Because health behaviors (smoking, BMI, and physical 
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activity) are possible mediators in the association between depression and 
inflammation
7, 19
, they were analyzed in a separate model that was added to the 
demographics model.  Mean levels of hsCRP were compared across the clusters 
using a Bonferroni correction to evaluate differences among classes and their 




Characteristics of the total sample are summarized in Table 2. The total sample (N = 
1166) consisted for 46.5% of boys, with a mean age at wave 3 of 16.2 years. Mean 
levels of hsCRP at wave 3 were 1.13 (SD = 2.05). 
Cross-sectional analyses of depression and hsCRP levels 
Cross-sectional linear regression analyses of wave 3 data did not reveal significant 
associations of depressive symptoms, somatic symptoms of depression, and 
cognitive symptoms of depression with hsCRP (β=.010, p=.17; β=.02 p=.14; β=.018 
p=.39 respectively). Additional adjustments for demographics and health behaviors 
did not alter the results.  
 
 
Table 2. Total sample characteristic 
N = 1166 (at wave 3)  N(%)* 
hsCRP (mg/L) Mean(SD)  1.13 (2.05) 
Demographics   
Sex (male)   542 (46.5%) 
Age (years) Mean(SD)  16.22 (0.64) 
Socio-economic status    
Low  284 (24.4%) 
Middle   534 (45.8%) 
High  276 (23.7%) 
Health behaviors   
Physical activity (METs) Mean(SD)  3460.9 (4577.2) 
BMI Mean(SD)  21.3 (3.2) 
Smoking   
No  513 (44.0%) 
Former  318 (27.3%) 
Current  328 (28.2%) 
*Numbers are presented as N(%) unless otherwise specified. 
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The course of depression over the 5-year period 
 
Depressive symptoms - Cluster analysis identified the presence of 5 trajectories for 
YSR depressive symptoms total score over 5 years of follow-up in the best-fitting 
model, explaining 65.7% of the total variance (Table 3 top panel). The 5 trajectories 
are visualized in Figure 1a and reflect (cluster 1) “consistently low depressive 
symptoms”, (cluster 2) “decreasing depressive symptoms”, (cluster 3) “increasing 
depressive symptoms”, (cluster 4) “consistently mild depressive symptoms”, and 
(cluster 5) “consistently high depressive symptoms”. Though the most important 
difference between the 5 trajectory classes was in the overall level of depression 
(i.e. the intercept), also the time effect significantly differed across classes (Wald 
statistic = 92.22, p <.0001). 
 
Somatic symptoms - Four trajectories were identified (Table 3, Figure 1b) in the 
best fitting model, explaining 62.8% of the total variance and reflecting 
“consistently low somatic symptoms of depression” (cluster 1), “decreasing somatic 
symptoms of depression” (cluster 2), “increasing somatic symptoms of depression” 
(cluster 3), and “consistently high somatic symptoms of depression” (cluster 4).  The 
largest trajectory contained 30% of the sample and the smallest trajectory 
contained 19%, with time having a different effect across the classes (Wald = 83.83, 
p <.001) Figure 1b). 
 
Cognitive symptoms - Three trajectories were identified for YSR cognitive 
symptoms in the best fitting model. These trajectories explained 50.0% variance 
and reflected  “low cognitive symptoms of depression” (cluster 1), “mild cognitive 
symptoms of depression” (cluster 2), and “high cognitive symptoms of depression” 
(cluster 3; Figure 1c). The effect of time was significantly different across the 
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Table 3. Identification of the number of latent classes using regression models for 
Depressive symptoms total score, Somatic symptoms subscore and Cognitive symptoms 
subscore 
Model  Statistics 
Depressive 
symptoms 
 LL  Npar  N  BIC 
Cluster 1  -14070.7951  24  2223  28326.5488 
Cluster 2  -13615.1104  28  2223  27446.0060 
Cluster 3  -13517.0762  32  2223  27280.7639 
Cluster 4  -1502.8825  36  2223  27283.2030 
Cluster 5  -13485.9691  40  2223  27280.2027 
Cluster 6  -13478.3165  44  2223  27295.7240 
Cluster 7  -13471.0096  48  2223  27311.9365 
Cluster 8  -13468.0568  52  2223  27336.8574 
Somatic symptoms  LL  Npar  N  BIC 
Cluster 1  -11246.1602  12  2222  22584.7943 
Cluster 2  -10886.3136  16  2222  21895.9259 
Cluster 3  -10824.1430  20  2222  21802.4092 
Cluster 4  -10807.7257  24  2222  21800.3994 
Cluster 5  -10795.3553  28  2222  21806.4833 
Cluster 6  -10789.2724  32  2222  21825.1421 
Cluster 7  -10787.3715  36  2222  21852.1648 
Cluster 8  -10784.8352  40  2222  21877.9169 
Cognitive symptoms  LL  Npar  N  BIC 
Cluster 1  -9851.3331  16  2223  19825.9719 
Cluster 2  -9493.0712  20  2223  19140.2746 
Cluster 3  -9451.2930  24  2223  19087.5447 
Cluster 4  -90438.0806  28  2223  19091.9464 
Cluster 5  -9430.7559  32  2223  19108.1234 
Cluster 6  -9425.4415  36  2223  19128.3212 
Cluster 7  -9421.5894  40  2223  19151.4433 
Cluster 8  -9418.7375  44  2223  19176.5660 
LL= log likelihood 
Npar = number of estimated parameters 
N = number of subjects in analysis 
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The association of the 5-year course of depression with subsequent hsCRP levels 
Table 4 shows the results of the General Linear Models ANCOVA, in which 
trajectory membership of total depression (left), somatic depressive symptoms 
(middle) and cognitive depressive symptoms (right) was used to predict hsCRP 
levels at wave 3.  
 
Depression - In the unadjusted model, the 5 trajectories were differentially 
associated with subsequent levels of hsCRP (p=.007). Pairwise comparisons of the 
mean hsCRP levels across the trajectories showed that adolescents with 
“decreasing depressive symptoms” had lower levels of subsequent hsCRP 
compared to adolescents with “mild depressive symptoms” (p=.01; Figure 2a). After 
adjusting for demographics, class membership remained associated with 
subsequent hsCRP. Additional adjustment for health behaviors however, made the 
association with inflammation no longer significant across membership classes, 
with BMI and smoking being significant covariates (p-values <.001) (Table 4, left 
panel).  
 
Somatic symptoms of depression - Trajectories of somatic symptoms were 
differentially associated with levels of hsCRP in the unadjusted model (p=.050; 
Figure 2b). Pairwise comparisons across the 4 trajectory classes showed that hsCRP 
levels were significantly higher in the high somatic symptoms group compared to 
the low somatic symptoms group (p=.04). Adjustment for demographics, however, 
made the association non-significant and the association was even further reduced 
after additional adjustment for health behaviors (Table 4). 
 
Cognitive symptoms of depression - The 3 classes were differentially associated 
with subsequent levels of hsCRP (p=.02) in unadjusted analysis, with adolescents 
who consistently reported ‘high cognitive symptoms of depression’ having higher 
levels of subsequent hsCRP than those who consistently reported ‘low cognitive 
symptoms of depression’ (Figure 2c). After adjusting for demographics, the classes 
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Table 4. Results of ANCOVA, comparing levels of hsCRP across class membership for 
depressive symptoms, somatic symptoms of depression, and cognitive symptoms of 
depression  
  Depressive symptoms 
  F Df p  η² Significant 
Unadjusted  3.54 4.12 .01 .007  
Demographics  2.71 4.11 .03 .006 1, 2 
Health behaviors  1.31 4.11 .26 .002 1, 4, 5 
  Somatic Symptoms 
  F df p  η² Significant 
Unadjusted  2.62 3.12 .05 .007  
Demographics  2.07 3.11 .10 .004 1, 2 
Health behaviors  0.53 3.11 .66 .000 1, 4, 5 
  Cognitive symptoms 
  F df p  η² Significant 
Unadjusted  3.87 2.12 .02 .012  
Demographics  2.02 2.11 .13 .010 1, 2 
Health behaviors  0.20 2.11 .82 .005 1, 4, 5 
Demographics: adjusted for age, sex, and socio-economic status. 
Health behaviors: adjusted for demographics + smoking, BMI, and physical activity. 




This study identified clusters in the course of depressive symptoms, somatic 
symptoms of depression, and cognitive symptoms of depression over a 5-year 
period in healthy adolescents and examined whether these course clusters were 
associated with subsequent systemic hsCRP concentrations. The results 
demonstrated the presence of 5 trajectories for depressive symptoms that differed 
in terms of intercept and slope. These trajectories were differentially associated 
with subsequent levels of hsCRP, with persistent mild to high depression having the 
highest hsCRP levels. Health behaviors, i.e. smoking and being more overweight 
explained a large part of this association. Four trajectories for somatic symptoms 
were identified and 3 trajectories were identified for cognitive symptoms. These 
trajectories were not associated with subsequent hsCRP in adjusted analyses. 
 
In order to evaluate the relationship between the course of depressive symptoms 
and hsCRP, cluster analyses for depressive symptoms, somatic symptoms and 
cognitive symptoms of depression over a 5 year follow-up period were performed. 
We found 3 (cognitive symptoms) to 5 classes (depressive symptoms) for the 
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separate depression scales over time, suggesting a substantial degree of 
heterogeneity in the experience of depression over time. Somatic symptoms of 
depression seemed to show more variation over time than cognitive symptoms of 
depression.  
Next to the time-stable depression classes, we also identified classes with 
increasing and decreasing depression (subscale) scores. In contrast, for cognitive 
symptoms only classes with consistent scores (low, mild, and high) were identified. 
This suggests that adolescents with high scores on depressive symptoms and 
somatic symptoms of depression tend to consistently report high scores, whereas 
adolescents with low scores at baseline can report increasing depressive symptoms 
or adolescents with mild scores at baseline can report decreasing scores over time.  
Our findings support the results of an earlier study on trajectories of depression in 
adolescents that identified 4 clusters of depression over an 11-year follow-up 
period, which were comparable to 4 out of the 5 classes identified in our study
28
. 
They did not, however, identify a mild depressive symptoms class. These 
differences could be the result of their longer follow-up period, but might also be 
explained by the different questionnaires used. Wickrama and colleagues used 8 
items from the Center for Epidemiological Studies of Depression (CES-D) Scale
28
, 
whereas we used the Affective Problems scale from the Youth Self Report (YSR). 
One major difference between both questionnaires is that the YSR is especially 
developed for children and adolescents. The DSM-IV affective subscale of the YSR 
has strong correlations with the major depressive disorder scale from the Revised 
Child Anxiety and Depression Scale
29
, and thus may be more sensitive in this age 
group. Despite these differences, Wickrama and colleagues also found that 
adolescents reporting moderate to high depressive symptoms tend to report 
moderate to high depressive symptoms over time. Taken together, this suggests 
that especially those adolescents with high scores on (somatic and affective) 
depressive symptoms already at the age of 11 are at risk for continued feelings of 
depression in later adolescent life. It could well be that these consistently mild and 
high classes of depressive symptoms are a reflection of recurrent or even chronic 
depressive symptoms, whereas the increasing and decreasing classes could be a 
reflection of single episodes of depressive symptoms.  
 
The identified classes were used to examine the association between the course of 
depressive symptoms, somatic symptoms of depression and cognitive symptoms of 
depression and subsequent hsCRP levels. The unadjusted results showed that the 
two subscales and the total depression score were individually associated with 
subsequent hsCRP, consistently showing adolescents with consistent mild to high 
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Figure 1. Mean scores for (1a) depressive symptoms, (1b) somatic symptoms of 






























































































% reflects percentage of participants in trajectory 
T1: wave 1; T2: wave 2; T3: wave 3 
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Figure 2. Levels of hsCRP (backtransformed) across classes of (2a) depressive symptoms, 






























































hsCRP = high sensitive C-reactive protein. Error bars represent standard error of the mean. 
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scores having higher levels of hsCRP than those with low or decreasing symptoms. 
However, both for somatic and cognitive symptoms, differences in hsCRP levels 
across the classes were no longer significant after adjustment for demographics i.e. 
age, sex, and education. Taken together, somatic and cognitive symptoms of 
depression were not differentially associated with inflammation, but total 
depressive symptoms were, suggesting a synergy of all symptoms of depression 
when combined using a 5 year perspective.  
The results for the depressive symptoms underline previous findings on the 
prospective association between depression and inflammation, which suggested 
that associations are most profound when multiple assessments of depressive 
symptoms were used. For instance, Copeland and colleagues recently published a 
study on the prospective association between depressive symptoms and 
inflammation in adolescents and young adults
11
. They found that participants who 
repeatedly experienced depressive symptoms had higher levels of subsequent CRP 
compared to those who did not, irrespective of demographic variables and health 
behaviors
11
. Furthermore, in a large sample of patients with stable coronary heart 
disease Whooley and colleagues found that depressive symptoms were not 
associated with inflammation in cross-sectional analysis
30
. However, in the same 
sample, prospective analyses on the depression-inflammation relationship showed 
that patients who repeatedly reported depressive symptoms had higher levels of 
inflammation than those who reported depressive symptoms at one interview only 
or reported no depressive symptoms
7
. The current results clearly show that 
especially those adolescents reporting at least mild symptoms of depression at all 
three assessments had higher subsequent levels of hsCRP. This can also explain 
why Chaiton and colleagues did not find a cross-sectional association between 
depressive symptoms and inflammation in adolescents
10
. Taken together, these 
results demonstrate that inflammation is most strongly associated with recurrent 
depression or persistent elevated depressive symptoms and that this relationship 
already exists in adolescence.      
 
We found that the association with hsCRP was explained by adverse health 
behaviors, especially smoking and BMI. It is well known from previous literature 




 are associated both with 
depressive symptoms and with hsCRP
19
. The findings of the current study regarding 





, and stable CHD patients
7
 in which the 
strength of the relationship between depressive symptoms and inflammation was 
affected after including one or more markers of health behavior.  
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HsCRP is involved in the development of various inflammatory diseases, such as 
cardiac disease and asthma, but also diabetes. For instance, Toprak and colleagues 
found that even in young adults, hsCRP was an independent predictor of carotid 
intima media thickness
34
. It could thus be argued that depressed young adults with 
higher levels of hsCRP may be more vulnerable for developing cardiac disease in 
later life. Furthermore, depression and inflammation are both associated with 
asthma
35
, potentially commonly induced by prenatal maternal stress
35
. Research 
has also shown that adolescents who smoke and have higher levels of hsCRP are at 
greater risk for abnormal lung function in adulthood
36
. In addition, obesity has 
been found to be an important environmental risk factor in the development of 
asthma
37
. Moreover, depression is also associated with a greater risk for diabetes, 
possibly through inflammation or obesity
38
. Intervening in eating and smoking 
habits could therefore be a potential therapeutic intervention strategy in 
adolescents with depression or depressive symptoms in order to affect future risk 
factors for health outcomes.  
The results of this study should be viewed in light of several limitations. Because 
hsCRP was only determined at wave 3, we were not able to take baseline levels of 
hsCRP into account in our analyses. Therefore we were not able to evaluate the 
change in hsCRP levels as well as the potential bidirectional association between 
depression and hsCRP, although research until now favors the view that repeated 
exposure to depressive symptoms eventually leads to increased systemic 
inflammation
7,11
. Furthermore, the internal consistency for the somatic symptoms 
scale can be considered as insufficient at all three waves and for the cognitive 
symptoms at the baseline assessment, suggesting that there is still heterogeneity 
across the subscales and mainly the somatic subscale.  The limited number of items 
in the somatic symptoms scale may serve as a potential explanation for the less 
than ideal internal consistency of the scale. Several strengths can be attributed to 
this study as well. First, because of the biennial assessments with 3 assessments 
over a period of 5 years, we were able to use a prospective design, enabling us to 
look into the course of depressive symptoms over time. Furthermore, because of 
the large sample size, we were able to properly adjust for confounding effects of 
demographics and health behaviors. 
 
In conclusion, this study shows that depressive symptoms have considerable 
heterogeneity over the course of 5 years in adolescence. These classes could be a 
reflection of recurrent and single episodes of depression. Somatic symptoms and 
cognitive symptoms showed a more stable course during the follow-up period. 
Furthermore, adolescents reporting consistent depressive symptoms over time 
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have higher subsequent levels of hsCRP. We did not find support for a differential 
association of somatic symptoms of depression and cognitive symptoms of 
depression with hsCRP. This suggests that total depressive symptoms are more 
strongly associated with hsCRP, than subscales of depression are. Finally, the 
association between depressive symptoms and hsCRP was mainly explained by 
health behaviors such as smoking and BMI. Interventions focused on improving 
adverse health behaviors in depressed adolescents might have positive effects on 
levels of hsCRP and possibly on future health status, and is worth investigating in 
the future.    
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Viral infections and subsequent 
depression in adolescence  

























Background: Research has linked virus infections to mental disorders such as 
schizophrenia, with a possible role for inflammation. Inflammation has also been 
associated with depression. However, little is known about depression and virus 
infections. We therefore set out to evaluate the cross-sectional and prospective 
association between markers of virus infection and depression in young 
adolescents.  
Methods: We used data from wave 3 and 4 from the TRacking Adolescents' 
Individual Lives Survey (TRAILS), a Dutch prospective cohort study (N = 1057). 
Depressive symptoms were assessed using the Youth Self Report (YSR) at wave 3; 
depression diagnosis was evaluated using CIDI interviews at wave 4. At wave 3, 
blood was collected to determine the presence of immunoglobulin G (IgG) 
antibodies in serum to Herpes Simplex Virus (HSV)-1, Cytomegalovirus (CMV), and 
Epstein Barr Virus (EBV). Antibodies were analyzed as a continuous variable. In 
addition, a categorical pathogen burden variable was created to reflect the number 
of infectious markers present (0= no markers to 3 = 3 markers).  
Results: HSV-1 was present in 257 (24.3%) adolescents, EBV in 258 (24.4%), and 
CMV in 261 (24.7%) adolescents. Depression was diagnosed in 127 adolescents 
(12%). Linear regression showed an inverse association between CMV and 
depressive symptoms, but only after adjustment for demographics. No associations 
were found between HSV-1 and EBV with depressive symptoms. Logistic regression 
analyses did not reveal an association between the presence of HSV-1, EBV, or CMV 
and depressive symptoms or clinical depression. Furthermore, pathogen burden 
was not related to depressive symptoms and depression diagnosis. 
Conclusions: We only found limited support for an inverse association between 
CMV for and depressive symptoms. This suggests that depression in adolescence is 
not affected by the presence of viral infections. However, it could be that the 









Infectious agents have been linked to mental disorders such as schizophrenia and 
bipolar disorder, with a possible role for inflammation
1
. Furthermore, it has also 





is affected by virus infection. For instance, Dickerson and 
colleagues found that both Herpes Simplex Virus (HSV)-1, and higher levels of 
hsCRP were associated with impaired cognitive functioning in patients with 
schizophrenia
1
. Inflammation has also been associated with depression
4-6
, with 
some research suggesting that a higher number of depressive symptoms
7
, as well 
as recurrent depressive symptoms
5, 6
 are associated with higher levels of 
inflammation. Until now, little attention has been paid to a possible relationship 
between depression and infectious agents. There is some evidence though in 
support of the association between viruses and depression
8-10
. For instance, Miller 
and colleagues found that recovering acute coronary syndrome (ACS) patients 
experiencing depressive symptoms had more latent viruses (Epstein-Barr virus 
(EBV), Cytomegalovirus (CMV) and HSV-1) than those without depressive 
symptoms
9
. In line with this, Philips and colleagues found that antibodies to CMV 
were associated with depression in an elderly sample in such a way that 
participants with higher CMV antibodies reported higher depressive symptoms
8
. 
One of the explanations could be that infectious agents such as HSV-1 and EBV
11
 
may reside in the brain, especially in the limbic system, an area involved in emotion 
processing. Areas in the limbic system, such as the amygdala, hippocampus, and 




The presence of antibodies to HSV-1 and EBV  increases with age
13
, but they may 
already be present in adolescence
13
 and often go by asymptomatically in 
childhood
14
. It could thus be hypothesized that the presence of viruses in the 
adolescent brain may be associated with psychological disorders, such as 
depression. We therefore set out to evaluate the cross-sectional and prospective 
association between markers of virus infection, i.e. the epstein-barr virus, the 
cytomegalovirus, and the herpes simplex virus 1 and 2, with depressive symptoms 









The study is part of the Tracking Adolescents’ Individual Lives Survey (TRAILS), 
which is a large ongoing prospective population study of 2230 Dutch adolescents 
from the north of the Netherlands. It is a multidisciplinary study on causes and 
effects of physical and mental health from childhood to adulthood. The design of 
TRAILS is further described elsewhere
15
.  In short, in the five major municipalities in 
the northern part of the Netherlands all 135 primary schools were asked to 
participate in this study. Of the children of the schools that decided to participate, 
children with mental retardation, physical incapability or language problems were 
excluded. Of all children approached for inclusion in the study (N = 3145), 2230 
(76.0%) were enrolled in the study. At wave 1 parents had to provide a written 
informed consent.  At waves 2, 3, and 4 the adolescents gave written informed 
consent. Of the total baseline sample (N = 2230, mean age = 11.09, SD = .56) 2149 
adolescents (96.4 %, mean age = 13.65, SD = .53) took part in wave 2, two to three 
years after the baseline assessment. At wave 3, 1816 adolescents (81.4%, mean age 
= 16.27, SD = .73) and at wave 4 1881 adolescents (84.3%, mean age = 19.1, SD = 
.60) participated in the study. For this study we used data from waves 3 
(September 2005 to August 2008) and 4 (October 2008 to September 2010). 
Immunoglobulin G (IgG) class for HSV-1, HSV-2, CMV, and EBV was determined for 
1220 adolescents at wave 3. Data on total depressive symptoms were available for 
1660 adolescents at wave 3 and depression diagnosis for 1584 adolescents at wave 
4. This resulted in a final sample of 1057 adolescents. TRAILS was approved by the 
Central Committee on Research Involving Human Subjects (CCMO).  
 
Depressive symptoms 
Depressive symptoms were measured at wave 3 using the Youth Self Report (YSR), 
a self-report questionnaire which assesses the emotional and behavioral problems 
during the past 6 months. The Affective Problems scale contains 13 items that are 
scored on a 3-point scale (0=not true, 1=somewhat or sometimes true, 2=very or 
often true). A previous study using the YSR in the TRAILS sample showed that 
omission of one sleep item (‘I sleep more than most kids’) increased the internal 
consistency of the scale, for which we excluded this item
16
. Scores on the remaining 
12 items (depressed mood, anhedonia, loss of energy, feelings of worthlessness 
and guilt, suicidal ideation, sleep problems, and eating problems) items were 
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summed up to construct the YSR Affective Problems Scale with an internal 
consistency (Cronbach’s α) of .79 at wave 3.  This scale reflects the symptoms of a 





. The good reliability and validity of the 





The Composite International Diagnostic Interview (CIDI) version 3.0 was used at 
wave 4 to determine depression diagnosis. The CIDI is a comprehensive, fully-
structured interview designed for the assessment of mental disorders according to 
the definitions and criteria of ICD-10 and DSM-IV
19
. The participants were 
individually interviewed by a trained interviewer. For this study minor and major 
depressive episodes of depression during the 12 months preceding the interview 
were included (N = 19 and N = 106 respectively).  
 
Measurement of antibodies 
During the third assessment, all participants were asked to donate a blood sample 
for various biomarker analyses. After consent had been obtained from the parents 
and the adolescents, 39.5 ml fasting blood was drawn at the schools and delivered 
to the University Medical Center Groningen within four hours, where serum was 
extracted and stored at −80 °C until analysis. Infection of the human body by most 
infectious agents is associated with the development of persistent IgG class 
antibodies that can be measured in the blood of individuals years after the 
infection and are therefore suitable for epidemiological studies. IgG serum 
antibodies to the Herpes virus family (Herpes Simplex Virus Type 1 (HSV-1) Herpes 
Simplex Virus 2 (HSV-2) Epstein Barr Virus (EBV), Cytomegalovirus (CMV), were 
measured using solid-enzyme immunoassay methods, as previously described
20
. 
For each assay, a result was defined as positive or negative based on comparison 
with the reactivity of specific antibody standards saved along with the blood 
samples. The standards that tested antibodies to the herpes viruses consisted of 
samples with defined levels of reactivity of the specific herpes antigens
21
. All 
serological tests were carried out by standard procedure at the Stanley Laboratory 
of Developmental Neurovirology, Baltimore, Maryland, USA. A categorical variable 
reflecting pathogen burden was calculated as the sum of the number of virus 
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markers present at wave 3 defined as follows: no virus = 0; 1 virus = 1; 2 viruses = 2; 
3 viruses = 3.  
 
Covariates 
Age, sex and socio-economic status were included in the analyses as these 
demographic variables are associated with depressive symptoms
22
. Socio-economic 
status was based on baseline data (wave 1) on the education, income, and 
occupation from either the adolescents’ father or mother using the International 
Standard Classification
23
, and the lowest 25%, intermediate 50% and highest 25% 
of the scores were defined as low, middle, or high. 
As inflammation has been found to be associated with depression
4
, but also with 
viral infections, the possible mediating effects of high sensitive C-reactive protein 
(hsCRP) was explored as well by adding hsCRP to the analyses in an additional step. 
hsCRP was determined using a immunonephelometric method, BN2, CardioPhase® 
hsCRP, Siemens with a lower detection limit of .175 mg/L. Intra-assay coefficients 
of variance ranged from 2.1 to 4.4, and inter-assay coefficients of variation 
coefficients of variance ranged from 1.1 to 4.0. HsCRP was not normally 
distributed, so we applied a log transformation to achieve normality.  




, and body mass index (BMI)
26
, 
that are associated with depression were included in a subsequent step to explore 
their possible mediating effects. Smoking, physical activity, and BMI, measured at 
both wave 3 and wave 4. Smoking was defined as no, former, or current smoker
27
. 
Physical activity was calculated by means of metabolic equivalent scores (METs). 
METs are the ratio of the work metabolic rate to the resting metabolic rate. One 
MET is defined as 1 kcal/kg/hour and is roughly equivalent to the energy cost of 
sitting quietly. A MET also is defined as oxygen uptake in ml/kg/min with one MET 
equal to the oxygen cost of sitting quietly, equivalent to 3.5 ml/kg/min
27
. BMI was 





T-test, ANOVA, and χ
2 
were used to assess differences in proportions and means of 
covariates between adolescents with and without depression diagnosis. HSV-1 was 
present in 257 (24.3%) adolescents, EBV in 258 (24.4%), and CMV in 261 (24.7%) 
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adolescents. Because only 12 adolescents were found seropositive for HSV-2 (< 
2%), we did not include this marker in further analyses. 
We used linear regression analyses to determine the cross-sectional association 
between HSV-1, EBV, and CMV and depressive symptoms at wave 3 in 3 separate 
unadjusted analyses. In addition, the association between pathogen burden and 
depressive symptoms was analyzed. Prospective logistic regression analyses were 
conducted to explore the association between the individual virus markers and 
depression diagnosis at wave 4 and to examine the association between pathogen 
burden and depression diagnosis.  
All analyses were adjusted for potential confounders. In the first step, demographic 
variables (age, sexe, and SES) (demographics) were added.  Additionally, hsCRP was 
included to demographics model to adjust for possible mediating effects (hsCRP). In 
the final step, physical activity, smoking, and BMI were added to the hsCRP model 
(health behaviors). In the prospective analyses only, depressive symptoms 
determined at wave 3 were added to the health behaviors model. All analyses were 




Table 1 shows the sample characteristics at wave 4 according to the presence of a 
depression diagnosis in the past 12 months. Of the 1057 adolescents 127 were 
diagnosed with a major or minor depressive disorder in the past 12 months. 
Compared to adolescents without a depression, those with a depression were on 
average older (p=.02), more often female (p<.001), more often had a low socio-
economic background and less often had a high socio-economic background 
(p=.03). Finally, depressed adolescents were more often current smoker and less 
often former smoker (p=.03).  
Cross-sectional analysis of virus infection and depressive symptoms  
Linear regression analyses revealed evidence for a cross-sectional association 
between EBV (p=.03), but not HSV-1 (p=.26) and CMV (p=.17) and depressive 
symptoms in adolescents (Table 2). Adjusting for demographics, hsCRP, and health 
behaviors made the association between EBV and depressive symptoms non-
significant (p≥.13), but hardly changed the magnitude of the association.  
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Table 1. Sample characteristics (N = 1057) 
 Depressed (N = 127)  Not depressed (N=   
 N or M % or SD  N or M % or SD  p-value 
Age 19.1 0.6  19.0 .5  <.01 
Sex (male) 34 26.8  448 48.2  <.01 
Socio-economic        
Low 26 20.5  149 16.0  .131 
Middle 67 52.8  453 48.7   
High 34 26.8  328 35.3   
        
BMI 23.4 4.6  22.9 3.7  .21 
Smoking        
No 41 32.3  443 47.6  <.01 
Former 35 27.6  267 28.7   
Current 51 40.2  220 23.7   
Physical activity 3180.7 3345.0  3548.9 4956.1  .42 
        
hsCRP mg/L median .50 .20-1.6  .40 .20-1.00  .04 
HSV1 median (IQR) .16 .11-.96  .16 .11-.96  .70 
HSV 2 median (IQR) .07 .05-.10  .07 .06-.11  .16 
EBV median (IQR) .78 .14-1.18  .69 .12-1.08  .43 
CMV median (IQR) .32 .22-.80  .32 .23-.98  .69 
Pathogen burden        
None 53 41.7  433 46.6  .23 
One 54 42.5  345 37.1   
Two 19 15.0  120 12.9   
Three 1 0.8  32 3.4   
Virus and hsCRP are determined at wave 3, socio-economic status is determined at wave 1. 
All other variables wave at 4. BMI = Body Mass Index, hsCRP = high sensitive C-Reactive 
protein, HSV 1 = Herpes Simplex Virus 1, HSV 2 = Herpes Simplex Virus 2, EBV = Epstein Barr 
Virus , CMV = Cytomegalovirus. 
 
The association between CMV and depressive symptoms showed a significant 
inverse association between CMV and depressive symptoms (p = .04) after 
adjustment for demographics, with sex being the most important covariates (Table 
2). However, the magnitude of the association was hardly affected, suggesting that 
the significant association is a result from sex. The results remained essentially 
unchanged for HSV-1.  
When the presence of a virus infection was analyzed as a pathogen burden, no 
significant results were found for number of viruses predicting depressive 
symptoms (p=.44).  
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Table 2. Virus infection as a predictor for depressive symptoms (N = 1057) 
 Depressive symptoms at wave 3 
 β  95%CI  p-value 
HSV 1      
Unadjusted .06  -.09-.35  .26 
Demographics* .03  -.11-.31  .36 
hsCRP .03  -.12-.30  .40 
Health behaviors** .02  -.15-.27  .60 
EBV      
Unadjusted .07  -.04-.82  .03 
Demographics* .05  -.09-.66  .13 
hsCRP .04  -.10-.66  .14 
Health behaviors** .03  -.18-.57  .30 
CMV      
Unadjusted -.04  -.38-.07  .17 
Demographics* -.06  -.46--.02  .04 
hsCRP -.06  -.46--.02  .04 
Health behaviors** -.06  -.47--.01  .04 
*Adjusted for wave 3 age, sex, and socio-economic status. 
**Adjusted for demographics and wave 3 BMI, smoking, and physical activity 




Prospective analysis of virus infection and depression diagnosis 
Table 3 shows the results for the logistic regression analyses with depression 
diagnosis as outcome measure. None of the viruses were associated with a 
subsequent depression  diagnosis (p>.24). Essentially the same results were found 




The results from this study show an inverse association between CMV and 
depressive symptoms. We did not find support for an association of HSV-1 and EBV 
with the presence of depressive symptoms or any of the virus markers with 
subsequent depression diagnosis in adolescents. To our surprise CMV was 
associated inversely with depressive symptoms, but only after adjustment for  
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Table 3. Virus infection as a predictor for depression diagnosis (N = 1057) 
 Depression 
 OR  95%CI  p-value 
HSV 1      
Unadjusted .97  .79-1.19  .80 
Demographics* .95  .77-1.17  .63 
hsCRP .94  .76-1.15  .54 
Health behaviors** .92  .74-1.13  .43 
Depressive symptoms .90  .72-1.12  .33 
EBV      
Unadjusted 1.17  .83-1.16  .37 
Demographics* 1.06  .75-1.51  .74 
hsCRP 1.05  .74-1.50  .79 
Health behaviors** 1.03  .72-1.47  .88 
Depressive symptoms .98  .67-1.44  .92 
CMV      
Unadjusted .96  .78-1.18  .71 
Demographics* .90  .73-1.12  .35 
hsCRP .91  .73-1.12  .37 
Health behaviors** .88  .71-1.09  .24 
Depressive symptoms .94  .75-1.18  .59 
*Adjusted for wave 4 age, sex, and socio-economic status. 
**Adjusted for demographics and wave 4 BMI, smoking, and physical activity 
 
demographics. Sex was found to be the most important confounder and probably 
explains the inverse association between CMV and depressive symptoms. It should 
be kept in mind that the magnitude of the association was reasonably small and 
therefore probably not clinically relevant. 
 
 To our knowledge this is the first study to report on viral infections and depression 
in a young, adolescent population of healthy individuals. Previous reports have 
been published on presence of viruses and depression in adult samples, and reveal 
results opposite to ours
8-10
. For instance, Miller and colleagues found in sample of 
patients with ACS that the presence of viruses was positively associated with 
depression. Moreover, especially those patients presenting with three viruses had 
more severe depressive symptoms
9
. In our sample, pathogen burden was still 
relatively low, with only a small number of participants presenting with three 
viruses, which may be an explanation for the discrepancy in results. Further 
support for the depression – viral infection link comes from a study in elderly 
participants. Philips and colleagues found that the seropositivity for CMV alone was 
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not associated with depressive symptoms, but that participants with higher anti-
body titers to CMV reported more depressive symptoms
8
, suggesting that the 
depressive symptoms are a reflection of recent or reactivated infection
8
. Increases 
in antibody titers to CMV, but also EBV have been associated with aging and could 
reflect increased frequency of virus reactivation in older people
28
. Psychological 
stress is one of the mechanisms that can reactivate latent viruses
29-31 
and it is 
plausible that the young sample used for this study, experienced relatively little 
psychological stressors that can contribute to virus reactivation.  
The results of our study suggest that virus infection is not associated with 
subsequent depression diagnosis, i.e. depression emerges independently of virus 
infection. However, based on results from other studies, it could be hypothesized 
that depression in the presence of latent viral infections can reactivate the 
viruses
29-32
. This could possibly lead to microglial activation, a process involved in 
neuroinflammation
33, 34
 which has been implicated to play a role in the 
development and progression of depression
35
. This neuroinflammatory induced 
depression could then possibly reactivate the virus again, suggesting a vicious 
circle. This vicious circle could serve as a possible physiological explanation for 
recurrent or persistent depression and warrants further research. 
The longitudinal nature of this study provided us with the opportunity to take a 
closer look into the prospective association between viral infections and depression 
in adolescents. However, some limitations need to be addressed as well. First, 
antibody status does not provide information regarding the specific time in life the 
viral infection took place, and thus the effects of longer or shorter duration of viral 
infections cannot be taken into account. Furthermore, because we only have data 
on antibodies from the wave 3 assessment available, we are not able to look into 
the possible long term effects of depression on virus reactivation. Because of the 
relatively young age of this sample, the results should be interpreted carefully, as 
the results are probably not generalizable to adults.    
In conclusion, we found little support for a cross-sectional association between 
CMV and depressive symptoms, but no prospective associations between virus 
infection and depressive symptoms or subsequent depression. These findings can 
be attributed to the relatively young age of the sample used for this study. This 
does not rule out an association between viral infections and depression. Further 
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The main objective of this thesis was to investigate the relationship between 
depression and inflammation over the lifespan. More specific, this thesis aimed to 
evaluate the association between recurrent and single episodes of depression, and 
to examine differences between somatic and cognitive symptoms of depression in 
their relationship with inflammation in various study samples. Within these 
research objectives, the effects of health behaviors on the depression-
inflammation link were investigated. Finally, another possible pathway between 
depression and immune function was investigated; the prospective association 
between viral infection and depression. 
In order to look into depression and inflammation in light of a life perspective, data 
from 3 prospective cohort studies were used that included samples increasing in 
age. The results presented in this thesis are summarized in table 1. 
The youngest sample came from the TRacking Adolescents’ Lives Survey (TRAILS) 
and was used to evaluate trajectories of depressive symptoms, somatic symptoms 
and cognitive symptoms of depression and their association with subsequent high 
sensitive C-reactive protein (hsCRP) in 1166 adolescents (chapter 7). Data was 
available from 3 time points assessed biennially over a 5-year follow up period. In 
chapter 8, the presence of herpes simplex 1 (HSV-1), epstein barr virus (EBV), and 
cytomegalovirus (CMV) was investigated in association with depressive symptoms 
and depression diagnosis in 1057 adolescents.  
Data from the Netherlands Study of Depression and Anxiety (NESDA) was used to 
examine depression and inflammation in a middle-aged community sample. In 
chapter 5 the cross-sectional association between depression diagnosis, as 
measured with the Composite Interview Diagnostic Instrument (CIDI)
1
, with hsCRP, 
interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α) was investigated in 2415 
participants. The differential associations between somatic and cognitive 
symptoms of depression and anxiety with hsCRP, IL-6, and TNF-α were examined in 
2681 participants (chapter 6). 
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The heart and soul study is a long term prospective cohort study, from which data 
of 667 patients with stable coronary heart disease (CHD) were used. Data from the 
baseline assessments and 5 consecutive annual assessments were available to 
evaluate the prospective bi-directional association of depression with high sensitive 
hsCRP, IL-6, and fibrinogen (chapter 3), and with total white blood cell (WBC) count 
(chapter 4). Furthermore, the presence of single episodes of significant depressive 
symptoms was compared to recurrent significant depressive symptoms in their 
bidirectional association with inflammation. 
 
Depression and inflammation 
Various studies have reported on the association between depression and 
inflammation both in healthy samples and in patients with CHD. Results reported 
range from negative associations to positive associations. A 2009 meta-analysis 
conducted by Howren and colleagues provided more insight and reported an 
overall positive association between depression and hsCRP (Cohen’s d = .15) and IL-
6 (Cohen’s d = .25) in healthy and clinical samples with a rather modest effect size
2
. 
Following this meta-analysis, we conducted a meta-analysis specifically aiming at 
patients with established CHD using a more strict definition of CHD (chapter 2). We 
only included patients with established CHD and not subclinical disease such as 
atherosclerosis, and end stage heart disease, such as heart failure. Overall, we 
found a small to moderate and significant effect size (Cohen’s d = .30) for 
depressive symptoms and CRP, but not for IL-6. This is in contrast with the findings 
from Howren and colleagues who reported a smaller effect size for CRP and a 
significant effect size for IL-6
2
. This could be due to our more strict inclusion 
criteria, which excluded studies with possible or subclinical CHD, but also excluded 
more advanced stages of heart disease. One major limitation of our meta-analysis 
is that we were not able to properly adjust for potentially mediating variables
3
, 
such as health behaviors. Furthermore, only cross-sectional studies were included 
which makes it impossible to draw conclusions on the direction of the association 
between depressive symptoms and CRP.  
 
Diagnosis versus symptoms 
The meta-analysis from Howren and colleagues showed that depression diagnosis 
was more strongly associated with inflammation than depressive symptoms were
2
. 
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On average the effect size for depression diagnosis could be considered moderate, 
whereas the effect size for depressive symptoms was small. In our meta-analysis, 
we found, compared to Howren and colleagues, a larger effect size for CRP and no 
significant effect size for IL-6 in relation to depressive symptoms in patients with 
CHD. This suggests that results can differ according to the study sample used in 
terms of age and disease status, but also type of depression assessment (self-
report versus clinical interview).  
In the oldest sample presented in this thesis, patients with CHD, we found that 
depressive symptoms averaged over a 6 year period were associated with 
subsequent inflammation (hsCRP, IL-6; chapter 3, and WBC count; chapter 4) (table 
1). Depression was also associated with higher levels of inflammation in middle-
aged men (chapter 5). More specifically, current depression diagnosis was 
associated with higher levels of hsCRP and marginally higher levels of IL-6, but not 
TNF-α in men only. Especially men with a late-onset of depression had higher levels 
of inflammation. In a subgroup of clinically depressed participants, hsCRP and IL-6 
levels were higher when participants used tricyclic (TCA) and tetracyclic (TeCA) 
antidepressants, and in men using serotonin noradrenergic reuptake inhibitors 
(SNRI). This is in line with previous studies that reported on antidepressant 
medication use and inflammation which showed that TCA use was associated with 
higher levels of inflammation
4
, whereas SSRI use was associated with a decrease in 
inflammation
5
. This may be a reflection of noradrenergic effects on inflammation.  
Comparable to a diagnosis of depression, depressive symptoms were also found to 
be associated with increased levels of IL-6, hsCRP, and TNF-α in the same study 
sample (chapter 6), even though the effect sizes were smaller than for clinical 
depression (Table 1) and mediated by health behaviors. Finally, we did not find 
support for a cross-sectional association between depressive symptoms and 
inflammation in adolescents. 
Depression and inflammation were associated in both middle-aged participants 
and patients with CHD. However, the effect sizes were strongest in CHD patients 
and when a depression diagnosis was used (table 1). This suggest that there may be 
a dose-response relationship in the association between depression and 
inflammation, with the most severe depression being most strongly associated with 
inflammation and with the highest effect sizes being present in patients with the 
most disease burden (table 1). Earlier research has indeed shown that depression 
diagnosis is moderately associated with inflammation
6-8
. In contrast, a recently 
published study reported no association between clinical depression and a broad 
range of cytokines, but this study consisted of a relatively small sample (depressed 





. Furthermore, our results showed that especially late-onset depression 
was associated with inflammation. Late-onset depression has been associated with 
a family history of vascular disease
10
 and atherosclerosis, a subclinical risk factor for 
cardiac disease
11, 12
. This suggests that the association between late-onset 
depression and higher levels of inflammation are possibly a reflection of subclinical 
disease, which becomes more prevalent with aging. Moreover, in comparison to 
the meta-analysis from Howren and colleagues
2
, we found stronger effect sizes for 
the studies presented in this thesis on patients with CHD (chapters 2, 3, and 4). This 
is possibly due to the prospective data we used which enabled us to disentangle 
the relationship between recurrent depressive symptoms and inflammation, 
compared to a single episode of depressive symptoms. Another possible 
explanation comes from the vascular depression hypothesis, which states that 
depression can be the result of vascular damage in the brain
13
, e.g. white matter 
changes
14
. As higher levels of inflammation are involved in vascular diseases
15
, this 
damage could be the result of inflammation. 
 
Single episode versus recurrent depression and inflammation 
Research has suggested that mainly recurrent depression is associated with 





, but also new cardiac events in post myocardial 
patients
18
 are found to be more prevalent in those who suffer from depression 
more frequently. It could be hypothesized that this also accounts for inflammation, 
as inflammation is associated with both depression and (risk factors for) CHD. 
This hypothesis has been evaluated in this thesis in a sample of 667 patients with 
stable CHD and in a sample of 1166 adolescents. The results showed that recurrent 
significant depressive symptoms were associated with higher levels of subsequent 
hsCRP (chapters 3 and 7), IL-6 (chapter 3), and WBC count (chapter 4) (table 1). 
Furthermore, the results showed that the associations with hsCRP and IL-6 were 
mediated by health behaviors, whereas the association with WBC count was not. A 
possible explanation for this difference could be that recurrent significant 
depressive symptoms are a reflection of chronic stress, which may stimulate 
hematopoietic stem cells in the bone marrow to produce WBCs
19
. In this cascade, 
the role of health behaviors might be less important than in the more downstream 
depression-cytokine relationship. One major limitation in the WBC study was that 
we only looked into total WBC count and that we were not able to differentiate 
between the individual WBC’s, such as monocytes and neutrophils. This is 
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important, as there is evidence that especially monocytes are associated with 
atherogenesis
20
, history of cardiac disease
21
, and psychological complaints
22
.  
We did not find support for a prospective association between inflammation and 
subsequent significant depressive symptoms. This is in concurrence with findings 
from other studies who also reported that depression predicted higher 
inflammation, but not vice versa
23, 24
. However, one study reported that 
inflammation preceded depressive symptoms
25
, though this study only looked into 
4 items of the General Health Questionnaire which does not cover all the 
symptoms of depression. In accordance with the results we reported on patients 
with CHD, we found that adolescents with persisting depressive symptoms over a 
5-year follow-up also had higher levels of subsequent hsCRP, suggesting that the 
pro-inflammatory effects of recurrent depressive symptoms are not restricted to 
older samples only (chapter 7). Also, the association between recurrent depressive 
symptoms and hsCRP in adolescents was mediated by health behaviors. 
The results on recurrent versus single episodes of depression presented in this 
thesis confirm previous findings in various populations. Earlier retrospective 
studies
26, 27
 and one prospective study
24
 conducted in various age samples reported 
that participants with recurrent depressive symptoms had higher levels of 
inflammation than those who reported a single episode of depression
24, 26, 27
.  
Integrating these findings with the results from this thesis provides substantial 
evidence that the association between depression and inflammation is especially 
apparent in those who repeatedly suffer from depressive symptoms and that this 
association is already present from early age on. However, we did not find support 
for an association between inflammation and duration of depressive symptoms in a 
middle-aged sample (chapter 5). One major difference between this study and the 
studies conducted in adolescents (chapter 7) and CHD patients (chapter 3 and 4) is 
that these were prospective studies, whereas duration of depressive symptoms in 
the middle aged sample was determined retrospectively which may be affected by 
recall bias.  
A possible explanation for the above described results could be that the recurrent 
depressive symptoms reflect a more chronic state of depression or chronic stress. 
In reaction to stress the hypothalamus is activated to produce corticotrophin-
releasing hormone (CRH) which stimulates the pituitary gland to produce 
adrenocorticotropic hormones (ACTH). Under the influence of ACTH, the adrenal 
cortex secretes cortisol, collectively termed as the hypothalamus-pituitary-adrenal 
(HPA) axis response to stress
28, 29
. Stress can be divided into acute stress and 
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chronic stress, with acute stress lasting for a period of minutes or hours and 
chronic stress being more persistent and experienced for several hours per day, 
during weeks or months
29
. Acute and chronic forms of stress have different effects 
on the immune system. In the case of acute stress, cortisol is immunosuppressive, 
i.e. enhancing the production of anti-inflammatory markers and inhibiting the 
secretion of pro-inflammatory markers
30
. However, it has been found that under 
the influence of chronic stress the immune system is less responsive to the anti-
inflammatory actions of cortisol. This glucocorticoid (GC) resistance of T cells 
results in an increased production of cytokines and may result in an upregulation of 
systemic inflammation
28, 31-33
. Another possible pathway linking stress to 
inflammation is the autonomic nervous system (ANS) (for an overview see
5, 32, 34-37
).  
Under the influence of stress the sympathetic nervous system (SNS) can be 
activated which results in increased levels of catecholamines. Catecholamines are 
found to be associated with higher levels of inflammation. Moreover, there is some 
evidence that reduced activity of the  parasympathetic nervous system is 
associated with reduced acetylcholine sensitivity, which is hypothesized to be 
associated with dysregulated inflammatory control and thus possibly higher levels 
of inflammation
34
. Furthermore, the immune responses to stress can be defined in 
terms of their end effects as 1) immunoprotective, which is characterized by a rapid 
and robust immune response, 2) immunoregulative, which concerns inhibiting of 
immune cells, and 3) immunopathological, which involves chronic inflammation
29
. 
It has been suggested that these latter immune responses depend on resilience, 
the capacity of psychological and interacting physiological systems to recover from 
challenging conditions
29
 and thus determine whether the response has a negative 
or positive influence. It could also be suggested that in this stress-immune model 
health behaviors play a mediating role by either stimulating persisting experience 
of stress or directly upregulate systemic inflammation. Stress and more specific, 





. Taking all this together results in a stress-behavior-immune 
model as depicted in figure 1. Under the influence of chronic stress cortisol is 
secreted by the HPA-axis. This prolonged stress reaction dysregulates the pro-
inflammatory processes through GC resistance.  
Furthermore in response to stress, the ANS upregulates inflammation, either in 
synergy with the HPA-axis or on its self. In this final pathway, the negative effect of 
GC on health behaviors could have an additional upregulating effect on 
inflammation. This stress-behavior-immune model is worth to be considered in 
future research. 




Figure 1: Graphical representation of stress-behavior-immune model. Chronic stress 
activates the HPA-axis and the sympathetic nervous system (SNS), whereas it reduces the 
activity of the parasympathetic nervous system (PNS), resulting in immunopathological 
responses through adverse health behaviors. 
 
Somatic versus cognitive symptoms of depression and inflammation 
Research suggests that mainly the somatic symptoms of depression (e.g. sleeping 
difficulties, psychomotor retardation or activation, changes in eating behavior, and 
fatigue), and not the cognitive symptoms of depression (e.g. difficulties 
concentrating, loss of interest, and depressed mood) are associated with worse 
prognosis in CHD patients
41-43
. Based on the sickness behavior theory, this idea has 
been adopted and applied to depression-inflammation research. The sickness 
behavior theory states that motivational behaviors, such as less moving and eating, 
and more sleeping, emerge in the presence of higher levels of inflammation as a 
reflection of sickness
44
. These motivational behaviors show a resemblance with the 
somatic symptoms of depression. It could thus be argued that the worse health 
outcomes associated with somatic symptoms of depression are associated with 
inflammatory processes that may reflect the presence of cardiac disease. With this 
idea in mind we investigated whether somatic symptoms and cognitive symptoms 
are differentially associated with inflammation in a middle-aged sample and an 
adolescent sample. 
188 Chapter 9 
 
 
In line with this idea, we found that somatic symptoms of depression, but not 
cognitive symptoms of depression were significantly associated with hsCRP, IL-6 
and TNF-α in middle-aged participants (chapter 4), but health behaviors played an 
important mediating role in this relationship. This is in line with findings from 
previous studies Elovainio and colleagues who found that somatic symptoms were 
more strongly associated with inflammation in men than in women
45
. However, 
these results were not mediated by the effects of health behaviors
45
. Contrasting 
results have also been published though. Kupper and colleagues found that both 
somatic and cognitive symptoms were cross-sectionally and prospectively 
associated with inflammation
46
. One possible explanation for this difference could 
be that the study from Kupper and colleagues consisted of an older sample of heart 
failure patients. Levels of inflammation have been found to increase with age and 
patients with heart failure patients are exposed to inflammation for a longer period 
of time, due to their condition. Prolonged exposure to inflammation can result in a 
priming effect, in which the pro-inflammatory response to a pathogen or invader is 
exaggerated
47
 and might therefore result in greater depressive symptoms. 
Furthermore, depressive symptoms are possibly associated with vascular damage, 
as suggested by the vascular depression hypothesis
13
. 
In contrast to the findings in the middle-aged sample, we did not find support for a 
differential association between somatic and cognitive symptoms of depression 
and inflammation cross-sectionally and over a 5-year follow up period in 
adolescents. This suggests that somatic symptoms of depression are experienced in 
the presence of systemic inflammation, but not until adulthood. This may represent 
another possible pathway through which depression and inflammation interact 
next to the stress-behavior-immune model. Based on the sickness behavior theory, 
which suggests that somatic symptoms of depression emerge in the presence of 
upregulated inflammation
44
, it could be argued that somatic symptoms are 
preceded by inflammation. According to the sickness behavior theory, these 
somatic symptoms can be viewed as a motivational state. This is supported by 
studies in cancer patients. Patients with cancer treated with IFN-α therapy were 
found to develop the somatic symptoms of depression. Only a subgroup of patients 
developed cognitive symptoms of depression, but these could effectively be 
treated with an antidepressant (Paroxetine)
48, 49
.  This suggests that the somatic 
symptoms are a direct response to the inflammatory process present in the body. 
This is also supported by a study from Kupper and colleagues who found that 
change in somatic symptoms over a 12-month period was associated with 
inflammation at 12 months follow-up, and not baseline levels of somatic symptoms 
of depression. This suggests that those who had higher levels of somatic symptoms 
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at follow-up than they had at baseline, were also having higher levels of 
inflammation
46
. In fact, this could be the effect of higher levels of inflammation at 
follow-up. Taken together, somatic symptoms of depression are possibly a direct 
response to inflammation, but not until adulthood. This association might be a 
reflection of (subclinical) disease, but data on this is currently lacking.   
 
Anxiety symptoms and inflammation 
As with depressive symptoms, anxiety symptoms are associated with higher risk for 
CHD in healthy
50
 and cardiac patients
51
. Some research has even suggested that 
mainly the somatic symptoms of anxiety are associated with CHD risk
52
 and 
inflammation could possibly play a role in this relationship.  
Chapter 6 provides preliminary evidence for an association between symptoms of 
anxiety and inflammation in middle-aged men (table 1). This is in line with previous 
findings
53-55
, though our results suggest that the anxiety-inflammation relationship 
is mainly driven by somatic symptoms. This sheds a new perspective on the 
association between anxiety and inflammation. Somatic symptoms of anxiety 
consist of hot flushes, respiration, heart pounding, shaking hands and difficulty 
breathing. In contrast to somatic symptoms of depression, somatic symptoms of 
anxiety are not similar to symptoms of sickness behavior, but merely a reflection of 
increased sympathetic autonomic control, suggesting a role for the sympathetic 
nervous system (SNS). The SNS has been associated with higher levels of 
inflammation
5, 35, 3
6 and could thus be involved in the anxiety-inflammation link. 
However, studies examining anxiety and the ANS show conflicting results
56-58
 as to 
whether the ANS and anxiety are associated. Possibly, the ANS is only involved in 
the somatic symptoms of anxiety and affects immune function simultaneously. As 
with depression, health behaviors played an important mediating role in the 
association between anxiety and inflammation and may serve as a therapeutic 
target for interventions. Based on the results presented in this thesis it could be 
hypothesized that inflammation plays a role in the link between anxiety and CHD. 
Further research on this subject in which inflammation, ANS function and 
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Viral infection and depression 
There is some evidence suggesting that the presence of viruses is associated with 
depression in adulthood, but also CHD. It may be another physiological explanation 
of the relationship between depression and CHD.  
In this thesis the association between viral infection and both depressive symptoms 
and clinical depression was evaluated in adolescents. We found little cross-
sectional evidence for an inverse association between CMV and depressive 
symptoms. For the other virus markers we found no association with the 
development of depressive symptoms and subsequent depression (chapter 8). 
However, the possibility of an association between viral infections and depression 
cannot be ruled out based on these results only. First, previous research has shown 
positive associations in adult populations
59-61
 and secondly, a clear association 
might not be present until (frequent) reactivation of the virus
59
. Reactivation can 
be determined by antibody titers and is found to be more prevalent with aging
62
. 
One of the mechanisms behind reactivation of latent viruses is psychological 
stress
63-65
, resulting in the activation of microglia, which is involved in 
neuroinflammation
66,67
. Neuroinflammation in the limbic area has been implicated 
to play a role in the development and progression of depression
68
, which might 
reactivate a dormant virus. This whole process might be a reflection of a vicious 
circle and could serve as another possible physiological explanation for recurrent or 
persistent depression and is worth to be investigated in future research. 
 
Clinical implications of adverse health behaviors 
Throughout this thesis, health behaviors were found to play an important 
mediating role in the association between depressive symptoms and inflammation.  
In all chapters, health behaviors were considered as mediators of the relationship 
between depression and inflammation, and were therefore added to the analyses 
as a separate group of variables.  In support of previous research
23, 27
, this thesis 
showed that markers of (un)healthy behaviors play an important role in the 
association between depressive symptoms and inflammation in all samples 
(Chapters 3, 6, 7), but not in the presence of depression diagnosis (Chapter 5). 
Especially BMI and (former) smoking were found to be important health behaviors 
in this relationship (chapter 6 and 7). This is consistent with other findings
23, 69, 70
. It 




 are associated 
with both depressive symptoms and inflammation
3
. Obesity has been found to be 




. A meta-analysis on the 
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prospective association between overweight and depression showed that the 
relationship is bi-directional: depression predicted obesity and obesity was a risk 
factor for depression
72
. An alternative explanation for this bidirectional association 
is that there is a third, common denominator, i.e. a genetic predisposition to both 
higher weight and depression. Obesity has also been found to be associated with 
higher levels of inflammation
3, 74
 and this may be attributed to the pro-





Higher levels of inflammation are involved in the development of various 




, and it has been 
suggested that depression may be associated with diabetes through 
inflammation
79
. These effects are already present in adolescence as hsCRP levels 
were found to be independent predictors of carotid intima media thickness in 
adolescents
80
. Taken together, it could be argued that depressive symptoms 
contribute to the development and progression of somatic diseases through 
inflammation with a possible role for adverse health behaviors. Promoting a 
healthy lifestyle could thus be an important therapeutic intervention strategy in 
lowering levels of inflammation and may finally have a positive effect on health 
outcomes. This is supported by Dod and colleagues who found that intervening on 
lifestyle by changing participants dietary intake and enhancing moderate exercise, 
had positive effects on lowering inflammation levels after 12 weeks
81
. Improving a 





 and it has been shown that maintaining a healthy 
lifestyle during adolescence is associated with a better cardiovascular risk profile in 
later life
85
. Promoting a healthy lifestyle should therefore be part of standard 
treatment of depression or depressive symptoms, already in adolescence and 
adults without overt CHD in order to lower the possible adverse effects of 
inflammation on health.  
 
Methodological considerations 
Many methodological strengths come with the use of large observational studies to 
examine the association between depression and inflammation, but there are also 
important limitations that need to be addressed and taken into account when 
interpreting the results. 
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One of the major strengths that accounts for all the observational studies 
conducted in this thesis is the large sample sizes (N > 667). Large samples sizes are 
especially important in order to detect true relationships, reflected in statistical 
power. With this we were able to provide more insight on the associations 
between depression and inflammation and relevant characteristics of this 
association.  
 
In this thesis health behaviors were considered as possible mediators in the 
association between depression and inflammation.  In order to consider health 




1.  Depression must be significantly associated with inflammation. 
2. The association between depression and health behaviors must be 
significant. 
3. Health behaviors must significantly predict inflammation in an equation 
which also includes depression 
 
Figure 2: Graphical representation of mediation model including depression as a predictor of 
inflammation, with health behaviors as a mediator. 
 
Theoretically, health behaviors can be considered as mediators in the depression 
and inflammation relationship, as been proven by our and other studies; 1) 
depression was associated with inflammation in every study (Chapters 2-7), 2) 







, and 3) some of our results have 
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associated with inflammation with depression in the equation. Statistically 
however, in the analyses conducted in this thesis (regression analyses and general 
linear models), it is not possible to determine if health behaviors were actually 
acting as mediators or as confounders. These analyses are restricted to adding 
covariates and do not distinguish between confounding or mediating effects of 
these covariates. More advanced methods, such as structural equation modeling, 
can be used to determine estimations for paths 1, 2, and 3 (figure 2). Preferably a 
prospective design to evaluate change over time in the outcome variable and 
multiple mediators
89
 are needed to elucidate the mediating effects of health 
behaviors in the depression-inflammation relationship.  
Finally, due to the observational nature of the studies used in this thesis it is not 
possible to draw any conclusions regarding causality. Causality can only be 
determined with a randomized control trial design, in which participants are 
randomly assigned to either an “exposed” group in which they are exposed to a 
manipulated condition, or a “control” group. It cannot be ethically justified to 
“expose” participants to depression and is thus not feasible in this research area. 
Longitudinal data is therefore the next best thing. In this thesis we were able to use 
longitudinal data in 4 studies and this presented us with the opportunity to 
determine that (recurrent) depression precedes inflammation. However, we were 
not able to rule out effects of, for instance high levels of inflammation preceding 
the baseline assessments. Therefore long term observational cohort studies 
consisting of frequent and careful assessments of depression and inflammation 
plus confounding and mediating variables, are needed to further elucidate the 
association between depression and inflammation.   
 
Future directions 
Future research should consist of a more thorough follow-up, in which depression, 
depressive symptoms and inflammatory markers should be assessed together, with 
attention for hsCRP, IL-6, TNF-α, and individual WBC’s.  As anxiety is another 
important predictor of adverse cardiac outcomes, and there is preliminary evidence 
that anxiety is associated with inflammation, this pathway should be considered in 
new research initiatives.  
As health behaviors were found to play an important role in the relationship of 
depression and anxiety with inflammation, it is worth to further investigate the 
effects of intervening in health behaviors in patients with depression or anxiety. 
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This should be examined, preferably with a randomized control design, by 
promoting a healthy lifestyle aiming at smoking cessation and lowering dietary 
intake in both patients with cardiac disease and cardiac disease free people. Finally, 
the association between viral infections and depression needs to be further 
elucidated in adolescents and adults to provide more insight in the possible vicious 
circle regarding depression and viruses. 
 
Overall conclusion 
This thesis extends previous studies on the association between depression and 
inflammation. We found that this relationship is already present in adolescence, 
but becomes stronger with increasing age. Especially a depression disorder is most 
strongly associated with inflammation. Particularly recurrent depressive symptoms 
precede inflammation, but inflammation does not precede recurrent depressive 
symptoms. Moreover, somatic symptoms, but not cognitive symptoms, seem to be 
associated with inflammation, possibly as a reflection of sickness behavior. 
Furthermore, we found preliminary evidence for an association between symptoms 
of anxiety and inflammation. 
 
Adverse health behaviors, especially BMI and smoking explain the associations 
found for depression and anxiety with inflammation. These health behaviors can 
serve as a possible therapeutic target to reduce levels of inflammation which may 
have positive effects on health outcomes. Finally, we did not find an association 
between viral infections and depression probably because of the young age of the 
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Depression is found to be associated with subsequent cardiovascular risk in initially 
healthy people. Also, people who already have established coronary heart disease 
(CHD), have a higher risk of developing a depression or feelings of depression. 
Around 20% of all CHD patients suffer from depression in the months following a 
myocardial infarction (MI). Another 20% report depressive symptoms that do not 
fulfill the criteria for a depression diagnosis. Together, these rates are around three 
times as high as in the general population. Furthermore, these depressive episodes 
of depressive symptoms have a negative influence on cardiac morbidity and 
mortality after a MI. The past decennia a range of potential (physiological) 
mechanisms have been proposed to explain the negative influence of depression 
on CHD and one of these is inflammation. Inflammation is a collective term that 
describes the body’s response to infection or injury and is involved in destroying 
the invader and initializing tissue repair in the affected area. Inflammation can be 
determined with a range of inflammatory markers measured in the blood. 
Inflammation is also involved in the development and progression of 
atherosclerosis, which is a risk factor for CHD. There is some evidence suggesting 
that depression and inflammation are associated in both healthy people and 
patients with cardiac disease. However, little is known about the direction of the 
relationship, does depression cause inflammation or does inflammation cause 
depression?   
The general aim of this thesis was to thoroughly investigate the association of 
depressive symptoms and depression with inflammation across the lifespan, 
especially focusing on the nature of the depression (clinical vs. subclinical 
depression, type of symptoms (somatic versus cognitive), and recurrence) and the 
directionality of the relation between depression and inflammation. Furthermore, 
in this thesis the influence of adverse health behaviors on the depression-
inflammation relationship will be examined. Finally, other possible pathways will be 
investigated; the association between anxiety and inflammation and the 
relationship between viral infections and depression. The inflammatory biomarkers 
included in this thesis were C-reactive protein (CRP), interleukin (IL) 6, tumor 







Depression and inflammation 
Systematic reviews of the literature and meta-analyses have shown that depression 
is associated with CRP and IL-6 in various populations, including CHD patients and 
psychiatric patients. These studies showed that the strength of the association is 
stronger as the depression becomes more severe (symptoms versus diagnosis).  
Following an earlier meta-analysis, we conducted a meta-analysis in chapter 2, for 
which we used a more strict definition of CHD than previous meta-analyses did. 
Our results showed a small to medium effect size for the association between 
depressive symptoms and CRP, but no significant effect for the association with IL-
6. The association between depression diagnosis and inflammation was further 
examined in chapter 5 in 2415 middle-aged participants with and without a current 
depression diagnosis. The results showed that men with a current depression, but 
not women, had higher levels of inflammation (CRP and IL-6) than men without a 
current depression. More specifically, especially men with an older age of onset of 
depression had the highest level of inflammation (CRP and TNF-α). Furthermore, 
when we compared the use of specific antidepressant medication, the results 
showed that levels of CRP and IL-6 were higher in men using serotonin-
norepinphrine reuptake inhibitors, and in men and women using tri- and tetracyclic 
antidepressants (CRP). However, in men, CRP decreased when using selective 
serotonin reuptake inhibitors. These findings clearly show a relationship between 
depression and inflammation and suggest that the association is especially present 
when the age of onset of depression is higher. Comparable to chapter 5, we found 
in chapter 6 that depressive symptoms were associated with higher levels of 
inflammation. However, adverse health behaviors (smoking, BMI, physical 
inactivity, and alcohol use) played an important role in this association. Taken 
together, these results show that the relationship between depression and 
inflammation was strongest in participants with a depression diagnosis, which 
suggests a dose-response relationship; the most severe depression is most strongly 
associated with higher levels of inflammation. Furthermore, our results showed 
that especially late-onset depression was associated with inflammation. Previous 
research reported that late-onset depression is associated with a family history of 
vascular disease and atherosclerosis. This suggests that the association between 
late-onset depression and higher levels of inflammation are possibly a reflection of 
subclinical disease, which becomes more prevalent with aging. 
In chapter 3 and 4 we investigated the direction of the association between 
depressive symptoms and inflammation in an older sample of CHD patients. We 




with subsequent inflammation (CRP, IL-6; chapter 3, and WBC count; chapter 4), 
but not vice versa. This suggests that depressive symptoms predict levels 
inflammations, but that inflammation does not predict future depressive 
symptoms. The results presented in chapter 7 underline these findings. We 
examined the association between depressive symptoms and CRP in 1166 
adolescents over a seven year period and found that depressive symptoms precede 
higher levels of inflammation. The associations found in chapter 3 and chapter 7 
were explained by the presence of adverse health behaviors, e.g. physical 
inactivity, smoking, and overweight, suggesting an important role for lifestyle 
factors. Taken all these studies together, we showed that depression and 
depressive symptoms in combination with adverse health behaviors predict higher 
levels of inflammation. 
 
Single episode versus recurrent depression and inflammation 
Research has suggested that mainly recurrent episodes of depression are 
associated with the adverse effects on health outcomes. It has been shown that 
greater progression of coronary artery calcification, hypertension, but also new 
cardiac events in post MI patients are more prevalent in those who suffer from 
depression more often. Possibly this also accounts for inflammation. In chapter 3 
and chapter 4 we assessed whether CHD patients who repeatedly reported 
significant depressive symptoms had higher levels of inflammation than those who 
did not. In a sample of 667 stable CHD patients we found that those who reported 
significant depressive symptoms at two or more yearly assessments, compared to 
those who reported no significant depressive symptoms or at one assessment only 
had higher levels of IL-6, CRP (chapter 3) and white blood cell count (WBC) (chapter 
4). Furthermore, the results showed that the relationship with IL-6 and CRP was 
mainly explained by adverse health behaviors, such as physical inactivity, 
overweight, and smoking. This was not the case for WBC count. In chapter 7, we 
evaluated the course of symptoms of depression in 1166 healthy adolescents over 
a period of seven years. The results showed that adolescents who persistently 
reported mild to high depressive symptoms had higher levels of CRP at follow-up. 
Comparable to chapter 3, we found that health behaviors played an important role 
in the association. Taken together, these results suggest that a cluster consisting of 
repeated experience of depressive symptoms, poor health behaviors and higher 
levels of inflammation could be a plausible explanation why people with depressive 
feelings are at greater risk for cardiac disease, new cardiac events or cardiac death 




Somatic versus cognitive symptoms of depression 
Research suggests that mainly the somatic symptoms of depression (e.g. sleeping 
difficulties, psychomotor retardation or activation, changes in eating behavior, and 
fatigue), and not the cognitive symptoms of depression (e.g. difficulties 
concentration, loss of interest, and depressed mood) are associated with a worse 
prognosis in patients with CHD. These somatic symptoms are comparable to the 
symptoms seen in sickness behavior. These symptoms emerge in the presence of 
upregulated levels of inflammation as a reflection of sickness. It could be 
hypothesized that the inflammatory processes present in cardiac disease are 
reflected in somatic symptoms of depression. In chapter 6 we cross-sectionally 
tested whether somatic and cognitive symptoms of depression were differentially 
associated with inflammation in a sample of 2861 participants with and without 
depression. The results showed that the somatic symptoms were associated with 
inflammation whereas the cognitive symptoms were not. However, the association 
was mainly explained by the effects of health behaviors, which suggests that the 
poor lifestyle of depressed patients puts them at risk for higher levels of 
inflammation. Chapter 7 discussed if somatic and cognitive symptoms of 
depression preceded higher levels of inflammation (CRP) in 1166 adolescents. In 
contrast to chapter 6, we did not find support for a differential association between 
somatic and cognitive symptoms with inflammation, both cross-sectionally and 
prospectively. This suggests that the association between somatic symptoms of 
depression and inflammation is only present in adults, possibly as a reflection of 
sickness behavior.  
 
Anxiety symptoms and inflammation 
It has been shown that next to depression, experiencing feelings of anxiety also has 
a negative influence on the development and progression of CHD, with some 
research suggesting that mainly the somatic components of anxiety (trembling, 
sweating, heart pounding) play an important role. In chapter 6 we examined if 
symptoms of anxiety were associated with inflammation, and if somatic and 
cognitive symptoms of anxiety were differentially associated with inflammation. 
Data from 2861 participants with and without a depression were analyzed. The 
results showed that especially men reporting symptoms of anxiety had higher 
levels of CRP and IL-6. Furthermore, the somatic symptoms of anxiety explained 
most of this association. Comparable to the findings on depressive symptoms 




feelings of anxiety, together with an unhealthy lifestyle have a higher risk for 
upregulated levels of inflammation. This unhealthy lifestyle could serve as a 
possible therapeutic target in order to lower the risk for future CHD but more 
research is needed to further elucidate this.    
 
Viral infections and depression 
Earlier research has linked viral infections to mental disorders such as 
schizophrenia, with a possible role for inflammation. However, there is little known 
about an association between viral infections and depression. In chapter 8 we 
therefore set out to evaluate the cross-sectional and prospective association 
between markers of viral infection (epstein barr virus, cytomegalovirus and herpes 
simplex virus 1) and depression in 1057 adolescents. The results showed that viral 
infections were not associated with current depressive symptoms or future 
depression status in this relatively young sample. However, this does not rule out 
the possible effects of virus infections on depression status. As positive associations 
have been reported in adult populations it could be argued that associations are 
not visible until adulthood. More research is needed to further elucidate the 
association between viral infections and depression. 
 
Concluding remarks 
The overarching aim of this thesis was to provide more insight in the association 
between depression and inflammation using a life perspective. Overall it can be 
concluded depression and depressive symptoms are associated with inflammation. 
This relationship was found to be  already present in adolescents and the strength 
of the depression-inflammation association increases with age. Moreover, this 
thesis showed that recurrent depressive symptoms predict subsequent 
inflammation, but inflammation does not predict (recurrent) depressive symptoms. 
Furthermore, this thesis showed that somatic symptoms of depression are cross-
sectionally associated with inflammation, but cognitive symptoms are not. This is 
possibly a reflection of sickness behavior. Next to depression, we also found 
preliminary evidence for an association between anxiety and inflammation. 
Another important and consistent finding was the role of health behaviors in the 
association between both depression and anxiety with inflammation. The presence 




explain most of the associations found. In conclusion, this thesis showed that a 
cluster of (recurrent) depression or anxiety, and adverse health behaviors predict 
higher levels of inflammation. This possibly puts this specific group of depressed or 
anxious people at risk for future cardiac disease. These health behaviors could 
therefore serve as a possible therapeutic target to reduce levels of inflammation 







































































Gezonde mensen met depressieve klachten hebben een verhoogd risico op het 
ontwikkelen van coronaire hartziekten (CHZ). Daarnaast is gebleken dat CHZ 
patiënten, en met name patiënten die recent een hartinfarct hebben gehad, vaker 
last hebben van een depressie of depressieve symptomen. Ongeveer 20% van alle 
CHZ patiënten ontwikkelt een depressie in de maanden nadat zijn een hartinfarct 
hebben gehad. Nog eens 20% rapporteert depressieve gevoelens te ervaren die 
niet voldoen aan de criteria voor een diagnose depressie. Daarmee komen 
depressie en depressieve gevoelens ongeveer drie keer zo vaak voor bij CHZ 
patiënten dan bij de algehele bevolking. Daarnaast heeft een depressie bij CHZ 
patiënten negatieve gevolgen voor de hartprognose; depressieve hartpatiënten 
hebben een verhoogd risico op nieuwe hartproblemen en vervroegd overlijden.  De 
afgelopen decennia zijn er verschillende potentiële (fysiologische ) mechanismen 
onderzocht die de negatieve invloed van depressie op hartproblemen zouden 
kunnen verklaren.  Een van deze mechanismen is inflammatie. Inflammatie is een 
verzamelnaam voor de afweerreactie van het lichaam tegen vreemde organismes 
(zoals virussen en bacteriën) en treedt op bij verwonding en ziekte. Inflammatie is 
betrokken bij het onschadelijk maken van deze vreemde organismes alsmede het 
repareren van schade aan het weefsel. De mate van inflammatie kan bepaald 
worden door de aanwezigheid van verschillende markers in het bloed te meten. 
Inflammatie is ook betrokken bij de ontwikkeling en het verloop van atherosclerose 
(ook wel aderverkalking), een belangrijke risicofactor voor het ontstaan van CHZ. 
Eerder onderzoek heeft eveneens een verband aangetoond tussen depressie en 
inflammatie. Echter, er zijn ook negatieve verbanden gevonden en er is nog maar 
weinig bekend over de kenmerken van de relatie tussen depressie en inflammatie. 
Zo is het onduidelijk of depressie een voorspeller is van verhoogde inflammatie of 
dat juist inflammatie voorafgaat aan depressieve klachten. Daarnaast is het niet 
bekend of het in de relatie tussen depressie en inflammatie gaat om specifieke 
symptomen van depressie of de duur van de depressieve klachten.  
Het doel van deze thesis was om een beter inzicht te krijgen in de relatie tussen 
depressie en inflammatie over de gehele levensloop. Meer specifiek hebben we 
onderzocht welke richting de relatie tussen depressie en inflammatie uitgaat en of 
het herhaaldelijk ervaren van depressieve klachten (recidiverende depressie) 
anders geassocieerd is met inflammatie dan het eenmalig ervaren van depressieve 
klachten. Tevens hebben we onderzocht of de meer somatische symptomen van 
depressie (o.a. eetproblemen en slaapproblemen) verschillend samenhangen met 




somberheid en concentratieproblemen). Binnen deze studies hebben we ook naar 
de effecten van gezondheidsgedrag gekeken (roken, overgewicht en fysieke 
inactiviteit), omdat eerder onderzoek heeft aangetoond dat gezondheidsgedrag 
sterk samenhangt met zowel depressie als inflammatie. Als laatste hebben we 
andere mogelijke relaties tussen psychische klachten en immuunactivatie 
onderzocht , die tussen depressie en virusinfectie en tussen angst en inflammatie. 
Om inflammatie te bepalen voor dit proefschrift zijn  c-reactief proteine (CRP) 
interleukine (IL) 6, tumor necrosis factor (TNF) α, fibrinogeen en witte bloedcellen 
(WBC) gemeten. 
 
Depressie en inflammatie 
Uit literatuuronderzoek is gebleken dat depressie en CRP en IL-6 geassocieerd zijn 
in diverse populaties, waaronder psychiatrisch patiënten en hartpatiënten. Tevens 
is aangetoond dat het verband sterker is naarmate de depressieve klachten 
ernstiger zijn (diagnose versus symptoom). In navolging van eerdere 
literatuurstudies en meta-analyses, hebben we in hoofdstuk 2 een meta-analyse 
uitgevoerd waarin de relatie tussen depressie en inflammatie onderzocht werd in 
CHZ patiënten. Hiervoor hebben we studies geïncludeerd die een stricte definitie 
van CHZ hanteerden. Uit de resultaten kwam een klein tot medium effect naar 
voren voor de associatie tussen depressieve symptomen en CRP, maar vonden we 
geen significant effect voor IL-6. De relatie tussen depressie diagnose en 
inflammatie hebben we verder onderzocht in hoofdstuk 5 in 2415 personen van 
middelbare leeftijd met en zonder diagnose depressie. Uit deze studie bleek dat 
vooral mannen met een huidige depressie hogere CRP en IL-6 waardes hadden dan 
mannen zonder depressie. Meer specifiek bleek dat de mannen waarbij de 
depressie pas op latere leeftijd voor het eerst tot uiting kwam (late onset) een 
sterker verband liet zien met inflammatie. Eerder onderzoek heeft aangetoond dat 
deze “late onset” depressie geassocieerd is met een familiegeschiedenis waarin van 
CHZ en atherosclerose vaker voorkomen. Dit suggereert dat de relatie tussen de 
late onset depressie en inflammatie die we gevonden hebben mogelijk een 
reflectie is van subklinische ziektes, die meer prevalent worden naarmate men 
ouder wordt. Tevens hebben we in een subgroep van depressieve personen 
hebben aangetoond dat diegene die tricyclische en tetracyclische antidepressiva 
gebruikten en mannen die serotonine-noradrenaline-heropname-remmers 
gebruikten hogere inflammatie hadden. Daarentegen bleken personen die 




Vergelijkbaar met de resultaten uit hoofdstuk 5, lieten de resultaten uit hoofdstuk 
6 zien dat ook depressieve klachten geassocieerd zijn met hogere inflammatie, 
maar het verband was minder sterk. Daarnaast bleek een ongezonde leefstijl 
(bepaald met roken, overgewicht, fysieke inactiviteit en overmatig alcoholgebruik) 
een belangrijke rol te spelen in deze relatie.  
In hoofdstuk 3 en 4 hebben we binnen de oudste groep deelnemers, CHZ 
patiënten, onderzocht in welke richting de relatie tussen depressie en inflammatie 
uitgaat. Uit de resultaten kwam duidelijk naar voren dat CHZ patiënten die 
gemiddeld meer depressieve klachten rapporteerden hogere inflammatie hadden 
na zes jaar (gemeten met CRP, IL-6, fibrinogeen en WBC). Daarentegen bleken 
hogere inflammatiewaardes niet voorspellend te zijn voor het later ervaren van 
depressieve klachten. Dit suggereert dat depressie een voorspeller is voor 
inflammatie en dat inflammatie geen voorspeller is voor het ervaren van 
depressieve gevoelens. Deze bevindingen werden onderschreven door de 
resultaten uit hoofdstuk 7. Hier hebben we 1166 adolescenten gedurende 7 jaar 
gevolgd en vonden we dat het ervaren van depressieve symptomen voorafgaat aan 
hogere CRP waardes. Daarnaast bleek dat de associaties die we in hoofdstuk 3 en 7 
vonden verklaard werden door een ongezonde leefstijl, zoals roken, overgewicht 
en fysieke inactiviteit.  
 
Samengevat laten deze studies zien dat depressie en depressieve symptomen 
geassocieerd zijn met inflammatie. De relatie bleek het sterkst te zijn bij diegene 
die daadwerkelijk een depressie diagnose hadden. Dit suggereert dat er mogelijk 
sprake is van een dosis respons relatie; de meest ernstige depressie is geassocieerd 
met de hoogste inflammatie. Ook kwam naar voren dat vooral de depressie die zich 
pas op latere leeftijd voor het eerst manifesteert geassocieerd is met inflammatie. 
Daarnaast bleek uit de resultaten dat het ervaren van depressieve gevoelens 
hogere inflammatie voorspelt en niet vice versa. In vrijwel alle studies kwam naar 
voren dat gezondheidsgedrag een belangrijke rol speelt in de relatie tussen 
depressie en inflammatie, waaruit geconcludeerd kan worden dat een combinatie 
van depressieve gevoelens in combinatie met een ongezonde leefstijl voorspellend 
is voor hogere inflammatie.        
 
Eenmalige versus recidiverende depressie 
Eerder onderzoek heeft aangetoond dat met name recidiverende depressieve 




prevalentie van atherosclerose, een hoge bloeddruk en nieuwe hartproblemen bij 
CHZ patiënten hoger is bij mensen die vaker depressief zijn. In hoofdstuk 3 en 4 
hebben we bij 667 CHZ patiënten onderzocht of inflammatie ook hoger was bij 
diegene die vaker depressieve gevoelens rapporteerden in vergelijking met diegene 
die eenmalig of geen depressieve gevoelens rapporteerden. De resultaten lieten 
zien dat patiënten die tijdens de studie vaker depressieve klachten rapporteerden  
hogere CRP en IL-6 waardes hadden (hoofdstuk 3) en meer WBC (hoofstuk 4). In 
hoofdstuk 7 hebben we in 1166 adolescenten het beloop van depressieve 
symptomen in relatie tot CRP onderzocht. Hieruit kwam naar voren dat het ervaren 
van milde tot ernstige depressieve klachten gedurende een periode van 7 jaar al in 
de adolescentie voorafgaat aan hogere CRP waardes. Zowel uit de resultaten bij 
CHZ patiënten, als bij de adolescenten bleek dat gezondheidsgedrag een grote rol 
speelt in de relatie tussen depressieve klachten en CRP en IL-6. Samengevat 
suggereren deze resultaten dat een cluster bestaande uit recidiverende 
depressieve klachten, een ongezonde leefstijl en hogere inflammatie een 
plausibele verklaring zou kunnen zijn waarom mensen met depressieve klachten 
een verhoogd risico hebben op het ontstaan van CHZ danwel een slechtere 
prognose van bestaande CHZ hebben dan mensen zonder depressieve klachten.  
 
Somatische versus cognitieve symptomen van depressie  
Onderzoek heeft aangetoond dat vooral de somatische symptomen van depressie 
(o.a. slaapproblemen, eetproblemen, vermoeidheid) en niet de cognitieve 
symptomen van depressie (concentratieproblemen, sombere stemming, gevoelens 
van lusteloosheid) geassocieerd zijn met een verslechterde prognose van 
hartpatiënten. Deze somatische symptomen zijn vergelijkbaar met de symptomen 
die worden beschreven bij ziektegedrag als reactie op inflammatie (ook wel de 
sickness behavior theory). 
In hoofdstuk 6 is specifiek gekeken naar het verschil tussen somatische en 
cognitieve symptomen van depressie in relatie tot inflammatie. Daarvoor zijn de 
data van 2861 volwassen deelnemers gebruikt. Uit de resultaten bleek dat 
deelnemers met meer somatische symptomen hogere inflammatie hadden. Dit 
werd niet voor cognitieve symptomen gevonden. Echter, wanneer er gecorrigeerd 
werd voor de effecten van gezondheidsgedrag, waren de resultaten niet langer 
significant. Deze resultaten suggereren dat somatische symptomen van depressie 
in combinatie met een ongezonde leefstijl zorgt voor hogere inflammatie. In 




verschillen gevonden tussen de somatische en cognitieve symptomen van 
depressie in relatie tot inflammatie bij adolescenten en bleek juist dat somatische 
en cognitieve symptomen van depressie samen voorafgaan aan meer inflammatie. 
Samengevat suggereren deze resultaten dat somatische symptomen van depressie 
alleen geassocieerd zijn met inflammatie in volwassenen, mogelijk als een reflectie 
van ziektegedrag.  
 
Angst en inflammatie 
Uit eerder onderzoek is gebleken dat naast depressie ook het ervaren van angst 
een negatieve invloed heeft op zowel het ontwikkelen van CHZ als het beloop 
hiervan. Er zijn zelfs aanwijzingen waaruit blijkt dat in het bijzonder de somatische 
component van angstklachten (o.a. beven, zweten en verhoogde hartslag) een 
belangrijke rol spelen in deze relatie. In hoofdstuk 6 hebben we onderzocht of 
symptomen van angst en inflammatie samenhangen en of er een verschil aanwezig 
is tussen de somatische en cognitieve symptomen. Hiervoor zijn de gegevens van 
2861 proefpersonen met en zonder diagnose depressie geanalyseerd. De 
resultaten lieten zien dat vooral mannen met angstklachten hogere IL-6 en CRP 
waardes hadden. Verder kwam er naar voren dat vooral de somatische symptomen 
van angst deze relatie verklaarden. Net als bij de relatie tussen depressieve 
symptomen en inflammatie bleek echter dat gezondheidsgedrag een belangrijke rol 
speelt in deze relatie. Dit betekent dat mensen met angstklachten en een 
ongezonde leefstijl een groter risico hebben op hogere inflammatie. Mogelijk kan 
ingrijpen in deze ongezonde leefstijl dienen als onderdeel van de therapie van 
patiënten met angst om zodoende het risico op CHZ te verlagen. Toekomstig 
onderzoek zal hier meer inzicht in kunnen geven.     
 
Virusinfecties en depressie 
Eerder onderzoek heeft aangetoond dat virusinfecties geassocieerd zijn met 
psychische stoornissen zoals schizofrenie, waarbij inflammatie mogelijk een rol 
speelt. Echter, er is nog weinig bekend over een relatie tussen virusinfecties en 
depressie. In hoofdstuk 8 hebben we onderzocht of de aanwezigheid van virussen 
(epstein barr virus, cytomegalovirus en herpes simplex virus 1) gerelateerd is aan 
het ervaren van depressieve gevoelens of een toekomstige depressie diagnose 




deelnemers virusinfecties niet geassocieerd zijn met depressieve gevoelens of het 
later hebben van een depressie twee jaar later. Echter, dit sluit niet uit dat 
virusinfecties wel degelijk een invloed kunnen hebben op het ontstaan van een 
depressie. Virussen kunnen latent aanwezig blijven in bij aan depressie 
gerelateerde hersengebieden. Onder invloed van stress kunnen deze latente 
virussen gereactiveerd worden en daarmee schade aanrichten in deze 
hersengebieden. Mogelijk is er bij de onderzochte groep adolescenten nog geen 
(frequente) reactivatie van de virussen geweest en daarmee nog geen schade 
aangericht die depressie kan veroorzaken. Dit suggereert dat een relatie tussen 
depressie en virussen mogelijk pas in de volwassenheid tot uiting komt. Toekomstig 
onderzoek zal hier meer duidelijkheid over moeten verschaffen.  
 
Conclusie 
Het overkoepelende doel van deze thesis was om meer inzicht te verkrijgen in de 
relatie tussen depressie en inflammatie gedurende de levensloop. Op basis van de 
resultaten kan er geconcludeerd worden dat er een relatie is tussen depressie en 
inflammatie. Deze relatie is al aanwezig in de adolescentie en wordt sterker 
naarmate men ouder wordt. Daarnaast is gebleken dat vooral de recidiverende 
depressieve klachten voorspellend zijn voor latere inflammatie, maar dat 
inflammatie geen (recidivirende) depressieve klachten voorspelt. Ook is naar voren 
gekomen dat de somatische symptomen geassocieerd zijn met inflammatie bij 
volwassen, mogelijk als reflectie van ziektegedrag. Tevens hebben we aangetoond 
dat inflammatie niet alleen samenhangt met depressie, maar ook met angst. Een 
belangrijke en consistente bevinding was dat een ongezonde leefstijl in belangrijke 
mate de relatie tussen zowel depressie als angst en inflammatie verklaart. 
Concluderend kan er gesteld worden dat een combinatie van (recidiverende) 
depressie of angst en een ongezonde leefstijl hogere inflammatie tot gevolg 
hebben. Deze groep mensen heeft daarmee mogelijk een verhoogd risico op 
toekomstige hartproblemen. Het behandelen van de ongezonde leefstijl van 
depressieve- of angstpatiënten zou mogelijk een positief effect kunnen hebben op 
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